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Abstract
Electrospray ionisation mass spectrometry (ESI-MS) was used to screen the relative
binding affinities of berberine and its derivatives (oSS14, mSS14, pSS14, SS104, BT80
and KG01) for double-stranded (ds) and quadruplex (q) DNA, and to compare this
against the intercalating anti-cancer drug, daunomycin. The DNA sequences used in this
study

were

the

dsDNA

(GCTGCCAAATACCTCC)

sequences:
(only

D1

one

(CCTCTCTGGACCTTCC),
strand

shown)

and

D2
F10

(TGCTGGACGAAAAAAAAAA/CGTCCAGC), and three quadruplex sequences: the
four-stranded Q4 (TTGGGGGT)4, the single-stranded Q1 GGG(TTAGGG)3 and the
two-stranded Q2 (GGGGTTTTGGGG)2. Circular dichroism spectroscopy was used to
confirm that the qDNA sequences were folded in solution conditions compatible with
ESI-MS, and consistent with CD spectra observed in other laboratories. ESI ion
mobility mass spectrometry using a mass spectrometer with a travelling wave ion
mobility cell, combined with experiments in which solution conditions were altered to
destabilise the qDNA structures, provided evidence that the qDNA secondary structure
was maintained in the gas phase under the conditions of the ESI-MS experiments.

Berberine had a high affinity for dsDNA and bound with multiple stoichiometries.
Berberine also had a relatively high affinity for Q1 and Q4 with lower levels of binding
(abundant free DNA was present in mixtures analysed by ESI-MS) to Q2. Daunomycin
bound substantially to both ds- and qDNA with a higher affinity for dsDNA. In
preliminary work oSS14 showed selectivity for Q4 DNA over dsDNA. The derivatives
mSS14, pSS14, SS104 and KG01 retained this selectivity but bound more tightly to Q4
DNA (smaller amounts of free DNA remaining in mixtures). KG01 also had moderate
iv

binding affinity towards Q1. BT80 had a high affinity for all the qDNA types and
retained substantial selectivity for qDNA over dsDNA. When pSS14 was left to bind to
Q4, ions appeared in the mass spectra that were consistent with the formation of qDNA
dimers with bound pSS14. The binding of ligands to Q2 increased its stability.

The selectivity of the berberine derivatives, especially BT80, for qDNA over dsDNA
may lead to their applications as leads for quadruplex DNA-specific chemotherapeutic
(anti-cancer) agents or as molecular probes for qDNA structures in cells.
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Chapter 1: General Introduction
DNA and RNA are prime targets for compounds which have anti-bacterial, anti-viral
and anti-cancer properties.1,

2

Therapeutic intervention in cellular function requires

interactions across specific base pairs, something which is the result of evolution for
cellular proteins, but difficult to achieve with small synthetic molecules. There are many
factors which determine the extent and way in which a small molecule will bind to its
target. Not only must the pharmacodynamic properties of the drug be considered, but so
must the structure-activity relationships with the receptor site. In many instances these
compounds are indiscriminate and react at many DNA sequences in addition to proteins.
This makes it difficult to target DNA without disrupting normal cell functions. For this
reason, treatments involving these drugs are reserved for severe illnesses such as
cancers, AIDS, malaria and severe bacterial infections. 2 This introduction outlines some
of the different secondary structures of DNA that have been characterised, the evidence
for the occurrence of triplex and quadruplex DNA and their structural features are
presented. The features of small molecules that bind non-covalently to dsDNA are
outlined in detail and some molecules that bind to quadruplex DNA are described.
Finally the techniques used in this thesis for the investigation of drug-DNA interactions,
among others, are described.

1.1 DNA structure
The structure of DNA resembles that of a spiralling ladder and consists of the four
bases: thymine (T), adenine (A), cytosine (C), and guanine (G). 3, 4 The bases are linked
through a glycosidic bond to the 1' carbon of deoxyribose (ribose in RNA). The
14

phosphate backbone of DNA consists of phosphodiesters of deoxyribose linked to
phosphate at the 3' and 5' positions. 3 Two single strands form double-stranded DNA
(dsDNA) and are arranged in an antiparallel fashion (3' end of one strand is adjacent to
the 5' end of the other). This is a consequence of H-bonding between the bases of each
strand (AT – 2 x H bonds; GC – 3 x H bonds) which stabilises the double helix. DNA
exists primarily as the right-handed helical B form; an A-form and the left-handed
helical Z-form have also been identified and are shown in Figure 1.1.5

0.34 nm

3.4 nm

(A)

(B)

(C)

Figure 1.1: The different forms of DNA. (A) B-DNA occurs under normal physiological
conditions. It is a right-handed helix containing 10 base pairs per turn. (B) A-DNA found in
RNA-DNA and RNA-RNA double helices, is a more compact structure with 11 base pairs per
turn. (C) Z-DNA is a left-handed helix with a zig-zag appearance of the sugar-phosphate
backbone. Taken from Darnell et al..5
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Most anti-cancer drugs work by targeting DNA within the nucleus of the cell.6 While BDNA is the major target of most anti-cancer agents,6 other forms of DNA are believed
to play a part in the control of gene expression and thus are becoming increasingly
investigated as targets.7, 8

1.2 DsDNA drug binding
Chemotherapy is currently at the forefront of treatment for cancer. Some of the most
commonly used chemotherapeutic drugs include cisplatin, daunomycin (daunorubicin),
bleomycin, and adriamycin (doxorubicin).2, 6, 9 The structures of these drugs affect the
rate of penetration into the nucleus of a cancerous cell, the conformation of the complex
between the drug and DNA, and the specificity and energetics of drug-DNA
interactions.10 Therefore a detailed understanding of the contributions of the structural
motifs is extremely important for the development of better analogues.

Clinically used DNA-binding drugs include those that bind covalently (e.g. cisplatin),
and drugs that bind non-covalently.2 The non-covalent DNA binders, on which the
following text will focus, usually bind by one of two different mechanisms. That is,
minor groove binding or intercalation. The minor groove binders typically interact with
4-6 bases, whereas intercalators can bind between every alternate base pair depending
on the presence of functional groups that might contribute to steric hindrance.11

16

1.3 Minor groove binders
Common characteristics of minor groove binders include a flat crescent shape (which
complements the helical DNA structure), at least one positive charge and many donor or
acceptor groups for H-bonding. They have several rings (e.g. pyrrole, benzene), which
are connected by bonds that allow them a certain degree of torsional freedom.10,

11

Minor groove binders have a high affinity for regions of DNA with at least four
consecutive A and/or T bases.11, 12 The interactions between the DNA and the drug are
stabilised by van der Waals forces, hydrophobic interactions, and the formation of
specific hydrogen bonds between the ligand and the C2 carbonyl oxygen of thymine or
the N3 nitrogen of adenine.13 Although similar binding opportunities exist in G-C base
pairs, the amino group of the guanine presents a steric block to hydrogen bond
formation at the N3 of guanine and C2 of cytosine. Minor groove binders have been
shown to exhibit anti-protozoal, anti-viral, anti-bacterial and in some cases, anti-tumour
activity.13, 14 Despite the synthesis of many new minor groove binders, only a few of
these have shown anti-tumour activity and reached clinical trials. 6 The structures and
activities of these compounds are discussed below.

17

(A)

(B)

(C)

Figure 1.2: Minor groove binders. (A) Distamycin, (B) Netropsin, and (C) Hoechst 33258.

1.3.1 Distamycin
Distamycin (Figure 1.2 (A)) is a naturally occurring antibiotic which was isolated from
Streptomyces distallicus in 1962.15 Though inactive as an anti-tumour agent, distamycin
has shown interesting anti-viral and anti-bacterial activity.6 True to the binding patterns
of minor groove binders, it binds reversibly at AT-rich regions of the minor groove of
18

B-DNA.16 The structure of distamycin has therefore generated much interest as a lead
compound for more specific DNA binding agents with numerous derivatives being
synthesised since its discovery. Many of these are active anti-virals,17-19 anti-bacterials20
and anti-protozoals.21 For example, the N-terminal formamide unit was removed from
distamycin in a tris-pyrrole derivative synthesised by Bhattacharya et al..22 This was
found to retain its AT sequence preference, showing that the loss of the formamide unit
did not affect the sequence selectivity.22 Conversely, the importance of the unsaturated
N-methyl pyrrole rings was confirmed, as saturation of these resulted in reduced
binding affinity.23 Increasing the number of pyrrole units was found to increase the
specificity for binding to longer AT tracts of DNA; the tetrapyrrole homologue has been
explored further and used to develop additional mustard-based DNA alkylating
derivatives. The pentapyrrole derivative of distamycin has been reported as an inhibitor
of telomerase activity (see section 1.5.2.2).21 More recently, novel porphyrin-distamycin
conjugates were synthesised with the fluorescent (porphyrin) label assisting in
observing interactions with calf thymus DNA. 24 The distamycin moiety was found to
retain minor groove binding properties while the porphyrin component appeared to bind
via intercalation.

Distamycin has also been successfully used as a basis for further lexitropsin
development.25 Lexitropsins are modular polyamide molecules that are designed to read
the base sequence of DNA.25, 26 They are constructed of three types of subunits: pyrrole,
imidazole and hydroxypyrrole, which allow full recognition of DNA base sequences. 27
The characterisation of netropsin (also a lexitropsin, section 1.3.2) and distamycin and
their interactions with DNA has led to better targeted development of derivative
19

lexitropsins.25 The medical applications of lexitropsins are promising, with some
showing anti-HIV-1 activity.25

Synthesis of bis-distamycin derivatives has yielded compounds with significant antiretroviral

activity.

Several

derivatives

were

synthesised

by

linking

two

deformyldistamycin residues to a dicarboxylic acid derivative. 17 Of these, one
derivative, possessing a terephthaloyl moiety as the linker, was determined to be eight
times more potent in inhibition of HIV-1 replication than the parent compound.18
Another bis-distamycin analogue, NSC 651016, developed by Howard et al., was
shown to selectively inhibit chemokine receptors (coreceptors for HIV-1 entry into
human cells). The data were obtained using laboratory and clinical drug resistant
isolates (resistant to reverse transcriptase inhibitors) of HIV-1 and representative
isolates of simian immunodeficiency virus (SIV) and HIV, type 2 (HIV-2) and showed
the potential of NSC 651016 as a candidate for chemotherapeutic treatment of HIV-1
infection and also as a microbicide.19 There are reports of other distamycin derivatives
with increased HIV-1 reverse transcriptase inhibition activity. A series of oligo-1,3thiazolecarboxamide derivatives which contain different numbers of thiazole units,
dimethylaminopropyl or EDTA moieties on the C-terminus, and aminohexanoyl or
EDTA moieties on the N-terminus were synthesised and found to be more potent
inhibitors than distamycin.28

While distamycin itself has weak anti-bacterial activity, Burli et al., have synthesised a
series of derivatives consisting of a four-ring core element and characterised by the
presence of various substituents at both termini. 20 These compounds were active for a
20

broad range of Gram-positive bacteria. It was also found that the position of basic
groups had strong effects on both DNA binding affinity and anti-microbial activity with
better activity for the analogue with the basic group at the C-terminus.

Derivatives have also been synthesised which improve the rate of localization into cell
nuclei. Vasquez et al. synthesized a series of tripyrrole-octa-arginine conjugates that
were found to have over 100-fold improved affinity (low nanomolar) over distamycin
for A-rich tracts of DNA.29 Additionally, they exhibited excellent membrane and
nuclear translocation properties in living HeLa cells where previously other similar
analogues (e.g. distamycin-like polyamides)30 were found to have slow cellular and
nuclear uptake.

1.3.2 Netropsin
Netropsin is a naturally occurring compound originally isolated from Streptomyces
netropsis.27, 31 Like distamycin, this molecule is known as a lexitropsin.25 The netropsin
ligand, Figure 1.2 (B), consists of guanidinium groups, two pyrrole rings, and a
propylamidinium moiety. Molecular dynamics simulations have shown that this
molecule has a convex conformation allowing it to fit into the concave shape of the
minor groove of DNA with the intrusion of the N2 of the amino group of guanine
preventing G-C pair binding.32 The charged tail provides non-specific electrostatic
interactions with the anionic backbone of DNA that strengthen binding.33 Full
knowledge of the molecular detail of binding has led to the rational design of various
new compounds. The first, which was simultaneously devised in two laboratories,
21

contained a hydrogen-bond-accepting imidazole in place of the pyrrole which mediates
a contact with guanine.25, 34 These analogues were shown to be able to bind to both G-C
and A-T base pairs in foot-printing experiments utilising a 139 base pair HindІІІ/NciI
restriction fragment from pBR322 DNA. 34 This change in binding preference was
attributed to the interaction between the two cationic tails and the anionic
phosphates.27,31

The structure of the netropsin-DNA complex revealed to researchers a mismatch
between the geometry of the DNA minor groove and the geometry of the drug. 25 The
amide-pyrrole subunit was slightly longer than the base-to-base repeat region along the
minor groove and disrupted the interactions required for specific minor groove binding
in A-T rich regions of DNA. This proves to be a problem when designing analogues
with longer polyamide chains as the mismatch problem becomes extended, and thus
limits the size of the DNA sequences which can be targeted.27 Linked polyamides have
also been synthesised with two netropsin molecules connected N-terminus to Nterminus through a hydrocarbon linker in an attempt to target longer DNA sequences.27

Much progress has since been made with bis-netropsins and netropsin–peptide
conjugates which are capable of selective inhibition of transcription initiation (“reading
of the genome”) from different promoters and influence the activity of transcription
factors in both eukaryotic and prokaryotic cells.35 Some of these can inhibit the activity
of DNA topoisomerases and HIV integrase. 18 De Clerk et al. investigated the anti-viral
activity of bisnetropsin derivatives in which the two monomers were bound through

22

various dicarboxylic acid residues. A number of these compounds were able to suppress
the reproduction of vaccinia virus more effectively than the parent compound. 36

Another approach has been to enhance useful binding features of the netropsin
molecule. For example, Goodsell and Dickerson increased the rigidity of the netropsin
molecule and thus reduced the entropy of binding.37 They added cyclic groups to form
extensive contacts with the DNA, and hydrogen bond donors facing the minor groove in
order to increase binding strength.37 From these experiments two potential candidates
were suggested for further study, one with a pyrrole-ketone polymer and the other with
a pyridyl-ketone polymer.14 The former proved quite difficult to synthesise, but has
been validated as an effective binding analogue in molecular mechanics studies, while
the latter proved to have no benefits over the parent compound. 14

Two synthetic derivatives of the netropsin ligand whose activities and binding
specificities have been extensively investigated include the bis-quaternary ammonium
heterocycles (BQAs), SN 6999 and SN 6570. These compounds contain aromatic rings
in place of the pyrrole rings.38 BQA analogue development has been directed towards
down-regulating expression of genes thought to be important in the progression of
Alzheimer‟s disease.25, 39

Netropsin and distamycin derivatives have also been found to be effective in
suppression of the reproduction of Herpes simplex virus type I in experiments
performed in Vero cells and in laboratory animals.35 A characteristic feature of all the
netropsin and distamycin analogues studied was that the N-methylpyrrole cycles were
23

replaced with N-propylpyrroles. This substitution increased the hydrophobicity of
ligands. It was proposed that this may simultaneously enhance their chemical stability in
solution and the ability to penetrate through the cell membrane.

1.3.3 Hoechst 33258
Hoechst 33258, Figure 1.2 (C), is a synthetic bis-benzimidazole derivative dye which
fluoresces when bound to DNA.40 Though cytotoxic, its mechanism of action has not
yet been fully elucidated, it is suspected that it inhibits the interactions of the enzymes
topoisomerase and DNA helicase with DNA.41 Binding has also been found to inhibit
transcription of specific genes.40 The four planar structural segments of the Hoechst
33258 molecule are the N-methyl piperazine ring, two benzimidazole moieties, and the
phenol group.32 The exocyclic amino group of guanine prevents the binding of the
molecule in G-C regions though G-C sequences can be tolerated if present at the
extremities of the binding site.32 There has also been some evidence to suggest that
Hoechst 33258 is a weak intercalating agent,42 though it is still classified as a minor
groove binder.

X-ray crystallography has shown that the replacement of the terminal piperazine ring
with an amidinium, an imidazole or a tetrahydropyridinium group reinforces the affinity
of the drug for A-T rich regions.43 One analogue of this drug containing a phenolic
hydroxy group in the meta rather than the para position was found to be less toxic than
the parent compound.44 Other analogues of the dye which appear to have a higher
cytotoxicity in vivo are believed to do so owing to their greater ability to traverse the
24

cell membrane and reach the target DNA. 45 Since these derivatives are able to traverse
both the nuclear and cytoplasmic membranes, they are able to accumulate, and thus are
capable of inhibiting the binding of regulatory proteins. 45

In other work, the DNA recognition properties of peptide nucleic acids have been
combined with those of Hoechst-based minor groove binders. Peptide nucleic acids
(PNA) are DNA mimics that can hydrogen bond to the bases of double-stranded DNA
resulting in regions of triplex nucleic acids.46 They dramatically enhance the binding
kinetics of some drug-DNA complexes.47 A peptide nucleic acid (PNA)-Hoechst
conjugate was prepared from an amino acid derivative of Hoechst.48 This conjugate was
found to bind more tightly to DNA than the PNA alone. The conjugate was also found
to bind with more affinity to AT-rich regions other than the one for which it was
originally designed.48 While peptide nucleic acids have been around for at least ten
years, the development of PNA oligomers into therapeutic drugs is still in its infancy. 46
At present, clinical trials of any conjugates are far off but there are currently
experiments under way to identify targets for the PNA-Hoechst conjugate.48

1.4 Intercalators
The intercalators are the most significant forms of non-covalent DNA binders and are in
widespread use as chemotherapeutic agents. 49 These include daunomycin, doxorubicin
and echinomycin. These generally possess a planar aromatic chromophore and
incorporate a positive charge.49 This allows them to stack between adjacent base pairs
within the DNA helix. In some cases, a preference for GC-rich regions has been
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demonstrated.50 The stacking occurs via interaction with pi orbitals of the base pairs,
thus causing the DNA helix to extend from its normal 3.4 Å to 6.8 Å.15 Intercalators
also bind to DNA through van der Waals forces.15 Furthermore, substituents of the
aromatic chromophore may participate in hydrogen bonding with the bases or the
phosphate backbone to further stabilise the complex.15,

50

There are also examples of

atypical intercalating agents lacking a planar aromatic chromophore. These are nonplanar, non-condensed molecules which are „inadequately shaped‟ for intercalation, but
which have been found to be excellent intercalating agents. 37 These include the drug
amiloride (a diuretic), and several trimethyl methane dyes.37 Figure 1.3 shows the
structures of some intercalators.

(A)

(B)

(C)

Figure 1.3: Typical intercalators. (A) Ethidium bromide, and the anthracyclines (B)
daunomycin, and (C) doxorubicin.
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1.4.1 Ethidium bromide
Ethidium bromide (Figure 1.3 (A)) has a central phenanthridine ring system that
intercalates into DNA2 with little preference for particular sequences. This fluorescent
purple dye remains the most extensively used in molecular biology to stain nucleic acids
in gels, and to study nucleic acid structures. 51 Its potent activity in inhibition of nucleic
acid synthesis has been known for some years.52 Despite being an anti-bacterial and
anti-trypanocidal,53 it is, however, a recognised mutagen (frame shift mutations), so
cannot be approved for use in humans.54

Early attempts to modify ethidium bromide to alter its DNA-binding properties included
substitution of the alkyl chain with groups other than ethyl such as methyl and propyl
groups.55 These were found to have approximately the same DNA affinity,56 but were
significantly more toxic.57 The six position of ethidium has also been substituted with
various groups (4-amino phenyl, 4-nitro phenyl, methyl, napthyl, etc).58 These were also
found to have similar DNA binding affinities to ethidium bromide.56 The exocyclic
amines of ethidium have been converted to azido (N3) groups, which are highly reactive
photo-cross-linking agents. These compounds were found to have similar DNA affinity
to ethidium bromide and were also mutagenic.59

Leudtke and co workers were the first to systematically substitute the exocyclic amines
of ethidium.60 A series of substituted derivatives has been synthesised by converting the
amines at the 3- and 8- positions of ethidium bromide into guanidine, pyrrole, urea, and
various substituted urea moieties. These modifications were found to have profound
effects on the spectroscopic properties of ethidium, as well as the affinity and specificity
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of the derivatives for DNA. The compounds were tested for their abilities to bind to calf
thymus DNA. One uncharged analogue, 3,8-diamino-6-phenylphenanthridine had a tenfold lower affinity for DNA than the parent ethidium compound. 60 This suggested that
the positive charge provided by the quaternary amine is very important for DNA
affinity.

Recently, the detailed characterisation of a novel ethidium bromide derivative, DB950,
has been published by Bailly and co-workers.51 This compound possesses two
guanidinium groups at positions 3 and 8. In this case, the derivative has vastly different
interactions with DNA than the parent compound. DB950 binds more tightly to DNA
than ethidium and exhibits distinct DNA-dependant absorption and fluorescence
properties. Most interesting is the method of binding; DB950 was determined to be a
minor groove binder with a preference for AT sequences. This was determined using
circular dichroism (CD) and LED (light emitting diode) spectroscopy. Additionally,
surface plasmon resonance experiments revealed that the binding to an AT-rich
sequence was 30 times stronger than binding to a GC-rich oligomer. It is believed that
the specificity of the drug arises from the guanidinium and amidinium groups, whose
cationic nature allows the drug to be anchored in the minor groove.

An extended analogue of ethidium bromide was also synthesised which was made by
fusing an additional aromatic ring to the parent molecule. 61 The resulting compound
was subjected to nucleic acid affinity studies with calf thymus DNA and AT-rich
synthetic dsDNA and RNA. No significant binding differences were found with calf
thymus DNA, however, the new compound had an improved affinity for the A-form of
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RNA. Using fluorescence binding affinity this analogue was also found to have an
improved affinity for triplex DNA. Additionally, thermal denaturation experiments
showed that for one of the triplexes tested, dT19.dA19.dT19, the analogue was able to
substantially stabilise the triplex.61

1.4.2 Anthracycline antibiotics, daunomycin and doxorubicin
Of the many drugs used in chemotherapy, anthracyclines are a class which has one of
the widest applications and has been in common use for almost half a century. 62 These
drugs are anti-tumour and antibiotic agents.9 Though the exact mechanism(s) by which
anthracyclines exert their effects has not been fully elucidated, it is suspected to be
primarily through inhibition of DNA biosynthesis, interference with topoisomerase II
and induction of DNA double-strand breaks.63-65 The structures of two anthracyclines,
daunomycin (B) and doxorubicin (C), shown in Figure 1.3, consist of a planar aromatic
anthraquinone ring system and are glycosylated.63

The planar aromatic chromophore of the anthracycline is able to intercalate between
DNA base pairs.9,66 These interactions are further stabilised by hydrophobic interactions
and hydrogen bond formation where the sugar moieties are able to interact with the
DNA.67 These anthracyclines also possess a positive charge at physiological pH which
contributes electrostatically to binding. 9 Furthermore, the sugar moiety has been shown
to be an essential component of anthracycline antibiotics for their topoisomerase
poisoning and anti-tumour activity.63
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Doxorubicin (hydroxyl daunomycin, or adriamycin) and daunomycin were originally
isolated from Streptomyces peucetius, and exhibit the most widespread anti-tumour
activity of the anthracyclines (Figure 1.3).9 The two have essentially the same skeleton
while doxorubicin possesses an OH group on the α-methyl ketone. Quantum chemical
calculations have also suggested that the phenolic OH bonds are orientated in opposite
directions on the two compounds.68 Despite the similarity in the structures of these
drugs, there are great differences in their activities. Doxorubicin is used for treatment of
various carcinomas and many sarcomas, while daunomycin has more limited clinical
use and has been primarily used to treat acute leukemia.69,9 Both bind to dsDNA by
intercalating between base pairs at GC-rich regions, and are further stabilised by the
presence of the 4-methoxy group which can form hydrophobic interactions with methyl
groups on the DNA sequence (i.e. with T bases). Additional stabilization is afforded by
the presence of the 9-OH which can form hydrogen bonds with nitrogen atoms present
on adenine bases as well as the oxygen on the deoxyribose of guanine.70

Although anthracyclines are in widespread clinical use, they are not without sideeffects. Their cardiotoxic effects have seriously limited their use as chemotherapeutic
agents.64, 71, 72 They produce a cardiomyopathy (weakening of the heart muscle). 66 The
cardiotoxic effects have been attributed to mechanisms such as free radical formation,
lipid peroxidation, changes in adrenergic functions, and changes in sarcolemmal * Ca

2+

transport.65, 73-75 The strongest and most recent evidence suggests that it is free radical
formation which initiates lipid peroxidation in cardiac tissue. This peroxidation causes

*
†

Pertaining to the plasma membrane covering the outer surface of a muscle fibre.1
Ammonium acetate (NH4OAc) was made up to 0.1 M and adjusted (from pH 6.8) to pH 7.0 using
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direct injury to cell membranes.76 Tissues of the heart are particularly susceptible owing
to their less developed antioxidant defence mechanism.77 The cardiac toxicity correlates
directly to the dose given, however in some cases, serious cardiac effects occur even at
minimal doses.78 The cancer can also develop resistance towards the anthracyclines.
The biggest problem is that many types of tumour cells have the ability to develop
resistance mechanisms not only to the drug being used for treatment, but also to those
which are structurally similar. Termed multidrug resistance (MDR), this is an issue with
many anti-tumour agents.79

Even slight changes in substituents of anthracyclines have been shown to cause
significant changes in anti-tumor activity. Zhang and co-workers recently developed a
series of seleno epi-daunomycin derivatives.80 The first of these was the 3'-[2(arylseleno)acetamido]epi-daunomycin derivative. This compound was assayed for
cytotoxicity by using cells from human stomach cancer, SGC-7901, and a human
leukaemia, HL60. While this derivative did display cytotoxicity (~100 µg/ml for SGC7901 and HL60, respectively), it was less active than the parent compound with an IC50
value of 51.3 µg/ml.80 Additional analogues were generated by these researchers by
changing the substituents on the aromatic ring attached to the sugar. 80 In these
compounds the seleno substituent was on C5 of the sugar. All these compounds were
less cytotoxic in vitro than the parent compound. A second series of selenotrifluoroethyl compounds was also synthesised. While these were inactive for human
stomach cancer SGC-7901, they did have greater toxicity than daunomycin against
HL60 cells. These are currently undergoing in vivo assays.80
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Despite the vast number of anthracycline analogues synthesised, there has been little
focus on altering the anthraquinone moiety. Fan et al. explored the importance of this by
synthesising analogues with truncated anthraquinone moieties lacking the quinone
functionality.81 These truncated compounds were tested for toxicity against the MCF-7
cancer cell line and it was found that the identity of the carbohydrate had no effect on
toxicity when compared to daunomycin or doxorubicin. The analogues with truncated
cores showed no toxicity, while those with extended cores were more active than the
parent compound.81 The effect of altering the sugar moiety has also been investigated by
substituting with halogens and alkyl groups. 82 Changing the sugar ring has been found
to have a profound effect on biological activity, with these types of analogues having
reduced activity by a factor of several hundred. This demonstrated the importance of the
charged sugar for binding affinity.82

1.4.3 Bleomycins
Bleomycins are used in the treatment of Hodgkin‟s lymphoma, testicular cancer,
squamous cell carcinomas and plantar warts.83 Bleomycin refers to a series of
structurally related glycopeptidic antibiotic compounds produced by the bacterium
Streptomyces verticillus.84 The anti-cancer and anti-viral properties of these compounds
arise from their complexation with ferrous ion triggering free radical formation which
breaks the DNA double helix.83 The chemotherapeutical forms are primarily bleomycin
A2 and B2 (Figure 1.4). There are two domains which have been shown to directly
interact with DNA, one of which instigates DNA cleavage after coordination to iron
(ІІ). The mode of binding of bleomycins remains ambiguous. There are reports of
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partial and full intercalation, a combination of partial and full intercalation, and minor
groove binding.85 Bleomycins have many of the characteristics of minor groove binding
ligands such as aromatic rings with linkages allowing for a crescent-shaped structure,
hydrogen bond donors on the inside edge and at least one positive charge to facilitate
stable complex formation.

Metal binding domain

DNA binding domain

Figure 1.4: Bleomycin A2 and B2.
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1.5 Higher order secondary structures of DNA
1.5.1 Triplex DNA
Triplexes occur when a third strand of DNA binds to the major groove of dsDNA. 86
When these structures are artificially induced during transcription, they are known to
halt the process and therefore reduce mRNA synthesis.87, 88 Formation of triplex DNA
has been shown to be highly specific. For example, Strobel and co-workers showed that
a 16 mer triplex-forming oligonucleotide (TFO) was able to bind to a single 16 bp (base
pair) triplex binding site among 3 × 109 bp of genomic DNA.89 This type of structure
can therefore be used in “anti-gene” strategies, where oligonucleotides are designed to
be artificial gene regulators.90

Such studies have stimulated interest in the potential of triplex-forming oligonucleotides
for parallel therapeutic strategies,7 for treatment of diseases including cancer. This
approach has already been employed by some researchers with promising results. A 20base pyrimidine oligodeoxynucleotide was prepared which forms a specific triplex
sequence at the cytochrome P-450 aromatase coding sequence.7 It was found that levels
of aromatase transcripts (mRNA), and enzyme activity were significantly lower in cells
transfected with the oligodeoxynucleotide when compared to controls.7

Such sequences can be produced in vitro when either purine or pyrimidine-rich
sequences are mixed together in the correct molar ratios under acidic conditions.87 In a
TFO, protonation of N3 of cytosine of the third strand is required for Hoogsteen basepairing with N7 of guanine91 (Figure 1.5). Therefore, this does not readily occur at
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physiological pH without further stabilization of the DNA.89, 91 This limitation has led to
the design of chemical agents that bind the triplex DNA to provide stability to the
structure.88 In order to minimise side effects it would be advantageous if ligands that
bind triplex structures bind less tightly or not at all to duplex DNA. Many of the drugs
currently in use in chemotherapy have already been reported as triple helix binding
agents.90 It is the aim of research in this field to discover the substituents and structural
moieties that make them suitable for binding. These can then be exploited in the
generation of more specific triple helical binding ligands.

Figure 1.5: Protonation of N3 of cytosine of the third strand is required for Hoogsteen basepairing with N7 of guanine to form triplex DNA. 92

1.5.2 Quadruplex DNA
This higher order structure of DNA was identified over forty years ago, but interest in
its possible presence and roles in chromosomes has been increasing. These structures
are assembled from the guanosine residues of up to four different strands of DNA, and
are often, but not in all cases,93 stabilised by a central cation such as K+ or Na+.94-96
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Differences in the type and relative amount of cation can determine whether a
quadruplex is parallel, antiparallel, a dimer, tetramer or other form of secondary
structure.95,

97

There are several different types of quadruplexes which have been

identified. Over the years various terms have been used to encompass the whole range
of these structures, such as „G4‟, „tetraplex‟, and most commonly, quadruplex DNA
(qDNA). They are composed of stacks of core guanine tetrads. There are three main
types of tetrads in vitro, one which is composed of four parallel DNA strands, one
which is made of two DNA strands, and finally one which is composed of one single
strand that is intramolecularly folded.94, 98 Within these types there are further subtypes
defined by the orientation of individual strands (Figure 1.6).

Figure 1.6: Predominant quadruplex DNA subtypes. The direction of the arrows indicates the
direction of the strands. Adapted from Arthanari et al.. 94
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1.5.2.1 Chromosomal location of potential quadruplex-DNA
forming sequences
Guanine-rich

sequences

occur

in

many

chromosomal

locations

including

immunoglobulin switch regions, telomeres and gene promoter regions. 99-101 Telomeric
DNA exists at the ends of most eukaryotic DNA and some prokaryotic DNA.102 These
non-coding sequences of DNA serve to correct for the „end replication problem‟102
whereby the chromosome is not copied by the assembly of replication proteins through
to the end. Telomeric repeats are added independently of normal double-stranded DNA
synthesis and shorten with each round of replication of a normal somatic cell.103 The
RNA coding for telomeric DNA is contained within the telomere-specific reversetranscriptase known as telomerase.102, 104, 105 Somatic cells will lose telomeres with each
round of replication as these have little to no telomerase activity. 104 The shortening of
telomeres to a critical length is a signal for cell senescence and chromosome
instability.106 In contrast, in approximately 90% of tumours, telomerase is activated and
it is believed that the resulting maintenance of telomere length is one factor that leads to
cell immortalisation.104 In the remaining 5-10% of tumours telomere length is
maintained via less well understood pathways known collectively as the alternative
lengthening of telomeres (ALT).107,

108

These observations raise the possibility that

tumours might be specifically targeted by compounds that interfere with telomeric DNA
or telomerase activity. Direct telomerase inhibition would only result in cell senescence
when a sufficient number of replication events had occurred and critical telomere
shortening is reached. With an average telomere length of about 4-5 kb, approximately
20-30 rounds of replication would have to occur before cell senescence would be
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triggered.109 Therefore it has been proposed that therapeutics that act by inhibition of
telomerase would have to be used as an adjunct therapy to other chemotherapeutic
treatment.109

One of the most salient features of telomeres is the sequence conservation from one
eukaryote to another. In eukaryotes the telomeric DNA is double-stranded for most of
its length and contains a short tandem repeat sequence (usually 5-8 bp long).102 This
sequence is almost always guanine-rich on the 3′ end and cytosine-rich in the
complementary strand, with the G-rich strand extending 100-200 nucleotides beyond
the C-rich strand.105,

109, 110

There are a few exceptions, most notably Drosophila

melanogaster which does not have conventional telomeres. 111 There is now
overwhelming evidence that these largely conserved features serve as more than just a
solution to the end replication problem. This conservation may be due to the ability of
such sequences to adopt conformations known as G-quartets which can stack to form
quadruplexes.94,

112

Telomeres have been implicated in chromosome association and

organization within the nucleus94 and in recognition sites for specific regulatory
proteins109 which act on these regions.

Quadruplex structures are also thought to be present in other parts of the genome.
Putative quadruplex-forming sequences have been identified in a number of nontelomeric genes and genomic sequences.113 Among these is the c-myc oncogene which
is one of the most commonly malfunctioning genes in human cancers. 109 In vitro, the
sequence forms an intrastrand fold-back DNA quadruplex which requires potassium ion
for stability. The major control element of the c-myc oncogene is the nuclease
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hypersensitive element ІІІ1 (NHE). Transcription of c-myc can be blocked with a
synthetic oligonucleotide targeting this site. Primer extension experiments demonstrated
that there was an extremely stable potassium-dependant compact structure causing DNA
synthesis arrest. Gel electrophoresis experiments were then used to characterise the
structure as an intramolecular DNA quadruplex.112

1.5.2.2 Proposed roles of quadruplex DNA in transcription and
replication
In recent years, there have been many proposed roles for quadruplex DNA including
involvement in replication, transcription, recombination and telomeric DNAs. There is
now evidence which suggests that the transient formation of these structures leads to
errors in many biological processes.102 Quadruplex DNA is also believed to contribute
to the regulation of telomere length in vivo.106 This may be either through direct
telomerase inhibition or by alteration of the dissociation rate of telomeric primers from
telomerase. Telomerase is also present in some mitotic stem cells from normal epithelia,
at low levels in human white blood cells and is upregulated during mitogenic
stimulation of normal T-lymphocytes.114

In Oxytricha nova (a ciliated protozoan) a heterodimeric protein which binds
specifically to the single-stranded overhangs of the DNA terminus forms a “telosome”
that effectively caps and protects the chromosome. 115 The β subunit of the Oxytricha
telomere-binding protein is present in a free, non-dimerised form during stages of
telomere synthesis and has been shown to greatly increase quadruplex DNA formation
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at nanomolar concentrations in vitro. This was found to be true whether the DNA
preceding the telomeric repeats was single- or double-stranded. This means that, in
Oxytricha at least, telomeric ends are potentially free for quadruplex DNA formation
during replication and telomere elongation.115

Other proteins have since been identified which also bind to quadruplex DNA with even
greater affinity. Defects in these proteins can lead to errors in replication, transcription,
recombination and also increase the rate of aging and tumour formation. Both Bloom‟s
and Werner‟s syndromes are caused by defects in RecQ helicase proteins which are a
family of helicase enzymes important in maintenance of the genome. Bloom‟s
syndrome is caused by a defect in the BLM gene, while Werner‟s syndrome is caused
by defects in the WRN gene, both of which have activity in the ATP dependant
unwinding of quadruplex DNA.116, 117 The functions of these proteins in vivo, however,
are not yet fully understood. It has been shown in vitro that they can take part in the
assembly of replication forks, DNA repair, and recombination both in E. coli and
humans.118-121

Additionally, there are instances where the presence of quadruplex DNA may be
required to activate transcription. The human insulin minisatellite of the insulin-linked
polymorphic region (ILPR) contains a G-rich strand which adopts an intramolecularly
folded hairpin G-quartet structure in vitro. Catasti et al. have shown that single or
double mutations in the ILPR which destabilise the formation of quadruplex DNA result
in lower transcriptional activity of the insulin gene. 122 Furthermore, a locus for insulindependant diabetes mellitus (IDDM) has been mapped to ILPR.123 The presence of
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potassium was also found to activate transcription, lending credence to the need for
formation of quadruplex DNA to facilitate transcription.122 It has also been shown that
ILPR is polymorphic in length and that this is directly related to the transcriptional
activity of the insulin gene and IDDM.124

1.5.2.3 QDNA binding ligands
In addition to understanding the different forms of quadruplex DNA structures formed
by telomeric and genomic sequences, it is of interest to characterise the types of
interactions involved in qDNA-ligand interactions. Ligands that selectively bind to and
stabilise qDNA over dsDNA may interfere with telomeric conformation and therefore
inhibit telomerase action and telomere elongation.94 Additionally, by stabilizing the
quadruplex structure, the levels of gene expression might be altered as unwinding of the
quadruplex is inhibited.113 There are numerous reports of ligands that bind to qDNA in
vitro.125-144 Since G-quadruplexes differ in loop length, sequence and groove size to
dsDNA, this provides different chemical functional groups and topology that can be
targeted for molecular recognition. Greater understanding of these specific binding
interactions can lead to development of principles for rational design of quadruplex
DNA-specific ligands.

In general, it has been shown that drugs that bind to quadruplex DNA tend to feature structures
that can mimic the G-quartet, such as those containing a large flat aromatic surface and cationic
charges.145 Molecules can stack externally into the end of the G-tetrads (tetrad mimics), or
intercalate between them. 146 The first generation of qDNA binders included anthraquinones 147,
148

and acridines,149 and later, porphyrins.150 Other types of ligands which have been found to be
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effective qDNA binders include perylene derivatives such as the extensively studied PIPER, 151
metal complexes, 152 and macrocycles based on oxazole,153 quinoline154 and quinacridine.155 The
first of these compounds was a 2,6-diamidoanthraquinone. Using NMR spectroscopy Sun et al.
found that this compound bound using an intercalative mode to bind to the parallel fourstranded quadruplex d(T 2AG3T)4.148

One of the most interesting of these compounds is BRACO19 ( 9-[4-(dimethylamino)
phenylamino]-3,6-bis(3-pyrrolidinopropionamido)acridine) (Figure 1.7 (A)), which was
synthesised by Neidle and coworkers.156 This „second generation‟ qDNA binding
compound was designed using computer modeling to optimise interactions with qDNA.
BRACO19 has been shown to be a potent telomerase inhibitor and inhibits tumor
growth both in vivo and in vitro at concentrations < 1 μM.156 Additionally, a series of
tri-substituted acridine-peptide conjugates has been synthesised which showed a tenfold preference for qDNA over dsDNA using surface plasmon resonance.142 There has
also been a large number of porphyrin compounds that have been screened for their
ability to bind to G-quadruplex DNA. Overall, these studies have shown that the charge,
the lengths of side-chains, and presence of hydrogen bonding substituents play a role in
the overall ability of the compounds to interact with qDNA.148 NMR and CD
spectroscopy have been used to show that the porphyrin TMPyP4 [tetra-(N-methyl-4pyridyl)-porphine] (Figure 1.7 (B)) is able to bind to both parallel and anti-parallel
qDNA.125, 157 TMPyP4 was also shown to be able to inhibit telomerase activity.125, 157

Some natural compounds have also been found to be qDNA binding agents.
Telomestatin (Figure 1.7 (C); discussed further in section 5.3.2.2) is a strong qDNA
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binder and also inhibits telomerase activity with high efficiency. 158 Berberine is an
antibiotic alkaloid whose anticancer abilities have been linked to down-regulation of
telomerase activity and subsequently its ability bind to qDNA. 159 The DNA-binding
abilities of berberine and other activities are discussed extensively in section 4.1 and
throughout later chapters of this thesis. The observations of the activities of berberine
have led to the synthesis of many derivatives based on this structure. 137, 144, 160-164

(A)

(B)

(C)

Figure 1.7: Structure of the G-quadruplex DNA binding compounds: (A) BRACO19, (B)
TMPyP4 and (C) telomestatin.

Daunomycin binds both triplex and quadruplex DNA sequences. Clark et al. produced
the first crystal structure of a ligand binding to qDNA.165 They were able to resolve the
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crystal structure of daunomycin binding to the quadruplex-forming sequence
d(TGGGGT).165 It was found that three binding sites exist for daunomycin in this
sequence and that the drug is involved in weak π-π interactions with the guanines in the
terminal tetrad of this parallel qDNA (Figure 1.8). The molecules are able to form
hydrogen bonds between the exocyclic OH groups and the phosphate oxygens on the
sides of the quadruplex. This structure shows that daunomycin prefers to stack onto a
terminal G-quartet rather than intercalate between the layers of the quadruplex.165 A
crystal structure has also been determined for a di-substituted aminoalkylamido acridine
compound

and

the

dimeric

antiparallel

qDNA-forming

sequence

d(GGGGTTTTGGGG).166 This crystal structure revealed that the acridine moiety is
bound at the ends of stacked G-tetrads, held in place by stacking interactions and
specific hydrogen bonds with thymine loops.

Figure 1.8: Structure of daunomycin bound to the quadruplex forming DNA sequence
d(TGGGGT). The arrangement of two quadruplexes crystal lattice in van der Waals spacefilling mode, and stacked end to end. The daunomycin molecules are shown in green ball-andstick. Several thymine residues have been removed to enhance clarity. Taken from Clark et
al..167
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Ligands that might have applications either as agents to specifically stain folded qDNA
in the laboratory (e.g. in situ in gels), in cultured cells or in development of anti-cancer
drugs need to have selectivity for qDNA structures over dsDNA.

1.6 Methods for investigating DNA-ligand complexes
The structure, binding specificity, and dynamics of DNA complexed to small molecules
is of great importance in understanding the nature of interactions of drugs with DNA.
Many different physiochemical and biochemical techniques have been used to study the
structures and sequence selectivity of these drugs with different sequences of DNA. 168
This section describes some of these methods. Particular attention is paid to
investigation of ligands that bind qDNA.

1.6.1 Surface Plasmon Resonance
Surface plasmon resonance (SPR) is a technique which can be used to observe the
interactions between a biomolecule and ligand. 169 SPR occurs at the interface between
two substances which have different refractive indexes. If an incident light beam travels
through the medium of higher refractive index, and reaches the interface at an angle
greater than a critical angle, the light will be completely reflected and will travel back
through the higher refractive index medium.170 The biomolecule being tested is
biotinlyated and immobilized onto the gold surface of a streptavidin-coated SPR chip.169
A buffer solution containing the ligand whose binding is being tested is then passed
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over the immobilised biomolecule to allow binding. This process is outlined in Figure
1.9.

Figure 1.9: Experimental set-up for surface plasmon resonance. Adapted from Gensch, T.171

When a binding interaction occurs between the immobilized biomolecule and the ligand
in solution, the increased concentration of ligand on the surface of the chip causes
localized increases in the refractive index near the sensor surface. 172 This in turn causes
a change in the SPR angle of incidence which results in a change in the angle at which
minimum light reflection is detected. The output is a sensorgram (example shown in
Figure 1.10), in which the resonance signal (proportional to the change of the SPR angle
and thus the degree of interaction) is plotted against time.170 After equilibrium between
the biomolecule and ligand is reached, a solution without ligand is applied, and a new
equilibrium will be reached. With this information, the 'on rate', v on, and 'off rate', voff,
can be determined and binding constants can be calculated.172
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Figure 1.10: Example of SPR sensorgrams. The traces represent simulated SPR recordings
showing an increase in responce units (RU) when two binding partners associate and a decrease
when they dissociate. Adapted from Gensch.173

There are numerous reports of this technique in use for the detection of the interactions
between dsDNA and small molecules, as well as more recent reports investigating the
interactions of quadruplex DNA and ligands. The binding affinities of the intercalator
ditercalinium to different DNAs have been studied using SPR by Gabelica et al.. It was
proposed that the ligand displays different binding modes depending on the type of
DNA to which it is bound.130 In B-DNA the compound binds at GC-rich sequences;174
for the sequence d(GCGC)2 it binds using a combination of both intercalation and endon stacking,175 and finally, it has also been suggested that this compound is able to
stabilise A-DNA type structures.176 These experiments revealed a high affinity for the
two

double-stranded

DNA

sequences

d[CGAATTCGTCTCCGAATTCG]

and

d[CGCGCGCGTTTTCGCGCGCG] (only one strand of each shown) as well as the
human telomeric sequence, with affinity constants ≥ 107 M-1.130 Binding to qDNA was
much stronger than for dsDNA and results required fitting with a nonequivalent two-site
binding model. The first binding constant, K1, at 3 x 107 M-1, was roughly ten times
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larger than the second binding constant. The nonequivalence of the two sites determined
by SPR is in agreement with studies on other quadruplex-binding compounds.177 This
technique has been used to quantitatively determine the association and dissociation
rates of other intercalating agents such as actinomycin D for a number of different
duplex sequences.178

SPR has also been used to determine the strength of binding of a phenylfuranbenzimidazole unfused aromatic dication, DB293, to numerous hairpin sequences.179
The control stem of the hairpin sequences used was CTATGAC. Changes in the G base
in the otherwise AT-rich sequence to either A, T, or C was found to reduce binding
affinity. This is very unusual and represents the first dimeric minor groove binder which
will strongly bind to GC base pairs and suggests a non-classical minor groove binding
mode. K2 values (association constant) for all but one sequence were higher than K1
values indicating that DB293 exhibits positive cooperative binding at AT sites. As
mentioned in section 1.4.1, SPR has also been used to investigate the binding affinities
of minor groove binders such as the ethidium derivative DB950. 51

1.6.2 Circular Dichroism
Circular dichroism (CD) is a relatively simple technique which is based on the
differential absorption of left- and right-handed circularly polarised light.180 The CD
spectra for the distinct types of secondary structures present in peptides, proteins and
nucleic acids are different.180 Thus, the analysis of these spectra can yield valuable
information about secondary structure of biological macromolecules. Common
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applications of this technique include detecting changes in B-DNA and Z-DNA,
characterisation of secondary structure, and analysis of interactions with small
molecules. For example, for the most common B-form of DNA, the CD spectrum
contains a negative band at approximately 240 nm and two intense positive bands at
approximately 275 and 180-190 nm. The CD-spectrum of Z-DNA however, displays
negative bands at 290 nm and between 190-200 nm and a positive band at 260 nm
allowing it to be readily distinguishable from B-DNA.180 This information can then be
used to observe the transition of this DNA into one of the other forms of DNA.

The amount and type of binding of a ligand to a biomolecule, such as a drug to DNA,
can also be observed using this technique. A CD spectrum is acquired of the DNA alone
and then again after it has been titrated and allowed to equilibrate with the ligand in
question.82, 85, 181, 182 Following this, comparisons can be made to determine the extent of
drug binding. Furthermore, by monitoring changes in the CD spectrum of DNA caused
by addition of increasing amounts of small molecules, it is possible to obtain additional
information about the DNA binding mode of the ligands.180 It is now generally accepted
that classical intercalation of small molecules into B-DNA results in an increase in the
ellipticity (intensity) of the CD signals at 275 nm and 240 nm due to strengthening of
base stacking interactions and stabilisation of the right-handed helical conformation. In
contrast, minor groove binding does not cause much perturbation of the base-stacking
and therefore has little effect on the ellipticity of the CD bands. 183 Finally, if there is a
change in intensity of the CD signal upon addition of a ligand, but the shape of the
spectrum remains the same, then it can be concluded that the mode of binding does not
change the shape of the DNA.180
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1.6.3 Electrospray ionisation mass spectrometry
Mass spectrometry can provide important information on the stoichiometry, and
sometimes the strength of binding of drug-DNA complexes. Once appropriate
conditions for particular complexes are established this sensitive technique can be used
in high-throughput procedures. In 1991 Ganem et al.184 showed that it was possible to
observe non-covalent complexes via electrospray ionization mass spectrometry (ESIMS), and shortly thereafter intact DNA duplexes were being observed.184 This was
rapidly followed by the observation of dsDNA-ligand interactions via mass
spectrometry.185 In ESI-MS, the sample is passed through a capillary tube with a weak
flux and nebulised using nitrogen gas.186 The droplets containing the analyte experience
an electric field applied under atmospheric pressure.186 This causes a build up of charge
at the liquid surface (the end of the capillary). The analyte is sprayed from the capillary
within the charged droplets. As the droplets evaporate, the repulsion of charges causes
smaller and smaller droplets to be produced which explode to form smaller droplets
which undergo further evaporation until there is only one charged molecule present in
each droplet.187 This process is outlined in Figure 1.11.

Counter
electrode
Sample
solution

Electrospray
capillary

MS analyzer

Atmospheric
pressure

High vacuum
Pressure gradient

Figure 1.11: Essential features of the electrospray interface. Adapted from Gaskell.187
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Initial concerns that complexes formed were non-specific, were addressed by Ding and
Anderegg in 1995.188 They compared the ratios of dsDNA formed by two
complementary DNA strands and two non-complementary strands at

high

concentrations, effectively investigating a specific and non-specific complex. ESI mass
spectra were acquired and the results compared to those predicted had there been no
specific interactions present. It was found that non-specific dsDNA ions were formed at
the expected abundances for random associations while the complementary strands far
exceeded this. This suggested that they were indeed observing a specific non-covalent
complex in the gas phase.188,

189

Additionally, it was shown that the non-specific

aggregations from random associations of non-complementary strands can be avoided
by using low concentrations (approximately < 100 µM).188

Recently there have been numerous studies which have used ESI-MS to study the nature
of dsDNA-drug complexes.189 Kapur et al. in our laboratory observed non-covalent
intercalative drug-dsDNA complexes.190 Complexes of nogalamycin and daunomycin
with 12 mer and 16 mer DNA were observed. By varying the ratios of drug to duplexDNA, and observing the resulting spectra, the complexation numbers of the drugs were
determined. Gabelica and co-workers have also examined the interactions between
different forms and sequences of dsDNA with anti-tumour agents.191 Competition
experiments were carried out to determine the relative binding affinities of the minor
groove binding and intercalating drugs which were studied. 191 These experiments
provided information regarding stoichiometry and affinity of particular drug-DNA
complexes. These experiments and others suggested that a rapid drug screening method
based on ESI-MS could be developed.183, 191 Gross and co-workers have previously used
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ESI-MS to examine the binding affinity of a large number of compounds to various
sequences of double-stranded DNA. The binding specificities of well known minor
groove binders (e.g. Hoechst 33258 and distamycin) and a number of compounds that
bind via mixed binding modes (e.g. porphyrin H2TMpyP-4 and metalloporphyrin
CuTMpyP-4) were studied. They were able to show that the minor groove binders
retained their preference for AT rich sequences.192

More recently, Brodbelt and co-workers have used ESI-MS to investigate the binding
preferences of a perylene diimide and benzannulated perylene diimide ligand to
quadruplex DNA.193 Using a combination of ESI-MS and solution spectroscopic
techniques (such as fluorescence spectroscopy and resonance light scattering), they
determined that all except one of the compounds will bind to quadruplex DNAs.193
These experiments and others involving ESI-MS of quadruplex DNA are described in
Chapter 5. Overall, these studies highlight the usefulness of this (potentially) highthroughput technique when determining sequence selectivity of DNA binding
molecules.

Whether the helical structure of dsDNA is retained in the gas phase is also being
addressed. Ion mobility MS experiments (see section 1.6.4 below) of Bowers and coworkers were consistent with the presence of the helical structure of dsDNA in the
solvent free environment of an ESI mass spectrometer.194 Theoretical collision crosssection models were generated using molecular dynamics simulations and compared to
those of dsDNA ions generated by ESI-MS. In the cases of 10 mer and longer
sequences, only structures consistent with a double helix were observed.194 This
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observation correlates well with the increased stability of dsDNA that is observed in
solution as the length of the strand increases.

1.6.4 Ion mobility mass spectrometry
Ion mobility mass spectrometry is a technique which adds another dimension to
traditional mass spectrometry. In drift time ion mobility MS, ions are separated based
on their drift through an inert gas under the influence of a constant electric field. The
separation they experience will depend on their size, collisional cross section, and the
charge on the ion. Therefore it becomes conceptually possible to separate different
conformations of ions with the same mass-to-charge ratio. In recent years, ESI-MS has
been combined with ion mobility and has been applied to biomolecules.195-197 There are
a number of different types of ion mobility mass spectrometers including ambientpressure ion mobility spectrometry (APIMS), reduced-pressure ion mobility
spectrometry (RPIMS), aspiration ion mobility spectrometry (AIMS), field-asymmetric
ion mobility spectrometry (FAIMS), differential-mobility spectrometry (DMS), and
travelling-wave ion mobility spectrometry (TWIMS).198

TWIMS is the most recent of these and is now available in a commercial instrument.
The Waters HDMSTM SynaptTM, (Figure 1.12), consists of a quadrupole time-of-flight
(Q-TOF) mass analyser with a TWIMS ion mobility cell between the quadrupole and
TOF mass analyser.199 This new instrumentation facilitates the ion mobility mass
spectrometry of biomolecules.200 The ions are directed by the “T-wave” ion guide first
into the quadrupole and then into the ion mobility cell. The ions are injected the ion
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mobility (IM) cell which contains argon gas and comprises the trap, ion mobility
spectrometry and transfer regions. Here, the ions are pushed through under the influence
of a travelling wave. The IM section comprises three travelling wave-enabled stacked
ring ion guides. The trap ion guide accumulates ions and then releases a packet of ions
for separation into the IM ion guide for mobility separation. 200 Collisions with this gas
also causes a broadening of the injected ion packet and helps to separate the ions based
on the number of collisions with the gas. 198 Finally, the transfer ion guide delivers the
mobility separated ions into the TOF mass analyser.

Figure 1.12: Schematic of the essential features of the Waters HDMS TM SynaptTM. Adapted
from the web page „Synapt High Definition Mass Spectrometer‟.199

At present there are very few reports on investigation of non-covalent biomolecular
complexes using the TWIMS instrumentation. Pringle et al. have used a travelling wave
ion mobility mass spectrometer to separate peptides and proteins.200 They were able to
show that the instrument allows the investigation of large multiply charged proteins.
Additionally they were able to examine the energetics behind conformational changes
by changing collisional activation energies. They also claimed that as an advantage over
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other ion mobility mass spectrometers the sensitivity of the TWIMS is not compromised
when operating in mobility mode because of the use of ion accumulation and radial ion
confinement. They also commented, however, that the resolving power of this
instrument is lower than that exhibited by some of the drift tube systems.

1.7 Scope of this thesis
In this work ESI-MS was used to screen the binding of berberine derivatives to ds- and
qDNA and to determine whether there was any selectivity for one type of secondary
structure over another. While ESI-MS has been recently used in our laboratory and
others to examine qDNA-ligand interactions, there is some question as to whether the
quadruplex fold is maintained in the gas phase. This is particularly important for
quadruplex folds involving a single-strand of DNA. In Chapter 3 circular dichroism was
used to confirm that qDNA was present in solution for each of the qDNA sequences,
Q4, Q1 and Q2. ESI ion mobility mass spectra of the qDNA under gentle conditions
were compared with those acquired under solution and instrument conditions where the
qDNA was expected to be less stable. Comparison of the ion mobility profile („Drift
scope”) showed the appearance of new ions with different mobilities under these
conditions suggesting that folded DNA was present under the original more gentle
conditions.

Chapter 4 describes improvements to synthetic methods used for the synthesis of the
berberine derivative oSS14 as well as the synthesis of the novel compound KG01.
Additionally, the purification of the compounds mSS14 and pSS14 in preparation for
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ESI-MS studies is presented. The other berberine derivatives used were BT80 and
SS104 which were kindly supplied by Dr. Siritron Samosorn.

In Chapter 5 the relative binding affinities of eight compounds, berberine, oSS14,
mSS14, pSS14, KG01, BT80, SS104 and daunomycin was determined using ESI-MS.
The results of these studies were also compared to those obtained by other researchers
using similar DNA sequences and ligands where possible. This study was conducted in
order to determine what effect, if any, changing the location of the indole moiety and
identity of the linker would have on the binding interactions of these types of berberine
derivatives with dsDNA and qDNA, and to determine whether any of these compounds
were selective for qDNA over dsDNA.
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Chapter 2: Materials and Methods
2.1 Materials
Reagents were of the highest grade commercially available. MilliQTM water from
Millipore (Bedford, USA), was used in all experiments. Acetic acid, acetonitrile,
methanol, ammonia, and ammonium acetate (NH4OAc) used in HPLC purification of
oligonucleotides and ESI-MS experiments were purchased from Ajax Finechem (Seven
Hills, Australia).

2.2 Oligonucleotides
Oligonucleotides

were

obtained

from

Geneworks

(South

Australia).

All

oligonucleotides were PCR grade and obtained as „trityl off‟ derivatives. The sequences
and their calculated masses are listed in Table 2.1.

2.2.1 HPLC purification of oligonucleotides
Dried single DNA strands were redissolved in (1 ml) 0.01 M ammonium acetate
(NH4OAc), and purified by HPLC using a Waters 1525 Binary HPLC pump with a
Rheodyne injector. A C18 octadecylsilyl column (8 x 100 mm Waters Delta Pak Radial
Cartridge) was used in all purifications. The column was equilibrated with 0.01 M
NH4OAc and the DNA was eluted using a linear gradient of 0% to 60% acetonitrile in
0.01 M NH4OAc over 35 minutes at a flow rate of 1 ml.min-1. The peaks corresponding
to the ssDNA were collected, combined and then freeze dried using a Savant Speed Vac
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(Selby-Biolab, Australia). The dried ssDNA was then redissolved in MilliQTM water
giving concentrations of the stock in the range 0.3-1.0 mM. The redissolved DNA was
then stored at -20 C.

Table 2.1: List of the DNA sequences used in this projecta
Annealed
sequence
name

Name
of
ssDNA

Base sequence
(5'- 3')

Mass
(Da)

No.
Bases

D1a

CCTCTCTGGACCTTCC

4744.1

16

D1b

GGAAGGTCCAGAGAGG

5020.3

16

D2a

GCTGCCAAATACCTCC

4786.2

16

D2

D2b

GGAGGTATTTGGCAGC

4977.3

16

F10A

F10A1

TGCTCGGACGAAAAAAAAAA

6145.1

20

F10A2

AAAAAAAAAACGTCCGAGCA

6176.1

20

Q4

Q4

TTGGGGGT

2496.7

8

Q1

Q1

GGG(TTAGGG)3

6653.3

21

Q2

Q2

GGGGTTTTGGGG

3788.5

12

D1

a

Masses of oligonucleotides were calculated using Mongo Oligonucleotide Mass Calculator:
http://library.med.utah.edu/masspec/mongo.htm

2.2.2 Determination of oligonucleotide concentration
DNA concentrations were determined from the UV absorbance at 260 nm. The molar
absorption coefficient of each sequence was obtained from the website Oligonucleotide
Properties

calculator

(http://www.basic.northwestern.edu/biotools/oligocalc.html).

These are listed in Table 2.2.
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Table 2.2: List of absorption coefficients for ssDNA sequences used in this study
Sequence
name

Absorption coefficient
(M-1 cm-1)

D1a

137,620

D1b

194,580

D2a

159,370

D2b

177,370

F10A1

222,030

F10A2

253,190

Q4

85,250

Q1

240,120

Q2

129,680

2.2.3 Preparation of double-stranded DNA
Appropriate volumes of D1a and D1b, D2a and D2b, or F10A1 and F10A2, were mixed
together and dried down using a Savant SpeedVac. The dried DNA was redissolved in
sufficient 0.1 M NH4OAc†, pH 7, to give 1 mM stock solutions of the DNA. The DNA
strands were annealed by heating to 70˚C for 15 min and then allowed to cool slowly to
room temperature overnight then stored at 5°C.

†

Ammonium acetate (NH4OAc) was made up to 0.1 M and adjusted (from pH 6.8) to pH 7.0 using
ammonium hydroxide solution.
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2.2.4 Preparation of quadruplex DNA
The sequences Q1, Q2 and Q4 favour formation of quadruplex DNA.93 An appropriate
volume of each DNA sequence was freeze-dried, redissolved in 0.15 M NH4OAc, pH 7,
to give a concentration of 1 mM for quadruplex DNA, and then heated to 95°C for 15
minutes. The solutions were then allowed to slowly cool to room temperature and stored
at 5°C.

2.3 General synthetic chemistry methods
Since several new synthetic or purification methods were developed during this project,
the description of the method development appears in Chapter 4. General methods and
final purification details are described here.

The novel compounds oSS14, mSS14, pSS14, SS104, KG01 and BT80 used in this
study are shown later in Figure 4.1. Berberine chloride, daunomycin hydrochloride and
2-bromomethylnaphthalene (starting material for KG01) were purchased from SigmaAldrich (USA). The compounds mSS14 and pSS14 were a kind gift from Dr. Michael
Kelso (School of Chemistry, University of Wollongong, Australia) and the synthetic
methods have been reported elsewhere.201 Modified purification methods for these two
compounds and oSS14 were developed in this work and the method development is
described in detail in section 4.4. The final methods used are detailed in section 2.3.1.

The compounds BT80 and SS104 were a gift from Dr. Siritron Samosorn (Department
of Chemistry, Srinakharinwirot University, Thailand) and the synthetic methods have
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been reported elsewhere.162 The compound oSS14 was originally synthesised by
Samosorn et al..202 The oSS14 used in this work however, was re-synthesised using a
modified synthetic scheme (details in section 4.3). The novel compound KG01 was
synthesised for the purpose of this study. The development of the method is described in
section 4.3 and the final synthetic method is detailed in section 4.5.3.

Reagents were used as received from commercial suppliers without further purification.
Tetrahydrofuran (THF) and diethyl ether were distilled from sodium with benzophenone
indicator. Acetonitrile and dichloromethane (DCM) were dried with anhydrous sodium
sulfate and removed under reduced pressure (in vacuo) by a Büchi rotary evaporator
before use.

Reaction monitoring by thin layer chromatography (TLC) was carried out using Merck
Silica Gel 60 F254 (0.2 mm) plates. Compounds were visualized by examination under
UV light and by staining with cerium ammonium molybdate. Unless otherwise stated all
semi-preparative HPLC purification was performed using gradient elutions (30%
solvent B to 100% solvent B over 30 mins) with solvents A (100% H 2O) and B (10%
H2O, 90% CH3CN, 0.1% HCl), run at 10 ml.min-1. For all compounds synthesised
(oSS14, KG01) reaction monitoring and testing purity (mSS14, pSS14) of final products
was carried out by analytical RP-HPLC using a Waters 600 chromatography system
fitted with a Waters tunable 486 UV-Vis detector. The separations were performed
using gradient elutions (30% solvent B to 100% solvent B over 30 min) with solvents A
(100% H2O, 0.1% HCl) and B (10% H2O, 90% CH3CN, 0.1% HCl) on a Phenomenex
C18 4.6 x 150 mm (5 m) column run at 1.0 ml.min-1. This gave ≥ 98% purity for each
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compound. High resolution ESI mass spectra were obtained using a Waters ESI QToF
UltimaTM mass spectrometer. NMR spectra were recorded at 299.92 and 75.42 MHz
with a Varian Unity-300 spectrometer and at 499.91 and 125.71 MHz with a Varian
Inova-500 spectrometer.

2.3.1 Purification of mSS14 and pSS14
The compounds mSS14 and pSS14 provided by Dr Kelso required additional
purification before ESI-MS experiments (see section 4.4 for method development).
Semi-preparative HPLC using gradient elutions (30% solvent B to 100% solvent B over
30 mins) with solvents A (100% H2O) and B (10% H2O, 90% CH3CN), run at 10
ml.min-1. The retention times for mSS14 and pSS14 respectively, were tR = 15.9 mins
and 15.0 mins. This gave ≥ 98% purity for each compound.

2.3.2 Preparation of drug stock solutions
Stock solutions (1 mM) of daunomycin, berberine, oSS14, mSS14, pSS14, BT80,
SS104 and KG01 were prepared by dissolving the compounds in 40:60 0.1 M
NH4OAc:MeOH to aid in solubilisation. These solutions were stored at -20°C.
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2.4 Mass spectrometry
2.4.1 ESI Mass spectrometer conditions
All ESI mass spectra (except for ion mobility experiments) were obtained using a
Waters Q-TOF UltimaTM ESI mass spectrometer (Manchester, UK). Different
conditions were required to give optimal spectra for each type of DNA structure. Table
2.3 lists the parameters that were varied for each of the different DNA types. Unless
otherwise stated all spectra were obtained in the negative ion mode. The instrument
was calibrated using 1 mg/ml caesium iodide in 70% isopropanol. Samples were
injected at a flow rate of 20 µl/min with a Harvard Model 22 syringe pump (Natick,
USA). In all experiments the capillary voltage (2.5 kV), collision energy (4 V), cone gas
flow (0.0021 l/h), and TOF (9.1 kV), remained the same.

Table 2.3: ESI-MS parameters used for each of the different DNA structures investigated.
Parameter

DsDNA

Q1

Q2

Q4

Cone voltage (V)

100

80

100

150

Desolvation temperature (˚C)

100

100

100

200

RF lens (V)

70

70

45

70

Desolvation gas flow (l/Hr)

50

150

150

150

In some experiments, the stabilities of various drug-DNA complexes were tested by
changing these conditions. The changes made (e.g. cone voltage and desolvation
temperature) are described in the relevant sections of the text.
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2.4.2 ESI-IMMS conditions
Ion mobility mass spectra were acquired using a Waters HDMSTM SynaptTM ESI-IM
mass spectrometer (Manchester, UK). Samples were injected into the source of the mass
spectrometer using a Harvard model 22 syringe pump (Natick, MA, USA) at a flow rate
of 5 μl/min. The instrument was calibrated using caesium iodide (1 mg/ml) over the
same mass range used to acquire spectra. Table 2.4 lists the different parameters used in
order to obtain optimal spectra for the three different types of quadruplex DNA
molecules investigated in this thesis.

Table 2.4: ESI-IMMS conditions used for the analysis of all quadruplex DNAs.
MS Parameter

Values

MS Parameter

Values

Scan time (sec)

3.9

Trap DC bias (V)

28

Scans in driftscope function

200

Trap DC exit (V)

5

Trap pressure (millibar)

2.04e-2

IMS DC entrance (V)

5

IMS pressure (millibar)

4.86e-1

IMS DC exit (V)

2

TOF pressure (millibar)

1.30e-6

Transfer DC entrance (V)

2

Capillary (V)

2100

Transfer DC exit

2

Sampling cone (V)

40

Source wave velocity (m/s)

300

Desolvation temperature (oC)

150

Source wave height (V)

0.2

Trap collision energy (V)

6

Trap wave velocity (m/s)

300

Transfer collision energy (V)

4

Trap wave height (V)

8

IMS gas flow (ml/min)

24

IMS wave velocity (m/s)

350

Trap DC entrance (V)

5

IMS wave height (V)

8

Transfer wave height (V)

3

Transfer wave velocity (m/s)

248
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In some experiments the stability of the DNA was tested by changing solution or
instrument conditions. These are described in detail in the relevant sections of the text.

Tandem mass spectrometry experiments (ESI-MS/MS) were used to examine the
stabilities of Q1, Q2 and Q4. For tandem mass spectra, the collision energy was varied
over the range 2 – 16 V.

2.4.3 Titration of DNA with ligands
Previous experiments in this laboratory showed that small molecules (ligands, drugs)
equilibrated with DNA on mixing.203 The dsDNA sequences D1, D2, and F10 were
titrated with daunomycin, berberine, oSS14, mSS14, pSS14, BT80, SS104 and KG01.
Stock 1 mM solutions of all drugs and annealed dsDNAs were prepared in 0.1 M
NH4OAc, pH 7. Appropriate volumes of stock solutions were prepared to give DNA:
ligand mixtures of 1:1, 1:3, 1:6, and 1:9. This gave final concentrations of dsDNA of 20
µM, and drug concentrations of 20, 60, 120, and 180 µM, respectively (see Table 2.5).
These solutions were equilibrated for 15 min and then diluted two-fold with 100 µl of
0.1 M NH4OAc, pH 7, prior to ESI-MS analysis.

For titrations of the DNA quadruplex sequences Q1, Q2 and Q4, the same method was
used, except for the solvent. An appropriate volume of drug (Table 2.5) was freezedried and then redissolved in 0.15 M NH4OAc at pH 7. Appropriate volumes of
annealed DNA, as outlined in Table 2.5, were then added to give DNA: ligand mixtures
of 1:1, 1:3, 1:6, and 1:9.
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Table 2.5: Volumes of stock solution required to make DNA: drug mixtures in the ratios 1:1,
1:3, 1:6, and 1:9.
0.1a or 0.15b M
Ratio of DNA: drug

1 mM DNA (µl)

1 mM ligand (µl)
NH4OAc, pH 7 (µl)

a

1:1

2

2

96

1:3

2

6

92

1:6

2

12

86

1:9

2

18

80

For experiments using dsDNA, b for experiments using qDNA.

2.5 Circular

dichroism

spectra of

DNA

and DNA-ligand

mixtures
CD spectra (200 – 320 nm) were obtained using a Jasco J-810 spectropolarimeter and a
0.1 cm pathlength quartz cell. For experiments involving dsDNA, a CD spectrum was
initially obtained using a solution of 20 µM dsDNA in 100 mM NH4OAc, pH 7, at
25°C. When acquiring spectra the sensitivity was set to standard, data pitch was 0.1 nm,
scanning mode was continuous, scanning speed was 100 mm/min, response was 4
seconds, bandwidth 1 nm, and accumulation was set to 6 scans. For experiments
involving qDNA, CD spectra were obtained using a solution of 10 µM qDNA in 150
mM NH4OAc, pH 7, at 25°C. In some experiments the stability of the DNA was tested
by changing solution or instrument conditions. These are described in detail in the
relevant sections of the text.

For analysis of dsDNA-ligand mixtures, aliquots of stock solutions (0.5 mM ligand; 20
µM dsDNA) in 100 mM NH4OAc, pH 7, were added to give reaction mixtures
containing 1:1, 1:2, 1:4, 1:6, 1:8, 1:10, 1:12, 1:14 and 1:16 ratios of dsDNA to ligand.
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All solutions were allowed to stand for 10 min at room temperature prior to CD spectra
being obtained. Experiments involving quadruplex DNAs were performed in a similar
fashion using reaction mixtures containing DNA: ligand ratios of 1:1, 1:4 1:8, 1:12,
1:16, 1:20, 1:24, and 1:28. In these cases, the solvent used was 150 mM NH4OAc, pH 7,
and the concentration of the DNA was 10 µM. Details of the final concentrations of
DNA and ligand appear where the relevant results are presented.
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Chapter 3: Characterisation of quadruplex DNAs

3.1 Introduction
The telomeric DNA sequence of Oxytricha nova, a ciliated protozoan, is one of the most
well-characterised quadruplex DNA-forming sequences. Following the sexual phase of
its life cycle, a copy of its chromosomal nucleus is transformed into a macronucleus
containing short linear DNA molecules. This phenomenon has facilitated studies of
telomeres and telomerase204 and its telomeres and related sequences have been used to
study quadruplex DNA in vitro.

The sequence d(G4T4G4) consists of one and a half units of the telomeric repeat of
Oxytricha nova and has been used in many studies. It was using this sequence that a
discrepancy was found between X-ray crystallographic97 and NMR205 structures. The
two proposed structures were fundamentally different, and in 1999 Schultze et al.
confirmed that this variation was due to the different counter ions used in the two
studies.95 While the NMR sample was prepared in 50 mM NaCl, the crystallization
sample was prepared with K+ as the counterion. Although both sets of data yielded a
symmetric dimeric quadruplex, the two differed in the conformation of the diagonal T
loops as indicated in Figure 3.1. Overall, potassium was determined to be a better
stabilizing cation for quadruplex structures than sodium. 206 Additionally, at lower
concentrations of K+ there was a gradual increase in the rate of formation of quadruplex
DNA while at higher concentrations of K+, quadruplex DNA formation was inhibited (1
M or more).206 These types of studies have used CD, electrophoresis, and NMR to show
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that there may be multiple conformations of quadruplex DNA (in slow exchange)
present for the same oligonucleotide.95 This difference is not observed in sequences
which only contain single runs of three or more guanines.206

(A)

(B)

Figure 3.1 Schematic illustration of d(G 4T4G4)2 in: (A) solution, and (B) crystal structures.
Strand direction along each edge of the quadruplexes is indicated by arrows. Adapted from
Schultze et al..205

The human telomeric repeat, TTAGGG, is found across a wide range of vertebrate
telomeres and is another sequence of great interest.207 The region of the chromosome
containing this repeat is 5-10 kb long and is thought to form an intramolecular
quadruplex structure (structures (C) and (D) from Figure 1.6.106 This proposal has arisen
from in vitro experiments using this sequence and variations of it. Most of these report a
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qDNA structure which is intramolecular with a mixture of parallel and antiparallel
quadruplexes.93, 130, 208, 209

ESI-MS has been used to detect qDNA in several laboratories. 130, 138, 208, 210 While ESIMS can provide valuable information concerning the stoichiometry and relative binding
affinities of ligands, ambiguities arise when analysing secondary structures. For
example, a homotetrameric qDNA with n charges will have the same m/z as a single
strand of the same sequence with n/4 charges. With ESI-IMMS it may be possible to
separate isobaric ions of different secondary structures as well as compare relative drift
times.200 This type of information becomes especially valuable when observing ions of
single-stranded quadruplexes. This is because it is not possible from an ESI mass
spectrum (which gives only m/z values) to determine whether ions are from a single
strand in the gas phase free of secondary structure or it is folded into a quadruplex.

There have been a few recent studies in which IMMS has been used to detect qDNA or
at least tetrameric clusters of nucleosides in the gas phase. Baker et al. studied the
aggregation of isolated deoxyguanosine clusters from an ammonium acetate solution
using an ESI ion mobility mass spectrometry instrument (constructed in their laboratory
and using an ion funnel as the interface between the source and drift cell) and applied
molecular dynamics calculations. The experimental collisional cross sections in helium
were all in agreement with the theoretical cross sections for clusters of four
deoxyguanosines.210 This method has also been used to confirm the retention of
structure of varying lengths of the quadruplex DNA-forming human telomeric repeat.208
The experimentally determined cross sections were found to match the theoretical cross
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sections which included specific strand orientation details. At the time of preparation of
this thesis the maintenance of qDNA structures in the gas phase had been assumed in
many studies, although sometimes supported by the detection of bound monovalent
cations93, 132, 193 or by agreement with calculated drift times in a drift cell type IM mass
spectrometer.211

The presence of quadruplex structures in solution is often determined using CD
spectroscopy. In general, the CD spectra of antiparallel quadruplex structures have a
major positive band at 295 nm and a negative band near 265 nm while parallel
quadruplex structures show a positive band at 260 nm and a negative one at 240 nm.212
This is very different to the bands observed for dsDNA, where the most common BDNA spectrum contains a positive band centred at approximately 275 nm, a negative
band at 240 nm and another large positive band at 180-190 nm.180

3.2 Scope of this chapter
The overarching goal of this research project was to examine whether a range of
berberine-based compounds exhibited selectivity for binding to quadruplex- over
double-stranded DNA. When this work commenced there was substantial experience in
the laboratory for preparation and ESI-MS analysis of dsDNA. As a starting point for
investigating quadruplex DNA, the behaviour of several quadruplex-forming sequences,
in our hands, was investigated. The three sequences had previously been reported in the
literature.

These

were

the

anti-parallel

intramolecular

quadruplex

Q1

(GGGTTAGGGTTAGGGTTAGGG),93 the anti-parallel dimeric quadruplex Q2
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(GGGGTTTTGGGG)2,93 and the parallel tetrameric quadruplex Q4 (TTGGGGGT) 4.132
Note that the names designate the number of DNA strands forming the quadruplex,
where Q1 is a quadruplex formed from one strand, Q2 is formed using two strands, and
Q4 is formed using four strands.

The sequence Q4 served as a stable control for optimising instrumental parameters for
detection and ion mobility MS of quadruplex DNA.

The sequence Q1,

d(GGG(TTAGGG)3), is an intramolecular quadruplex-forming sequence which has
previously been used in the literature as a human telomere-like sequence.93 The
sequence Q2, is well characterised, and is analogous to the telomeric repeat in
Oxytricha nova. There are numerous reports of biochemical studies where two or more
units of this telomere sequence have been investigated. These include NMR205, 213 and
X-ray crystallography structures97, 214 which were discussed in section 3.1.

The ESI-MS, circular dichroism and ESI-IM mass spectra of the three different
synthetic quadruplex-forming sequences are described. The CD spectra of each of the
three quadruplex DNAs were obtained in order to confirm the quadruplex subtypes
present in solution. Conditions were determined to observe intact quadruplex DNAs
using both ESI-MS and ESI-IMMS. Furthermore, solution conditions were altered to
intentionally disrupt any higher order structures. The CD spectra of the qDNA in these
solutions were recorded to detect the changes in structure and the drift times in ESI-IM
mass spectra before and after changing the solution conditions were noted. These were
compared to differentiate among the ion mobility behaviors of the folded qDNA and
single strand (Q2 and Q4) or unfolded DNA (Q1). In this way, the ion mobility of the
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DNA was used to confirm whether the folded DNA detected by CD in solution was
maintained in the gas phase. In addition, the experiments compared the relative
stabilities of these sequences in the gas phase and in solution.

3.3 Results and discussion
3.3.1 Circular dichroism spectra of Q4
As a prelude to the studies described in this thesis, different conditions were trialed for
annealing Q4 DNA, (TTGGGGGT)4, to obtain the highest quality mass spectra (high
signal-to-noise, absence or low abundance of ions from single strands).215 The best
conditions were found to be 150 mM NH4OAc, pH 7, in agreement with the work of
David et al..132 The experiments are briefly described in section 3.3.2. In this PhD
project, these experiments were supported by obtaining CD spectra of the solutions as
evidence for the presence of qDNA. The circular dichroism spectrum of Q4 was
acquired as described in section 2.5, in 150 mM NH4OAc. At the time of this work there
were two reports of ESI mass spectra of this sequence but neither included circular
dichroism spectra.132,

216

Figure 3.2 shows the CD spectrum of Q4 acquired under

several solution conditions. In 150 mM NH4OAc, the spectrum showed a maximum at
263 nm and a minimum at 242 nm. Another maximum was present at 208 nm. This is
consistent with a parallel-stranded structure and is in agreement with the structure
proposed for this sequence using other methods.132, 216 In order to confirm that Q4 was
present in solution as qDNA, conditions were altered to destabilise the structure. It is
expected that as qDNA was converted to single strands or other non-quadruplex
structures, the CD spectra would reflect this change. The samples were heated to 30, 40,
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50, 60, 70 and 80ºC with spectra collected at each of these temperatures (from 25 ºC).
This constitutes single temperature melting point determinations (i.e. not a temperature
gradient). Even at the maximum temperature of 80ºC no significant changes were
observed (Figure 3.2). This is interesting as the sequence d(TGGGGT)4 (one fewer G
and T base), has been reported to have a melting temperature of 36ºC as judged by UV
melting experiments.93 This suggests that one more tetrad stacked in the structure
imparts considerable stability to the sequence. This general trend has very recently been
observed by Joachimi et al..217 They found that the lower the number of G-tetrads, the
lower the melting temperature of a number of quadruplex-forming sequences. It was not
possible to clearly observe the melting of this sequence using CD, or similar
experiments, as above 80ºC solvent evaporation became a problem. This substantial
stability is not unknown for qDNA with some reported to retain their conformation even
after heating for up to 30 minutes at 100°C in 7 M urea. 218 In particular, Mergny et al.
found using absorbance spectroscopy that generally tetrameric quadruplexes with runs
of more than four guanine residues did not dissociate during melting experiments.219

It has been proposed that it is not possible to accurately determine the melting
temperature for some tetrameric quadruplex DNAs. 219 Mergny et al. have shown that
since some quadruplex DNAs are capable of reannealing, the apparent „melting
temperature‟ is an approximation of T1/2.219 Furthermore, they have shown that the T1/2
is dependent on the temperature gradient, where larger gradients (e.g. 5°C/min vs
0.5°C/min) will provide an increased T1/2. The purpose of the experiments described
here was to compare the stabilities of each of the quadruplexes under the same
experimental conditions.
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Figure 3.2: Circular dichroism spectra of 20 µM Q4 under different conditions.
Q4 in 150
mM NH4OAc;
Q4 in 150 mM NH4OAc heated to 80ºC;
Q4 in 5 mM NH4OAc;
Q4
in 5 mM NH4OAc/ 80% ACN. All at pH 7.

The importance of the ionic strength of the solution was also investigated. The
concentration of the ammonium acetate was serially reduced from 150 mM to 5 mM
and spectra were obtained at each concentration. The CD spectra of Q4 in 5 mM
NH4OAc and 150 mM NH4OAc were essentially the same, supporting that Q4 was
stable as a quadruplex in solution under both conditions (Figure 3.2). The only
significant change to the CD spectrum was observed when organic solvent (acetonitrile,
ACN) was present. When CD spectra of Q4 were obtained using 5 mM NH4OAc/ 80%
ACN there was a clear shift to a much broader maximum at 272 nm and to a minimum
of 246 nm (from 242 nm). Additionally, the signal was reduced in intensity overall
despite the concentration of DNA being the same in both experiments. This is consistent
with the disruption of the quadruplex structure of Q4. It would be useful to compare the
CD spectra of single-stranded Q4 with these „denatured‟ structures; however, it was not
possible to obtain such spectra of Q4 as temperatures high enough to denature Q4 to
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single strands could not be reached. When CD spectra of known ssDNAs are obtained,
the maxima and minima vary among different sequences such that there is no distinctive
wavelength which can be used to identify ssDNA. 180 Furthermore, quadruplex DNA
could be observed by CD and ESI-MS for Q4 even prior to annealing (discussed in
more detail below).

3.3.2 ESI-MS characterisation of Q4
In preliminary ESI-MS experiments, carried out prior to the commencement of this
doctoral project,215 Q4 was annealed under a range of conditions and analysed by ESIMS using a Waters Q-TOF UltimaTM under a range of different NH4OAc
concentrations. The Q4 DNA was annealed in 50, 100, 150, 200, 250, 300, and 500 mM
NH4OAc. It was found that the best spectra were obtained in 150 mM NH4OAc, pH 7 as
both the annealing and spray solution. This is in agreement with other work.93, 220, 221
Cations are often required to stabilise quadruplex DNA structures (as discussed in
section 3.1) and can affect the type of quadruplex DNA formed.109 To date there have
been a number of crystallographic structures of quadruplex DNAs determined in which
central cations reside between the guanosine tetrads.214, 222, 223 For this reason, addition
of Li(OAc) and Mg(OAc)2 to the quadruplex Q4 during annealing was also tested. This
was found to have no effect on quadruplex formation as judged by ESI-MS. Under these
conditions, ions from Q4 DNA were observed in ESI mass spectra without any added
metal ion or annealing step.

76

The mass spectrometer instrument parameters also required optimisation. The cone
voltage, desolvation temperature, desolvation gas flow, and RF lens voltage were
systematically varied to arrive at the conditions outlined in section 2.4.1. Figure 3.3
shows the negative ESI mass spectra of Q4 DNA in 50 mM NH 4OAc (A) and 150 mM
NH4OAc (B) acquired under optimised conditions. At lower concentrations of
ammonium acetate (Figure 3.3(A)), single-stranded DNA was observed along with fourstranded quadruplex DNA. ESI mass spectra revealed ions that could only arise from
qDNA (e.g. odd numbered charge states; m/z 2010.0). Denaturation of the qDNA
structure in 50 mM NH4OAc was not able to be observed using CD spectroscopy. This
may be either due to dissociation in the mass spectrometer, or is an indication that CD
was not sensitive enough to pick up small increases in single-stranded DNA relative to
quadruplex DNA.
563-

2-

5-

64-

Figure 3.3: Negative ion ESI mass spectra of 8 mer Q4 quadruplex DNA under two sets of
conditions. (A) Q4 in 50 mM NH4OAc. (B) Q4 in 150 mM NH4OAc. Quadruplex DNA is
marked with ■, and ssDNA is marked with ◊.
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The calculated average mass of the annealed quadruplex Q4 is 9986.8 Da. The ions
observed for quadruplex Q4 correspond to a mass of 9986.8 + 72 Da (the 4-, 5- and 6ions at m/z 2512.7, 2010.0, and 1674.8, respectively, in Figure 3.3). This mass
corresponds to the inclusion of four NH4+ ions in the structure. The inclusion of NH4+ in
the structure is significant and supports the maintenance of quadruplex DNA in the gas
phase since NH4+ bound to ss- and dsDNA is not usually observed in ESI mass spectra.
The purpose of NH4OAc in ESI-MS is to provide a volatile salt that can donate protons
and lose NH3 (for positive charging), or abstract protons and lose acetic acid (for
negative charging) and therefore do not normally remain bound to the analyte. The
presence of NH4+ in the quadruplex DNA shows that it is an intrinsic part of the
structure, stabilised against dissociation in the gas phase (mass spectrometer) and
explains how this quadruplex structure was observed in this study without the addition
of other monovalent cations. These results are in accordance with other ESI-MS
research on quadruplex DNA where the inclusion of NH4+ was observed.93, 193 The ions
at m/z 831.2 and 1247.3 are assigned to the [M-3H]3- and [M-2H]2- ions of ssDNA and
do not incorporate NH4+.

The ESI mass spectra included ions at lower intensity arising from DNA adducts with
different numbers of NH4+ present. Figure 3.4 shows an enlarged view of the 5- ions of
Q4. In 150 mM NH4OAc (B) the [Q4+4NH4+-9H]5- ion was twice as abundant as the
[Q4+3NH4+-8H]5- ion. The most abundant ions for each charge state corresponded to
the [M+4NH4+-10H]6- (not shown), [M+4NH4+-9H]5- and [M+4NH4+-8H]4- (not shown),
at m/z 1674.8, 2010.0 and 2512.7, respectively. In 50 mM NH4OAc (Figure 3.4 (A)),
the [M+4NH4+-9H]5- ion is of lower abundance than when the spectrum was obtained in
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150 mM NH4OAc. The destabilisation of the qDNA structure as a result of the loss of
some NH4+ from the structure is consistent with the appearance of ssDNA in the
spectrum obtained in 50 mM NH4OAc (Figure 3.3(A)). It is also possible that the ions
carrying an even number of charges correspond to double-stranded DNA; however, this
sequence is most likely too short to form a two-stranded quadruplex, and a WatsonCrick H-bonded dsDNA sequence would not form with this sequence of bases.
Additionally the high abundance of the odd charge state (5-) argues against this. The
possibility that structures other than qDNA may be present is examined in more detail in
the discussion of ion mobility experiments carried out on this sequence (section 3.6.1).

(A)

(B)

Figure 3.4: Enlarged view of NH4+ adducts of 5- ions of Q4 from Figure 3.3 in (A) 50 mM
NH4OAc and in, (B) 150 mM NH4OAc. ♦ [Q4+2NH4+-7H]5-; □ [Q4+3NH4+-8H]5-; ■
[Q4+4NH4+-9H]5-; ○ [Q4+5NH4+-10H]5-.

The ions observed here were not the same as those observed by David et al.,132 who
studied the same quadruplex sequence by negative ion ESI-MS. They reported
quadruplex ions with 6 and 7 NH4+ ions bound in the 7- charge state as the most intense
peaks. The method of quadruplex DNA preparation and concentrations of Q4 used were
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different. David et al.132 used successive freeze-thaw cycles to prepare the quadruplex
and the spray solution was 3/1 water/methanol solution. Further, a different ESI mass
spectrometer was used by David et al. (ThermoFinnigan LCQ, c.f. Waters Q-TOF
UltimaTM used here).132 The different ionization sources might affect the distribution of
ions formed in the electrospray source.

The literature supports the validity of the incorporation of 4NH4+ ions for this particular
sequence. Different studies have demonstrated that quadruplexes are stabilised by
cations between the G tetrads.224 This is known as the N-1 rule and predicts the number
of cations incorporated into the quadruplex. The predominant ions observed in the mass
spectra obtained here are consistent with this (5 guanosine residues, N; 4 NH4+ bound,
N-1). Gabelica et al. performed ESI-MS studies on the four-stranded parallel
quadruplex d(TGGGGT)4, which contains one less guanosine tetrad. 93 They observed
three ammonium adducts in the 5 - and 4- charge states using an LCQ ESI ion trap
instrument. This study therefore also supports that the N-1 proposal holds true
depending on the optimization of conditions in ESI-MS experiments.

As mentioned earlier, under some experimental (gas phase and solution) conditions, and
without annealing the sequence, it was noted that the number of ammonium ions bound
in the most abundant complex differed from when the DNA was annealed. In these
instances the predominant species observed for the 5- charge state corresponded to
[M+3NH4+-8H]5-. One possible explanation for this is the possibility of „slipped‟
quadruplex structures. That is, the structure could have one or two shifted strands
resulting in a lower number of intact G-tetrads.225 For example, instead of the first
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guanine of each of the 4 strands participating in a tetrad, in one or more strands, the
second guanine could participate in a tetrad with the first guanine of 3 or fewer strands.
Figure 3.5 shows a proposed scheme for formation pathways of quadruplex DNA as
determined by molecular dynamics simulations. 225 In the model, the dots represent
cations and each of the black lines represents a strand of DNA. Where one line or strand
of DNA is not aligned, it indicates a „slipped‟, out-of-register strand. For some of the
possible arrangements, multiple strands can be out-of-register and in these cases the
number of G-tetrads is reduced, thus, so is the number of cations residing in the stem.
There are also NMR experiments which show that the stabilising cations in
quadruplexes are in exchange with the cations of the available solvent and that the
nature of the exchange is dependent upon loop constraints of the quadruplex in
question.213, 226 Thus, it is also possible that such structures might be detected in the ESI
mass spectra. The issue of loop constraint however, is not relevant to the structure of
four-stranded Q4.

Figure 3.5: A proposed mechanism for formation of a parallel-stranded quadruplex as
determined by molecular dynamics simulations, where
represents a cation. Adapted from
Vorlı´cˇkova´et al.225 (A) Represents a structure in which two strands are slipped. (B)
Represents a structure in which one strand is slipped.

•
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3.4 Characterisation of Q1
3.4.1 Circular dichroism spectra of Q1
Q1 (GGG(TTAGGG)3) is a single-stranded human telomere-like sequence which forms
intramolecular quadruplexes. The circular dichroism spectra of Q1, acquired as
described in section 2.5, were obtained in 150 mM NH4OAc (Figure 3.6). The circular
dichroism spectra of this sequence in 150 mM NH4OAc,93 NaCl and KCl212, 227 have
been previously described in the literature. This is a well studied qDNA sequence
because of the interest in targeting human telomeres for the development of
chemotherapeutics. A maximum near 295 nm and a minimum near 260 nm were
observed which is indicative of an antiparallel quadruplex conformation212 and is
consistent with the literature for a CD spectrum for similar sequences acquired in
NH4OAc.93 The spectrum of Q1 which has not been subject to an annealing procedure
was substantially different suggesting that annealing is important for forming secondary
structures involving this sequence. Further experiments were carried out to explore the
stability of Q1.

Figure 3.6: Circular dichroism spectra for 20 µM Q1 under different conditions.
Q1 in 150
mM NH4OAc;
Q1 in 150 mM NH4OAc heated to 80ºC;
Q1 in 5 mM NH4OAc;
Q1 in 5 mM NH4OAc/ 80% ACN;
unannealed Q1 in 150 mM NH4OAc. All at pH 7.
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Samples of Q1 were heated to 30, 40, 50, 60, 70 and 80ºC with spectra collected at each
of these temperatures (as for Q4, section 3.3.1). At approximately 60ºC, the maximum
and minimum of the spectrum began to shift. At 80ºC a consistently different spectrum
was obtained and is shown in Figure 3.6. Gabelica et al. have previously performed UV
melting experiments on the same sequence and observed a melting temperature of
56ºC.93 Our results are consistent with the unfolding of Q1 around 60ºC. Above this
temperature, the maximum and minimum were 260 nm and 240 nm, respectively. In
addition to the possibility of ssDNA formation, this may be indicative of a change in
some of the DNA towards a parallel-stranded quadruplex. These types of changes (i.e.
shift of maximum and minimum) have previously been reported in the literature for the
same DNA sequence.212, 227 Vorlı´cˇkova´ et al. surmised an antiparallel structure using
CD and observed a parallel quadruplex using crystallography. These parallel
intramolecular quadruplexes differ to the predominant chair and basket type
quadruplexes pictured earlier in Figure 1.6 and have a more complicated strand
arrangement. Figure 3.7 shows a parallel intramolecular quadruplex and a mixed
antiparallel/parallel intramolecular quadruplex. Another possibility is the formation of a
multi-stranded structure (e.g. a two-stranded quadruplex).228 This possibility is
discussed in more detail in section 3.6.2.

(A) Propeller
Parallel

(B) Parallel/Antiparallel
Mixed

Figure 3.7: Different strand orientations for single-stranded intramolecular quadruplexes. (A)
Propeller type parallel quadruplex. (B) Mixed parallel/antiparallel quadruplex. Taken from
Baker et al..208 The direction of the arrows represents the direction of the strands.
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Deacreasing the concentration of the ammonium acetate (5 mM, Figure 3.6), did not
cause any apparent changes in the CD spectrum and therefore no apparent change from
the proposed antiparallel structure. This is consistent with the observations of
Vorlı´cˇkova´ et al. who observed no changes as judged by CD when changing from
low concentrations of KCl to up to 300 mM. The effect of the solution conditions were
further investigated by addition of acetonitrile. Increasing the concentration of this
organic solvent gave a clear shift in the CD spectrum (Figure 3.6), no clear maximum
and minimum could be observed and it became difficult to maintain the DNA in
solution at the higher concentrations of acetonitrile.

3.4.2 ESI-MS characterisation of Q1
Conditions were determined for preparation of annealed Q1 and its analysis by ESI-MS.
Q1, annealed as described in section 2.2.4, was diluted in solutions containing different
NH4OAc concentrations from 5 mM to 500 mM. These solutions were then analysed
under a range of instrumental conditions using a Waters Q-TOF UltimaTM ESI mass
spectrometer until optimised conditions were determined (described in section 2.4.1).
The effects of adding Li(OAc), Mg(OAc)2 or K+ were also tested with no observable
improvement to the spectra. The solution conditions giving the best spectra were again
in agreement with those established in the literature, at 0.15 M NH 4OAc, pH 7.93 An
example of an optimised spectrum is shown below in Figure 3.8.
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Figure 3.8: Negative ion ESI mass spectrum of 21 mer Q1 single-stranded quadruplex DNA.
DNA (no adducts) is marked with ■. Inset shows enlarged view of 4- ions with proposed Na+
and K+ adducts.

The most abundant ions corresponded to the [Q1-4H]4- and [Q1-5H]5- ions, at m/z
1662.3 and 1329.7, respectively. This is in agreement with the calculated mass for Q1
with no bound NH4+. An ion of lower abundance was also observed at m/z 2216.8
corresponding to the [Q1-3H]3- ion. This assignment is explored later in ion mobility
experiments which suggest that this ion may also correspond to the two-stranded
quadruplex ion [2*Q1-6H]6-. This will be discussed in detail in section 3.6.2 (see
below).

In contrast with Q4, there were no clear differences between the ESI mass spectra of
DNA which had been annealed and DNA which had not. The spectra obtained gave ions
with multiple salt adducts arising from adventitious cations (detail for the 4 - ions in the
inset of Figure 3.8). The mass spectrometer parameters could not be modified such that
these adducts were lost without significantly affecting the quality of the spectra. Since
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the predominant ions in the spectra observed for Q1 correspond to DNA alone with no
bound ammonium ions, there is some ambiguity regarding the structure of Q1 in the gas
phase. Q1 is a single strand of DNA and will give the same mass irrespective of whether
it is present in the solution and mass spectrometer as an unfolded single strand with no
stable secondary structure or whether its G-rich sequence is folded into a quadruplex
structure. The presence of Na+ and K+ adducts (inset Figure 3.8) supports that qDNA
may be present and that these adducts are more stable than NH 4+ adducts. For other
qDNA sequences and structures (Q4 and Q2) purified and prepared using the same
source of water and solvents, less abundant Na+ and K+ adducts were observed. Rosu
and coworkers were also unable to observe ions from Q1 + nNH4+ in ESI-MS
experiments.93 In agreement with the current work, they were able to use CD to
demonstrate an antiparallel quadruplex conformation existed in solution. 93

There are also reports of other intramolecular qDNA-forming sequences lacking integral
NH4+ in ESI-MS.193,

208

It has been proposed that in these cases the conformational

strain due to loops of the quadruplex inhibit binding of central cations.93,

193, 208

In

contrast, Sponer et al. propose that it is not possible for quadruplex structures to be
stable when the central „stem‟ of the G-tetrads is not occupied by cations.229 This is
based on the findings of two reports involving molecular dynamics simulations.225, 229,
230

These studies however, were not based on single-stranded intramolecular

quadruplexes such as Q1, but on structures similar to the sequences Q4 and Q2 which
are a different class of quadruplex (sections 3.3.2 and 3.5.2, respectively). In order to
investigate the gas phase structure of Q1, its structure/collisional cross section was
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further investigated using ion mobility mass spectrometry. These experiments are
described later in section 3.6.

3.5 Characterisation of Q2
3.5.1 Circular dichroism spectra of Q2
Figure 3.9 shows the circular dichroism spectrum of Q2, (GGGGTTTTGGGG)2,
prepared as described in section 2.5, in a variety of solution conditions. The CD
spectrum of this sequence in NH4OAc has previously been obtained by others,93 and
was found to have a maximum near 295 nm and a minimum near 260 nm which is
indicative of an antiparallel quadruplex conformation. The results obtained in this study
in 150 mM NH4OAc are in accordance with these results when CD spectra of Q2 were
acquired at a concentration of ~20 µM. As well as this maximum and minimum, a
shoulder was observed at approximately 270 nm. This was also present in the CD
spectrum recorded by Rosu et al.93 though it was not discussed by these researchers.
Initial CD experiments with the quadruplex DNAs also included determining which
concentrations of DNA gave the best spectra. In the case of all three quadruplexes,
spectra of DNA obtained at a concentration between 10 and 20 µM gave adequate
responses. Some interesting behavior was observed for Q2 in that it yielded a different
CD spectrum at concentrations greater than 40 µM (Figure 3.9). The maximum
observed in this case was at 260 nm (cf. 295 nm if ≤ 20 µM) and the minimum was at
240 nm (cf. 260 nm if ≤ 20 µM). These results are consistent with the presence of a
parallel-stranded quadruplex.212 This may correspond to a parallel two-stranded
quadruplex or parallel four-stranded quadruplex DNA. Additionally, there was a
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shoulder at 295 nm which may indicate some residual antiparallel Q2. This is not the
first report of this sequence exhibiting structural polymorphism. Miura et al. used
Raman spectroscopy to determine that this quadruplex sequence changes conformation
from antiparallel to parallel upon increasing the concentration of the counter ion.231 At
the time of this work no reports were found in which CD spectra have been obtained
over a wide concentration range of Q2. Ion mobility experiments discussed in section
3.6.3 suggest that a four-stranded structure, possibly a quadruplex, can be formed by
this sequence.

Figure 3.9: Circular dichroism spectra of Q2 under different conditions.
20 µM Q2 in 150
mM NH4OAc;
20 µM Q2 in 150 mM NH4OAc heated to 80ºC;
20 µM Q2 in 5 mM
NH4OAc;
20 µM Q2 in 5 mM NH4OAc/ 80% ACN;
40 µM Q2 in 150 mM NH4OAc.

Experiments were carried out to explore the stability of Q2. The samples were heated to
30, 40, 50, 60, 70 and 80ºC with spectra collected at each of these temperatures (from
25ºC as for Q4). At approximately 60ºC, the maximum and minimum shifted slightly
and the ellipticities of the CD bands decreased. At 80ºC, a consistently different
spectrum was obtained and is shown in Figure 3.9. Previously, Rosu et al. performed
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UV melting experiments on the same sequence and observed a melting temperature of
58ºC.93 Our results are therefore consistent with the dissociation of Q2 at around 60ºC.
Above this temperature a decrease in the relative response was observed for the sample
at the same concentration. Additionally, the shoulder at approximately 270 nm was no
longer present.

Changing the NH4OAc concentration did not cause any changes in the CD spectrum of
Q2 and therefore no apparent change in the antiparallel structure. This is in
contradiction with the reports of Miura et al.. Using Raman spectroscopy and gel
electrophoresis they inferred the conformation of this sequence in different
concentrations of NaCl and KCl.231 Increasing the concentration of either of these ions
caused a change in conformation of the quadruplex from antiparallel to parallel. It was
noted, however, that the K+ counter ion was more effective at facilitating the change to
the parallel conformation. It is possible that our results differ because a different counter
ion was used. NH4+ may be less able to facilitate a conformational change over the
concentration range tested here as judged by CD (5 mM to 150 mM). Additionally, the
concentration range used by Miura et al. was much greater at up to 300 mM. The effect
of the solution was further investigated by including acetonitrile. Increasing the
acetonitrile concentration resulted in a change in the CD spectrum (blue line in Figure
3.9). No clear maximum and minimum could be observed and it became difficult to
maintain the DNA in solution at the higher concentrations of acetonitrile.
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3.5.2 ESI-MS characterisation of Q2
The sequence Q2 was analysed using the ESI-MS Q-TOF UltimaTM under the same
conditions as for Q4 and Q1. The spectrum is shown in Figure 3.10 (A). The most
abundant ion from the double-stranded quadruplex was [Q2-5H]5- at m/z 1514.4; low
abundance ammonium adducts were also present (shown in the inset of Figure 3.10
(A)). Under these conditions, it was not possible to observe N-1 NH4+ adducts (3) as the
predominant ions. Additionally, some ssDNA appeared to be present. The next most
abundant ion from qDNA was the [Q2+3NH4+-7H]4- ion at m/z 1906.0. While this ion
does appear to have ammonium adducts, these were of significantly lower abundance
than those observed for the 5- ion (not shown enlarged). Therefore, under the
experimental conditions, ammonium adducts of Q2 are not abundant in the negative ion
ESI mass spectra. Since there are four consecutive guanine residues in each strand it is
expected that up to three NH4+ ions would be bound between guanine residues. An ion
was also observed at m/z 1261.8 which corresponds the [Q2-6H]6- ion for the doublestranded quadruplex, or [Q2-3H]3- from a single strand of Q2. Ion mobility experiments
which follow in section 3.6.3 assisted in identifying this ion as the single-stranded
species.
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Figure 3.10: Negative ion ESI mass spectra of Q2 in 150 mM NH4OAc pH 7. (A) Conditions
used for Q1 and Q4. (B) Optimised conditions for Q2. Proposed quadruplex DNA is marked
with ■, and ssDNA is marked with ◊. The insets show an enlarged view of the 5- ions under
both conditions. ■ [Q2-5H]5-; ○ [Q2+NH4+-6H]5-; ♦ [Q2+2NH4+-7H]5-; □ [Q2+3NH4+-8H]5-.

This sequence was also studied by Rosu et al. using ESI-MS.93 The spectra in that study
were acquired using two different ESI instruments, a Waters ESI Q-TOF2 and a
ThermoFinnigan LCQ ion trap mass spectrometer. Using the Q-TOF2 they observed
ions which they assigned as corresponding to 3- ssDNA as well as the [Q2-5H]5- ion
observed in this study. They did not, however, observe the ion at m/z 1906.0 which
corresponded to [Q2+3NH4+-7H]4-. Similarly, under standard instrument conditions
used for other quadruplex DNAs, Rosu et al. were initially unable to observe N-1 NH4+
ions as the predominant species for this quadruplex. In order to observe the ions, the
conditions of the Q-TOF2 were changed by lowering the cone voltage to 15 V and the
collision energy from 10 eV to 6 eV.93 The spectrum of Rosu et al. is shown in Figure
3.11 with an inset showing the 5 - ions. In the case of the LCQ ESI-MS instrument, a
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capillary temperature of 110°C, a capillary voltage of 8 V and a tube lens offset of -35
V were required in order to obtain similar spectra.

Figure 3.11: ESI mass spectrum of Q2 in 150 mM ammonium acetate (pH 7). The spectra were
recorded using the Q-TOF2 by Rosu et al..93 The inset shows an enlargement of the distribution
of ammonium adducts on 5- ions at cone voltage = 15 V, and collision energy = 6 eV. The
numbers in the inset represent the number of ammonium ions present. Taken from Rosu et al..93

In the current study, after varying many parameters of the Q-TOF UltimaTM it was
found that by lowering the RF lens to 45 V, it was possible to observe the [Q2+2NH4+8H]5- ion at m/z 1521.2 as the base peak. In addition, under these conditions, the ion at
m/z 1261.8, assigned to ssDNA, was lost. This spectrum is shown in Figure 3.10 (B).
Ions from Q2 + 3NH4+ (obeying the “N-1” rule) were only observed at very low
abundance. In experiments where ligands proposed to stabilise qDNA were present
(section 5.3.3), it was possible to observe three bound ammonium ions across all charge
states. This is discussed in detail in section 5.3.3. Overall, the proposed double-stranded,
two looped Q2 appears to require much more gentle conditions than Q4 for observation
of bound ammonium ions. As with Q1, it is possible that conformational strain of the
loops affects the stability of the ammonium adducts. 93, 193, 208
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3.6 Optimisation of ESI-IMMS conditions for analysis of
quadruplex DNA
Ion mobility experiments add another dimension of gas phase separation as ions are
separated by their shape (collisional cross section) as well as mass-to-charge ratio.198
Quadruplex DNA is therefore expected to exhibit different ion mobility to single- or
double-stranded DNA. Bowers and co-workers have previously performed ion mobility
experiments on quadruplex DNA-forming sequences. These experiments were
performed using a drift tube ion mobility mass spectrometer and calculations of
theoretical drift times. They were able to use ion mobility to confirm that DNA
duplexes retain their structure in the gas phase. 194 More recently, Gabelica et al. used
ion mobility to study the stabilisation and structure of a number telomeric DNA
sequences, and some from the c-myc region, believed to form quadruplex DNA. 211
Using a combination of ESI-MS, IMMS and molecular modeling they demonstrated
that some intramolecular qDNA folds are stabilised by NH4+ in the absence of solvent.

A combination of CD (sections 3.3.1 to 3.5.1) and ESI-IMMS experiments using the
Waters HDMSTM SynaptTM ESI-MS mass spectrometer (called the “Synapt” below)
were performed to find evidence to support the presence of quadruplex structures for
each of the proposed qDNA sequences. Initial ion mobility experiments also explored
the effects of different solution conditions on the spectra obtained. The best solution
conditions were the same as those used in the ESI-MS experiments described above for
the ESI Q-TOF UltimaTM mass spectrometer (150 mM NH4OAc, pH 7) for each of the
three sequences.
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3.6.1 Optimisation for Q4
Negative ion ESI mass spectra (Figure 3.12 (A)) of Q4 acquired using the Synapt
showed the [Q4+4NH4+-9H]-5 ion was the most abundant at m/z 2010.0. Less abundant
ions were [Q4+4NH4+-10H]6- at m/z 1674.8 and [Q4+4NH4+-8H]4- at m/z 2512.7. These
ions are in agreement with the distribution of ions observed using the Q-TOF UltimaTM
(Figure 3.3). In order to obtain ion mobility spectra it was necessary to increase the trap
collision energy to 6 V from 4 V, and the transfer collision energy from 2 V to 3 V.
Without increasing these collision energies the spectra obtained exhibited a low ion
count. The higher energies were required to propel the ions through the mobility cell.
Under these conditions (Figure 3.12 (B)), an ion at m/z 1247.3 corresponding to ssDNA
was observed suggesting that some of the qDNA dissociated in the gas phase under the
more energetic conditions.
5(A)
645(B)
2-

6-

4-

Figure 3.12: Negative ion ESI mass spectra of Q4 DNA in 150 mM NH4OAc, pH 7, obtained
using the Waters HDMSTM SynaptTM. (A) Q4 in ESI-MS mode. (B) Q4 in ESI-IMMS mode.
The difference in the conditions is described in the text. Quadruplex DNA is marked with ■, and
proposed ssDNA is marked with ◊.
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Low abundance ions were evident on careful investigation of the region between m/z
1900-2020 when both ESI mass spectra and ESI-IMMS was carried out using this
instrument (Figure 3.12, enlarged view in Figure 3.13). The most prominent difference
between the two spectra is a significant increase in the intensity of the [Q4+3NH 4+8H]5- ion in IMMS mode as well as the appearance of [Q4+2NH4+-7H]5-, [Q4+NH4+6H]5- and [Q4-5H]5- (Figure 3.13 (B)). Some fragment ions were also observed under
both conditions which were consistent with the loss of guanine. In ion mobility mode,
ions were observed at m/z 1966.1, 1949.5, 1946.1 and 1939.3, corresponding to [Q4-G5H]5-,

[Q4+4NH4+-2G-9H]5-,

[Q4+3NH4+-2G-8H]5-

and

[Q4+NH4+-2G-6H]5-,

respectively. In ESI-MS mode, only [Q4-G-5H]5-, and [Q4+NH4+-2G-6H]5- were clearly
observed. Overall the conditions required to obtain IM mass spectra were harsher than
those required to obtain ESI mass spectra. Additionally, the Synapt was more sensitive
than the Q-TOF UltimaTM.

Figure 3.13: Expansion of the m/z 1900-2020 region (see Figure 3.12), of the negative ion ESI
mass spectra of Q4 DNA in 150 mM NH 4OAc obtained using the Waters HDMSTM SynaptTM.
(A) Q4 in ESI-MS mode. (B) Q4 in ESI-IMMS mode. ● [Q4+4NH4+-9H]5-; ♦ [Q4+3NH4+-8H]5; □ [Q4+2NH4+-7H]5-; [Q4+NH4+-6H]5-; ▲[Q4-5H]5-; ○ [Q4-G-5H]5-; ◄ [Q4+4NH4+-2G9H]5-; ◊ [Q4+3NH4+-2G-8H]5-; ∆ [Q4+NH4+-2G-6H]5-. G is guanine.
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In preliminary ESI-IMMS experiments, a range of different NH4OAc concentrations
were used as the spray solution. The best spectra were obtained using 150 mM
NH4OAc, pH 7, which is in agreement with the ESI-MS experiments. Figure 3.14
shows the ion mobility drift plots ((1)) of Q4 in 150 mM NH4OAc (A) and 5 mM
NH4OAc (B). The ESI mass spectrum is shown at the bottom of each image (2). The
driftscope (1) spectrum is a plot of the m/z against drift time in milliseconds (ms) with
the abundance of the ions as a third dimension which is denoted in the z-axis.
Abundance is represented by colors, where white is the most abundant, followed by
orange, and black is the background.

Ion mobility mass spectra of Q4 in different solution conditions revealed interesting
differences. Table 3.1 shows the observed m/z values, calculated m/z, drift time and
assignment of all ions observed in the ion mobility spectra. The drift times were
determined from the most intense point on the drift plot here and in all other ion
mobility spectra. The software also shows a plot of abundance against drift plot and
these plots were used to arrive at the values given in this work. In Figure 3.14 (A) the
arrival time of ion b at m/z 2010.0, [Q4+4NH4+-9H]5-, is approximately 8.2 ms. The
arrival time of ion c at m/z 1674.8, [Q4+4NH4+-10H]6-, is approximately 5.8 ms and is
of much lower abundance. There is also an ion of low abundance, [Q4+4NH4+-8H]4-,
(a), present at m/z 2512.8, with an arrival time of 12.8 ms. The appearance of the
driftscope image where ions a, b, and c are aligned diagonally suggests that these are
ions from the same conformational/structural form.208, 232 Upon reducing the NH4OAc
concentration (Figure 3.14 (B)) the ion distribution was affected with the appearance of
four additional ions (d-g) and loss of [Q4+4NH4+-8H]4- (a). These new ions are
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consistent with quadruplex DNA ions [Q4+4NH 4+-11H]7- (d) and [Q4+4NH4+-12H]8(e) at m/z 1435.4 and 1256.4, respectively. The base peak, f, in the conventional ESI
mass spectrum (B2), was very sharp (no bound NH4+) at m/z 1247.3, and with a drift
time of approximately 7.7 ms. This places this ion outside of the series of quadruplex
ions observed (not diagonally aligned with b, c, d, and e). Since Q4 is a four-stranded
quadruplex it means that when no ammonium ions are present as an indicator of
quadruplex structure, their identity can be ambiguous. The ion f, at m/z 1247.3 could
possibly arise from four different species. These are the four-stranded [Q4-8H]8- ion
with no included NH4+ ions, the three stranded [Q4-6H]6- ion, the two-stranded [Q44H]-4 ion, or the single-stranded [Q4-2H]2- ion (all at calculated m/z 1247.3). Given that
the ion f is very sharp with no adduct peaks from bound NH4+ ions, it seems unlikely
that it will correspond to quadruplex DNA. In support of this, if the only difference in
this ion to the other quadruplex DNA peaks is charge, then it would be expected to
appear to the left of the 7 - ions on the driftscope (Figure 3.14 (B) (1)), where 8- ions
with included NH4+ ions have already been proposed (e). This ion corresponding to
[Q4+4NH4+-12H]8- has a drift time of approximately 3.8 ms. This suggests a more
compact ion with a smaller collisional cross section. This lends greater credibility to the
assignment of the m/z 1247.3 ion as a single-stranded, non-qDNA species. Dissociation
patterns observed in MS/MS experiments also support that this is an ion from ssDNA
(see section 3.8.1).

97

Figure 3.14: Ion mobility spectrum of Q4 in (A) 150 mM NH 4OAc and (B) 5 mM NH4OAc.
Unless otherwise stated in the text the ions indicated are for four-stranded quadruplex DNA.
Under each set of conditions (A and B), (1) shows the driftscope image, (2) shows the ESI mass
spectra. The intensity scale for the driftscope is shown at the bottom of the figure.
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Table 3.1: Ions observed in IM mass spectra shown in Figure 3.14.
Conditions

Ions observed for Q4 (label, observed m/z,
calculated m/z, ms on driftscope, assignment)

150 mM NH4OAc

a, m/z 2512.6, m/z 2512.8, 12.8 ms, [Q4+4NH4+-8H]4-

(Figure 3.14 (A))

b, m/z 2009.8, m/z 2010.0, 8.2 ms, [Q4+4NH4+-9H]5c, m/z 1674.4, m/z 1674.8, 5.8 ms, [Q4+4NH4+-10H]6-

5 mM NH4OAc

a, m/z 2512.6, m/z 2512.8, 12.8 ms, [Q4+4NH4+-8H]4-

(Figure 3.14 (B))

b, m/z 2009.8, m/z 2010.0, 8.2 ms, [Q4+4NH4+-9H]5c, m/z 1674.4, m/z 1674.8, 5.8 ms, [Q4+4NH4+-10H]6d, m/z 1435.0, m/z 1435.4, 6.4 ms, [Q4+4NH4+-11H]7e, m/z 1256.2, m/z 1256.4, 3.8 ms, [Q4+4NH4+-12H]8f, m/z 1246.9, m/z 1247.3, 7.7 ms, ssDNA [Q4-2H]2g, m/z 831.1, m/z 831.2, 4.4 ms, ssDNA [Q4-3H]3-

Additionally, in 5 mM NH4OAc (Figure 3.14 (B)), the ion g, was observed at m/z 831.2.
The transformed mass of this peak corresponds to either the four-stranded [Q4-12H]12ion, the three-stranded [Q4-9H]9- ion, the two-stranded [Q4-6H]6- ion, or the singlestranded [Q1-3H]3-. The drift time observed for this ion was 4.4 ms. Since there were no
ammonium adducts observed with this ion it is also unlikely to be the four-stranded
quadruplex. Further, it is in diagonal alignment with the 2 - ion of the single strand (f).
There is also a signal of low intensity at approximately 6.2 ms and at m/z 950-1050
(unlabelled on the figure). There are a number of possibilities for ions which lie in this
range, however based on the assignment of the 2 - and 3- charge states of ssDNA, this
probably corresponds to a fragment ion. McLuckey et al. have previously determined
how DNA will fragment using ESI-MS techniques.233 A schematic for the general
fragmentation of DNA is shown in Figure 3.15. Possible cleavages are indicated by the
99

letters a, b, c and d for fragments which contain the 5'-OH group and w, x, y, s for those
containing the 3'-OH group. The numerical subscripts indicate the number of bases from
the termini. Based on this, it can be suggested that the fragment between m/z 950-1050
for Q4 is the w3- ion at m/z 979.6. The ion [Q4+4NH4+-8H]4- is no longer observed
under these conditions.

Figure 3.15: Schematic of the general fragmentation pattern for a 3 base oligonucleotide.
Adapted from McLuckey et al..233

3.6.2 Optimisation for Q1
Figure 3.16 shows the negative ion ESI mass spectrum of single-stranded qDNA, Q1,
acquired under optimal conditions (section 2.4.2) using the SynaptTM. The instrument
conditions were gentle and not targeted towards acquisition of an ion mobility spectrum.
The three most abundant ions were tentatively assigned as the ions [Q1-3H]3-(a), [Q14H]4- (b) and [Q1-5H]5-(c), at m/z 2200-2300, 1662.5 and 1330.0, respectively
(calculated values at m/z 2216.8, 1662.3 and 1329.7). These are the same ions, with the
same relative abundance as those observed for the QTOF UltimaTM; however, overall
the spectra showed more background noise. The ion a, originally assigned as [Q1-3H]3-,
was of low intensity and had many adducts such that it was difficult to determine the
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m/z. This assignment was based on the ions over the m/z range 2200-2300. Since the
ESI mass spectra of this qDNA sequence consistently showed numerous Na +/K+
adducts under the conditions where the other sequences, (Q2 and Q4) did not (e.g.
Figure 3.12), it was of particular interest to examine the ion mobility behaviour of this
single-stranded qDNA. In contrast with Q4, there were no substantial changes in the
spectra when the trap and collision energies were increased (from 2 to 16 V) to obtain
ion mobility spectra. It is important to note that given the multiple salt adducts present it
was difficult to detect relatively low abundance fragments of similar m/z to the
predominant ions (e.g. [Q1-4H]4- is at m/z 1662.5 and [Q1-G-4H]4- is observed at m/z
1624.5).

Figure 3.16: Negative ion ESI-MS spectra of Q1 DNA in 150 mM NH 4OAc, pH 7, obtained
using the Waters HDMSTM SynaptTM. Proposed single-stranded quadruplex DNA is marked
with ■.

Overall, the running conditions were optimal under the same solution conditions as Q4
using 150 mM NH4OAc, pH 7. The ion mobility mass spectra of Q1 in 150 mM
NH4OAc and 5 mM NH4OAc are shown in Figure 3.17. The assignments for the ions
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are shown in Table 3.2. As for Q4, a change was observed in the ion mobility spectrum
upon reducing the concentration of NH4OAc. When Q1 was sprayed from 150 mM
NH4OAc the arrival times of the three main ions, tentatively assigned as [Q1-3H]3-,
[Q1-4H]4- and [Q1-5H]5-, were approximately 6.4, 5.1 and 3.5 ms, respectively, and are
labelled as a, b, and c in Figure 3.17 (A1). The ion d at m/z values between 920-930 can
also be distinguished, however, only at low abundance. This ion was difficult to assign
conclusively for this reason and also since ions from many adducts were present. In this
range, however, for an intact single-stranded ion, 7- is the only possible assignment.
Alternatively, this may be an ion from a fragment of the single-stranded DNA where
bases have been lost. There are a number of possible fragment ions which would fall in
this range including the product fragment y3 - (m/z 924.7) or y62- (m/z 922.6). The ion e
at drift time 3.5 ms is at an m/z value in the range 700-780. This again is likely to be a
fragment ion, where the closest match is (a3-B3(G))- (m/z 755.5). The presence of these
fragments is a result of the harsher instrument conditions required to obtain ion mobility
mass spectra.

When Q1 was sprayed from 5 mM NH4OAc no significant changes were observed in
the ESI mass spectrum (Figure 3.17 (B2)). In contrast, even at a glance, two new ions
(Figure 3.17 (B1) can be distinguished in the driftscope in 5 mM NH4OAc compared to
150 mM NH4OAc. The appearance of these ions when solution conditions were
changed but under identical instrument conditions suggests that the secondary structure
(most likely potential qDNA) present in 150 mM NH4OAc has unfolded in 5 mM
NH4OAc. This also illustrates the potential of ESI-MS in checking for folded qDNA
before other experiments are carried out. While f and g are of very low relative
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abundance, their drift times can be used to confirm the identities of the ions of higher
abundance (see below). The ion g, at m/z 1107.9 and drift time 3.8 ms, corresponds to
[Q1-6H]6-. The ion f, with drift time 4.8 ms has an m/z in the range between 1900 and
1960 and does not fall into an m/z range identifiable as any ion for single-stranded
DNA; however, if f was from two-stranded DNA, this may correspond to the ion
[2*Q1-7H]7-, with a calculated m/z of 1900.0. If this ion corresponds to two-stranded
DNA, it casts doubt on the original identification of the ion a as [Q1-3H]3-. The ion
[2*Q1-6H]6- has the same calculated m/z as [Q1-3H]3-. Additionally, this ion is
diagonally in line with the 7- (f) ions of the two-stranded DNA. This suggests that these
two ions may arise from the same DNA secondary structure.

Table 3.2: Shows the assignment for ions in the driftscope spectra in Figure 3.17 (A1 and B1).
Conditions

Ions observed for Q4 (observed m/z, calculated
m/z, ms on driftscope, assignment)

150 mM NH4OAc

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6--

(Figure 3.17 (A))

b, m/z 1662.5, 1662.3, 5.1 ms, [Q1-4H]4c, m/z 1330.0, 1329.7, 3.5 ms, [Q1-5H]5d, m/z 920-930, 5.1 ms, fragment ion
e, m/z 700-780, 3.5 ms, fragment ion

5 mM NH4OAc

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6-

(Figure 3.17 (B))

b, m/z 1662.5, 1662.3, 5.1 ms, [Q1-4H]4c, m/z 1330.0, 1329.7, 3.5 ms, [Q1-5H]5d, m/z 920-930, 5.1 ms, fragment ion
e, m/z 700-780, 3.5 ms, fragment ion
f, m/z 1900-1960, 1900, 4.8 ms, [2*Q1-7H]7g, m/z 1108.0, 1107.9, 3.8 ms, [Q1-6H]6103

Figure 3.17: Optimised ion mobility spectra of Q1 in: (A) 150 mM NH 4OAc; (B) 5 mM
NH4OAc. Under each set of conditions (A and B), (1) shows the driftscope image, (2) shows the
ESI mass spectra. Unless otherwise indicated in the text the ions indicated are for singlestranded quadruplex DNA.
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3.6.3 Optimisation for Q2
Figure 3.18 shows the negative ion ESI mass spectrum of double-stranded qDNA, Q2,
acquired under optimal conditions (section 2.4.2) using the HDMSTM SynaptTM. The
instrument conditions were gentle and not targeted towards acquisition of an ion
mobility spectrum. It was not possible to obtain spectra of similar signal-to-noise ratio
as that obtained using the QTOF UltimaTM (shown in Figure 3.10). The ESI mass
spectrum showed three predominant ions previously identified in section 3.5.2. These
were the ions from double-stranded quadruplex Q2; [Q2-4H]4-, [Q2-5H]5-, and the ion
believed to correspond to the single-stranded Q2 ion [Q2-3H]3-, at m/z 1893.3, 1514.4,
and 1261.8 respectively. The latter single-stranded Q2 ion will henceforth be referred to
as [ssQ2-3H]3-. It was not possible to determine conditions under which the species with
ammonium ions were clearly observed, as was the case with the QTOF UltimaTM. An
additional very broad ion peak was observed over the m/z range 2100-2300. Given the
broadness of this peak, it was not possible to assign this to any ion from the twostranded or single-stranded form of Q2 based on ESI-MS data alone. The closest
matches are the two-stranded [Q2-3H]3- at calculated m/z 2524.7, or the single-stranded
ion [ssQ1-2H]2- at m/z 1893.2. Additionally, the abundance of this group of ions was
greatly reduced when the instrumental conditions were altered to optimise acquisition of
ion mobility mass spectra.
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Figure 3.18: Negative ion ESI-MS spectra of Q2 DNA in 150 mM NH4OAc, pH 7, obtained
using the Waters HDMSTM SynaptTM in ESI mode. Proposed two-stranded quadruplex DNA is
marked with ■ and denotes unidentified ions.

The optimised ion mobility spectra of Q2 in 150 mM NH4OAc and 5 mM NH4OAc are
shown in Figure 3.19. The assignments for the ions are shown in Table 3.3. In 150 mM
NH4OAc (Figure 3.19 (A1)), the drift times of the ions labelled a, b and c, previously
identified as [Q2-4H]4-, [Q2-5H]5-, and [ssQ2-3H]3-, respectively, are 8.4, 5.6, and 5.7
ms. That is, the drift time of the [Q2-5H]5-, and [ssQ2-3H]3- ions is the same within the
errors of the experiment. If the ion c at m/z 1261.8 represented the 6- charge state of the
two-stranded quadruplex we would expect this to have a shorter drift time than ion b (5charge). Since this is not the case, these observations strongly support the assignment of
this ion as [ssQ2-3H]3-. The ion b ([Q2-5H]5-) is sharp and its m/z value shows there are
no associated ammonium adducts. At higher m/z (Figure 3.19 (A2)), there are ions that
may arise from [Q2-5H]5- with associated ammonium ions. This is consistent with the
assignment of ion e as [Q2+3NH4+-9H]6-, which was observed when Q2 was sprayed
from 5 mM NH4OAc (Figure 3.9 (B)).
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When the NH4OAc concentration was 5 mM (Figure 3.19 (B1)) three additional ions
were observed. All ions observed in the spectra of Q2 (Figure 3.19) are summarised in
Table 3.3. The ion e, at m/z 1270.8, corresponds to [Q2+3NH4+-9H]6- and was observed
at a drift time of 4.4 ms. The assignment of this ion removes the ambiguity of the ion c,
identified previously as [ssQ2-3H]3-. Additionally, ion c also appears to be dissociating
under these conditions to give rise to ion d. The ions (includes salt adducts)
corresponding to [ssQ2-3H-G]3- (d) have a very similar drift time (average 5.5 ms) to
the precursor ion at 5.9 ms. Another ion labelled f, is observed at m/z 946.0 with a drift
time of ~3.6 ms. Based solely on its m/z value, this may correspond to either the [ssQ24H]4- ion, or the [Q2-8H]8- ion. Based on the drift time and the small peak width at m/z
946, this ion is most likely [ssQ2-4H]4-. This ion and the other single-stranded ion
[ssQ2-3H]3- appear to be forming a series of single-stranded ions in the driftscope (B1)
alongside the proposed double-stranded quadruplex DNA ions. The dissociation of Q2
to single strands when the salt concentration is reduced supports that under the
experimental conditions ( in 150 mM NH4OAc, pH 7) Q2 was folded into a qDNA
structure and is in agreement with the results from the CD spectra (Figure 3.9).
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Figure 3.19: Optimised ion mobility spectra of Q2 in: (A) 150 mM NH4OAc, pH 7; (B) 5 mM
NH4OAc, pH 7. Under each set of conditions (A and B), (1) shows the driftscope image, (2)
shows the ESI mass spectra. Unless otherwise indicated in the text the ions indicated are for
two-stranded quadruplex DNA.
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Table 3.3: Shows the assignment of ions in the driftscope spectra in Figure 3.19 (A1) and (B1).
Conditions

Ions observed for Q4 (observed m/z, calculated
m/z, ms on driftscope, assignment)

150 mM NH4OAc

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

(Figure 3.19 (A))

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5c, m/z 1262.1, 1261.8, 5.7 ms, [ssQ2-3H]3-

5 mM NH4OAc

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

(Figure 3.19 (B))

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5c, m/z 1262.1, 1261.8, 5.7 m/s, [ssQ2-3H]3d, m/z 1210.8, 1211.5, 5.5 ms, [ssQ2-3H-G]3e, m/z 1270.8, 1270.3, 4.4 ms, [Q2+3NH4+-9H]6f, m/z 946.0, 946.1, 3.6 ms, [ssQ2-4H]4-

3.7 ESI-IMMS of quadruplex DNAs in destabilising conditions
Further experiments were performed to try and disrupt the quadruplex structures of the
DNA sequences Q4, Q1, and Q2 and thus confirm the assignments of ions made earlier,
as well as lending support to the presence of qDNA structure under the more gentle
conditions. The experiments included gradually increasing the acetonitrile concentration
to denature the structures to single-stranded DNAs. For maximum effect, these
experiments used 5 mM NH4OAc. Additionally, attempts were made to observe the
effects of changing the desolvation temperature; however, for each of the DNAs this did
not result in any significant changes in the spectra. Similarly, heating the solution prior
to injection was not a feasible experiment since the DNA was cooled before reaching
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the cone. A separate experiment was performed to explore the effect of increasing the
temperature at the cone, which yielded some small changes in the spectra.

3.7.1 Q4
Figure 3.20 shows the ESI mass spectra and ion mobility mass spectra of Q4 sprayed
from 150 mM NH4OAc (A), 5 mM NH4OAc (B) shown again (cf. Figure 3.14 (B)), 150
mM NH4OAc where the cone has been heated to 75°C (C), and 5 mM NH4OAc/ 40%
ACN (D). Table 3.4 summarizes the ions that were observed in this experiment. Figure
3.20 (A) shows the spectrum of Q4 in 150 mM NH4OAc. As previously observed, the
most abundant ion was [Q4+4NH4+-9H]5- (b). As the cone temperature was increased,
guanine was lost from this ion and at higher temperatures single strands appeared in the
spectra. Figure 3.21 shows mass spectra for these experiments as the drift times of the
resulting products were not able to be resolved in the driftscope (Figure 3.20 (C); see
ion b). When the cone temperature was increased from 25°C to 50°C the intensity of ion
b, [Q4+3NH4+-8H]5-, increased in abundance relative to [Q4+4NH4+-9H]5-. Ions
corresponding to the loss of guanine were also observed under these conditions. Up to
three guanines were lost from the 5- ions. The drift times of these ions were the same as
the drift time for the [Q4+3NH4+-8H]5- ion. This suggests that loss of guanines is
occurring before the loss of additional ammonium ions or loss of the quadruplex
structure. Mazzitelli et al. made similar observations when performing ESI-MS
dissociation experiments on quadruplex DNAs.193 They observed the loss of guanine
residues before strand loss. These fragmentation patterns are discussed in more detail in
section 3.8.1. It was also interesting to note that the 6- ions increased in abundance
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relative to the 5- ions at higher temperatures. This may be an indication of enhanced
desolvation of ions.

When the temperature was increased further to 75ºC (Figure 3.20 1(C) and Figure 3.21
(C)), up to four guanine residues were lost from the 5- ion. Additionally, the ion(s) f,
appeared at drift time 7.7 ms and m/z 1247.0. This ion has been previously assigned as
arising from the ssDNA ion [Q4-2H]2-. This suggests that the increase in cone
temperature dissociated some of the qDNA. No ions from the three-stranded DNA were
evident suggesting that this was not stable. At 100ºC no 6- (c) ions were observed and
relatively little 5- (b) ions remained, where the most intense of these ions corresponded
to [Q4+3NH4+-8H-1G]5-. Above 100ºC mostly fragment ions were observed (Figure
3.21 (E)) and the low intensity quadruplex DNA ions were poorly resolved.
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Figure 3.20: Ion mobility spectra of Q4 in: (A) 150 mM NH4OAc, pH 7; (B) 5 mM NH4OAc, pH 7; (C)150 mM NH4OAc, pH 7 where the cone was heated to 75°C; (D)
5 mM NH4OAc/ 40% ACN, pH 7. Unless otherwise indicated in the text the ions are for four-stranded quadruplex DNA.
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Table 3.4: Shows the assignment of ions in the driftscope spectra in Figure 3.21.
Conditions

Ions observed for Q4 (label, calculated m/z, ms on
driftscope, assignment)

150 mM NH4OAc

a, m/z 2512.6, 2512.8, 12.8 ms, [Q4+4NH4+-8H]4-

(Figure 3.20 (A))

b, m/z 2009.8, 2010.0, 8.2 ms, [Q4+4NH4+-9H]5c, m/z 1674.4, 1674.8, 5.8 ms, [Q4+4NH4+-10H]6-

5 mM NH4OAc

b, m/z 2009.8, 2010.0, 8.2 ms, [Q4+4NH4+-9H]5-

(Figure 3.20 (B))

c, m/z 1674.4,1674.8, 5.8 ms, [Q4+4NH4+-10H]6d, m/z 1435.0, 1435.4, 4.6 ms, [Q4+4NH4+-11H]7e, m/z 1256.2, 1256.4, 3.8 ms, [Q4+4NH4+-12H]8f, m/z 1247.3, 1247.3, 7.7 ms, [ssQ4-2H]2g, m/z 831.1, 831.2, 4.4 ms, [ssQ4-3H]3-

150 mM NH4OAc at 75°C
cone temperature

a, m/z 2512.6, 2512.8, 12.8 ms, [Q4+4NH4+-8H]4-

(Figure 3.20 (C))

b, m/z 2009.8, 2010.0, 8.2 ms, [Q4+4NH4+-9H]5c, m/z 1674.2, 1674.8, 5.8 ms, [Q4+4NH4+-10H]6f, m/z 1247.0, 1247.3, 7.7 ms, [ssQ4-2H]2-

5 mM NH4OAc/ 40% ACN

b, m/z 2010.1, 2010.0, 8.2 ms, [Q4+4NH4+-9H]5-

(Figure 3.20 (D))

c, m/z 1675.0, 1674.8, 5.8 ms, [Q4+4NH4+-10H]6d, m/z 1435.2, 1435.4, 4.6 ms, [Q4+4NH4+-11H]7e, m/z 1256.2, 1256.4, 3.8 ms, [Q4+4NH4+-12H]8f, m/z 1247.0, 1247.3, 7.7 ms, [ssQ4-2H]2g, m/z 831.1, 831.2, 4.4 ms, [ssQ4-3H]3h, m/z 974.1, undetermined, 6.2 ms, fragment ion

In 5 mM NH4OAc there were series of ions corresponding to qDNA (b-e) and ssDNA
(f-h) as previously observed. When acetonitrile was present (Figure 3.20 (D)), all ions
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increased in abundance, most likely since desolvation in the source was facilitated and
possibly as a result of some dissociation of qDNA to single strands. As the acetonitrile
concentration was increased there were few changes observed apart from a decrease in
mobility “resolution” between the ions labelled b and c, corresponding to the 5- and 6ions, respectively. At 40% ACN the major ions of Q4, [Q4+4NH4+-9H]-5 (b), and
[Q4+4NH4+-10H]-6 (c) remained. There was significantly more noise present in the
spectrum. Additionally, an ion previously unidentified owing to its low abundance,
labelled h in the figure, is observed at greater intensity at m/z 974.1. This does not
correspond to any ions from intact four-stranded Q4, or any ssDNA ions. Overall this
ion is of low relative abundance so it is difficult to assign conclusively, but may
correspond to a fragment ion.

Figure 3.21: Negative ion ESI mass spectra of Q4 acquired when the cone temperature was
raised: (A) 25°C, (B) 50°C, (C) 75°C, (D) 100°C, and (E) 125°C. ■ [Q4+4NH4+-9H]5-;
[Q4+3NH4+-8H]5-; ● [Q4-5H]5-; ∆ [Q4-1G-5H]5-; ♦ [Q4-2G-5H]5-; ○ [Q4-3G-5H]5-; □ [ssQ42H]2-, DNA fragments. G is guanine.
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3.7.2 Q1
The effects of increasing the cone temperature and increasing the acetonitrile
concentration of samples of Q1 were also investigated. Figure 3.22 shows the ESI mass
spectra and ion mobility mass spectra of Q1 sprayed from 150 mM NH4OAc (A), and 5
mM NH4OAc (B) shown again for comparison (cf. Figure 3.17 (A) and Figure 3.17
(B)), in addition to 150 mM NH4OAc where the cone was heated to 75°C (C), and 5
mM NH4OAc/ 40% ACN (D). Table 3.5 summarizes the ions that were observed in this
experiment. In 150 mM NH4OAc (Figure 3.22 (A)), as previously observed, the most
abundant ions were [Q1-4H]4- (b), and [Q1-5H]5- (c). When the cone temperature was
increased (C) additional charge states were observed. The major changes observed were
the increase in abundance of DNA fragments such as d and e. Figure 3.22 (C1) shows
the driftscope spectrum obtained at 75°C where these ions are highlighted. Additionally,
where the ions c (5- charge state) had been the most intense at 25°C (Figure 3.22 (A1)),
b (4- ions) became the most intense at higher temperatures.

Increasing the acetonitrile concentration to 20% from 0% saw the appearance of the ion
h, at m/z 949, consistent with 7- ions, at calculated m/z 949.5. The ion d, previously
identified as a fragment (see section 3.6.2), is also present at m/z 920-930, thus the
initial assignment of this ion as the product y3 - (m/z 924.7) or y62- (m/z 922.6) appears to
be correct. Additionally, these new 7- ions have a drift time of approximately 3.3 ms
which places them almost at the same drift time as the 6- ions (g). Apart from further
loss of resolution, no significant changes were observed until the ACN concentration
was increased to 80% (not shown). At this ACN concentration, a completely
disappeared and the most intense ion was the fragment ion d.
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Figure 3.22: Ion mobility spectra of Q1 in: (A) 150 mM NH4OAc; (B) 5 mM NH4OAc; (C)150 mM NH4OAc where the cone has been heated to 75°C; (D) 5
mM NH4OAc/ 40% ACN. Unless otherwise indicated in the text the ions are for single-stranded quadruplex DNA.
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Table 3.5: Shows the assignments of ions in the driftscope spectra in Figure 3.22.
Conditions

Ions observed for Q1 (label, observed m/z, calculated
m/z, ms on driftscope, assignment)

150 mM NH4OAc

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6-

(Figure 3.22 (A))

b, m/z 1662.5, 1662.3, 5.1 ms, [Q1-4H]4c, m/z 1330.0, 1329.7, 3.5 ms, [Q1-5H]5-

5 mM NH4OAc

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6-

(Figure 3.22 (B))

b, m/z 1662.5, 1662.3, 5.1 ms, [Q1-4H]4c, m/z 1330.0, 1329.7, 3.5 ms, [Q1-5H]5d, m/z 920-930, 5.1 ms, fragment ion
e, m/z 700-780, 3.5 ms, fragment ion
f, m/z 1900-1960, 1900, 4.8 ms, [2*Q1-7H]7g, m/z 1108, 1107.9, 3.8 ms, [Q1-6H]6-

150 mM NH4OAc at cone

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6-

temperature 75°C

b, m/z 1662.4, 1662.3, 5.1 ms, [Q1-4H]4-

(Figure 3.22 (C))

c, m/z 1329.7, 3.5 ms, [Q1-5H]5d, m/z 920-930, 5.1 ms, fragment ion
e, m/z 700-780, 3.5 ms, fragment ion
f, m/z 1900-1960, 1900, 4.8 ms, [2*Q1-7H]7g, m/z 1108, 1107.9, 3.8 ms, [Q1-6H]6-

5 mM NH4OAc/40% ACN
(Figure 3.22 (D))

a, m/z 2200-2300, 2216.8, 6.4 ms, [2*Q1-6H]6b, m/z 1662.6,1662.3, 5.1 ms, [Q1-4H]4c, m/z 1330.2, 1329.7, 3.5 ms, [Q1-5H]5d, m/z 1434.9, 1435.4, 6.4 ms, [Q4+4NH4+-11H]7f, m/z 1900-1960, 1900, 4.8 ms, [2*Q1-7H]7g, m/z 1108, 1107.9, 3.8 ms, [Q1-6H]6h, m/z 949.0, 949.5, 3.3 ms, [Q1-6H]6117

3.7.3 Q2
The double-stranded quadruplex DNA Q2 was sprayed under the same destabilising
conditions as Q4 and Q1. Figure 3.23 shows the spectra obtained in 150 mM NH4OAc
(A), 5 mM NH4OAc (B) shown again for comparison (cf. Figure 3.19 (B)), 150 mM
NH4OAc where the cone was heated to 75°C (C), and 5 mM NH4OAc/ 40% ACN (D).
Table 3.6 summarizes the ions that were observed in these experiments. When the cone
temperature was increased to 50°C (not shown), the ions previously assigned as the
four-stranded quadruplex ions [2*Q2-7H]7-(g), and [2*Q2-8H]8- (h) were once again
present, though still at very low intensities (not shown). The base peak at this cone
temperature was the ion c, (single-stranded [ssQ2-3H]3-). Above a cone temperature of
50°C dissociation of the 3- ssDNA ion was observed. At cone temperatures of 75°C
(Figure 3.23 (C)) and above, up to three guanines were lost from the 3- single strand. At
120°C little folded qDNA could be identified, and the base peak corresponded to the w2product at m/z 675 (not shown). Overall, the predominant effect of the heating of Q2
was the fragmentation of existing ions.

As the acetonitrile concentration was increased from 0% to 20%, no major changes
were observed. When the concentration was increased to 40% (Figure 3.23 (D)), two
ions, g and h, which were previously of too low abundance to identify, were more
clearly observed between m/z 2150-2200 and 1890-1950. Neither of these ions appear to
correspond to calculated m/z values for fragment ions. Furthermore, they are both absent
at higher concentrations of ACN, so do not seem to correspond to ssDNA. If these ions
arise from a folded secondary structure, the ion g, between 2150-2200 could only
correspond to a four-stranded quadruplex ion [2*Q2-7H]7-, with calculated m/z 2163.9,
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and its corresponding salt adducts. The ion h, between m/z 1890-1950 may have
multiple assignments. In the same mass-to-charge region the ion a, [Q2-4H]4-, (m/z
1893.2) has already been identified. So the possibility remains that this ion is a different
conformation of the same ion, possibly some form of slipped structure of [Q2-4H]4-.
Given the tentative assignment of the four-stranded quadruplex ion (g) above, it lends
some weight to the assignment of h as the four-stranded quadruplex ion [2*Q2-8H]8(calculated m/z 1893.2), since they are in diagonal alignment across the driftscope. It is
also possible that this may be a quadruplex dimer rather than a four-stranded qDNA.
Such structures have been previously reported in the literature and are discussed in more
detail in section 5.3.2.1. The fragment ions which appear were difficult to conclusively
identify as the mass range was between m/z 850-1000. There are numerous possible
fragment ions which fall in this range.
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Figure 3.23: Ion mobility mass spectra of Q2 in: (A) 150 mM NH4OAc; (B) 5 mM NH4OAc; (C)150 mM NH4OAc where the cone was heated to 75°C; (D) 5
mM NH4OAc / 40% ACN. Unless otherwise indicated in the text the ions are for two-stranded quadruplex DNA.
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Table 3.6: Shows the assignment of ions in the driftscope spectra in Figure 3.23.
Conditions

Ions observed for Q2 (observed m/z, calculated
m/z, ms on driftscope, assignment)

150 mM NH4OAc

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

(Figure 3.23 (A))

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5c, m/z 1262.1, 1261.8, 5.7 ms, [ssQ2-3H]3-

5 mM NH4OAc

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

(Figure 3.23 (B))

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5c, m/z 1262.1, 1261.8, 5.7 ms, [ssQ2-3H]3d, m/z 1210.8, 1211.5, 5.5 ms, [ssQ2-3H-G]3e, m/z 1262.0, 1261.8, 4.4 ms, [Q2-6H]6f, m/z 946.0, 946.1, 3.6 ms, [ssQ2-4H]4-

150 mM NH4OAc at cone

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

temperature 75°C

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5-

(Figure 3.23 (C))

c, m/z 1262.1, 1261.8, 5.7 ms, [ssQ2-3H]3d, m/z 1210.8, 1211.5, 5.5 ms, [ssQ2-3H-G]3g, m/z 2150-2200, 2163.9, [2*Q2-7H]7-

5 mM NH4OAc/ 40% ACN

a, m/z 1893.0, 1893.2, 8.4 ms, [Q2-4H]4-

(Figure 3.23 (D))

b, m/z 1515.0, 1514.4, 5.6 ms, [Q2-5H]5c, m/z 1262.1, 1261.8, 5.7 ms, [ssQ2-3H]3d, m/z 1210.8, 1211.5, 5.5 ms, [ssQ2-3H-G]3e, m/z 1262.0, 1261.8, 4.4 ms, [Q2-6H]6f, m/z 946.0, 946.1, 3.6 ms, [ssQ2-4H]4g, m/z 2150-2200, 2163.9, [2*Q2-7H]7h, m/z 1890-1950, 1893.2, [2*Q2-8H]8i, m/z 850-1000, unidentified fragment ion
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3.8 CID of Q DNAs
Tandem mass spectrometry, (MS/MS or collision induced dissociation, CID) involves
selection of ions of a given m/z (precursor ion) for CID analysis of the resulting product
ions. In CID, the kinetic energy of an ion is converted to vibrational energy (also called
internal energy) when it collides with an inert gas.192, 234-236 In a Q-TOF ESI-IM mass
spectrometer, the ions are selected in the quadrupole. Dissociation can be induced by
increasing the collision energy at either the trap or transfer region (Figure 1.12,
schematic of the Synapt earlier in this thesis). Therefore dissociation can occur either
before or after ion mobility separation. In the present study, MS/MS experiments were
used to assess the gas phase stabilities of the 5 - and 4- ions of Q4 and Q1, and the 5- and
3- (where the 3- ion was previously assigned as ssDNA) ions of Q2. The qDNA was
sprayed from 150 mM NH4OAc, pH 7.

At present there are three other studies which have investigated the CID patterns of
qDNA.93,

132, 193

The first of these studies was by David et al., who investigated the

collision-induced dissociation of Q4 when it was bound to Tel01 (Figure 3.24).132 Tel01
is an N,N'-bis-(3-(4-morpholino)-propyl)-3,4,9,10-perylene tetracarboxylic acid diimide
which has been previously reported to stabilise with qDNA by stacking on terminal Gtetrads.237 Later, Rosu et al. investigated the dissociation pathways of Q1 and Q2.93 The
most recent study of this type was by Mazzitelli et al. who performed dissociation
studies on a number of similar quadruplex-forming oligonucleotides including
(TGGGGT)4 (one guanine fewer than Q4).193 These three studies were carried out using
ESI ion traps and an ESI Q-TOF instrument. In the current study, CID spectra of Q4,
Q1, and Q2 were compared to those obtained by Rosu et al.93 and Mazzitelli et al.193
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Figure 3.24: The structure of Tel01.

3.8.1 CID of Q4
CID ion mobility experiments were performed by selecting the [Q4+4NH4+-9H]5- ion as
the precursor and increasing the trap collision energy. Therefore dissociation occurred
before ion mobility separation, thus allowing the drift time of the fragment ions to be
determined. These spectra are shown in Figure 3.25 (A). It should be noted that the
quadrupole of the HDMSTM SynaptTM ESI-IMMS instrument was modified to cover the
m/z range 0-32,000 (for other projects). This extended mass range decreases the
resolution available for selection of the precursor ion so in Figure 3.25 (A) the precursor
[Q4+4NH4+-9H]5- is evident along with [Q4+6NH4+-11H]5-, [Q4+5NH4+-10H]5- and
[Q4+3NH4+-8H]5-. As a consequence, products may also arise from these ions. As the
trap collision energy was increased from 6 V to 10 V, the loss of a guanine residue was
observed along with a decrease in the relative abundance of [Q4+4NH4+-9H]5- and an
increase in the relative abundance of Q4+3NH4+ and Q4+2NH4+. As the collision
energy was increased further, the loss of two and three guanines was observed. At a trap
collision energy of 22 V the abundance of the [Q4-G-5H]5- (m/z 1966.4, calculated m/z
1966.1) ion was greater than ions from Q4 associated with ammonium adducts.
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Figure 3.25: CID spectra of [Q4+4NH4+-9H]5- at different trap energies. (A) Enlarged view of
m/z 1875-2025.  [Q4+6NH4+-11H]5-; ▲ [Q4+5NH4+-10H]5-; ■ [Q4+4NH4+-9H]5-;
[Q4+3NH4+-8H]5-;
[Q4+ 2NH4+-7H]5-; [Q4+ NH4+-6H]5-; ♦ [Q4-5H]5-; ○ [Q4-1G-5H]5-; ●
5[Q4-2G-5H] ;  [Q4-3G-5H]5-; [Q4-4G-5H]5-. G is guanine. (B) Driftscope spectrum at trap
CE 22 V. a [Q4-5H]5-, b [Q4-1G-5H]5-, c [Q4-2G-5H]5-, d [Q4-3G-5H]5-.

Figure 3.26 (A) shows the spectra over the m/z range 600-2000 as well as the driftscope
image acquired when the trap energy was 30 V (B). At 22 V the base peak was the [Q45H]5- ion and other product ions were observed at, m/z 650, and 705 (d) as well as at m/z
1247.3 (b). As discussed above (section 3.6.1), the ion at m/z 1247.3 may be from either
the four-stranded [Q4-8H]8- ion, the three-stranded [Q4-6H]6-, or the single-stranded
[ssQ4-2H]2- ion. This view of the CID spectra shows an ion at m/z 1171.8 (c) which
corresponds to [ssQ4-1G-2H]2-. If the ion at m/z 1247.3 corresponded to either the fourstranded [Q4-8H]8- or three-stranded [Q4-6H]6-, the ion at m/z 1171.8 would correspond
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to the loss of four or three guanines, respectively. Since no ions corresponding to the
loss of one and two guanines were present, the single-stranded ion at m/z 1247.3 is the
most likely [ssQ4-2H]2-. The drift times for the predominant ions change slightly with
each increase in trap collision energy as this affects the velocity with which the ions are
propelled through the ion mobility cell. However, even when the voltage was
maintained at 6 V and the 5 - ions were selected, there were low abundance ions present
in the region where the 3 - ssDNA ions are expected to occur. This suggests that at least
some of the ssDNA may be generated post injection to the mass spectrometer (not
shown). Additionally, the ion mobility spectra shown in Figure 3.26, shows that ion b,
m/z 1247.3, at drift time 8.4 ms, observed in this experiment had a similar drift time to
that observed in previous ion mobility experiments at 7.7 ms. It should be noted that the
drift time of the 5- ions have also shifted from 8.3 ms (Table 3.2) to 9.0 ms. Thus it
appears that the ssDNA ion observed in this experiment is the same as that observed
previously.
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Figure 3.26: (A) Negative ion CID of [Q4+4NH4+-9H]5- at different trap energies. ♦ [Q4-5H]5-;
○ [Q4-1G-5H]5-; ● [Q4-2G-5H]5-;  [Q4-3G-5H]5-; ▲ [Q4-2H]2-; ◊ [Q4-G-2H]2-;
DNA
product ions. G is guanine. (B) Driftscope spectrum at trap CE = 30 V. a [Q4+4NH4+-9H]5-; b
[Q4-2H]2-; c [Q4-G-2H]2-, d fragment ions.

When the trap collision energy was increased above 30 V, ions resulting from
phosphodiester backbone cleavage were abundant. A similar observation has been made
for duplex DNA, where shorter duplexes first undergo dissociation of non-covalent
bonds to give ssDNA, whereas longer duplexes undergo extensive loss of DNA bases
owing to cleavage of covalent bonds in addition to strand separation.238 Figure 3.27
summarizes the relative abundance of the ions observed as a function of trap energy,
where the relative abundance of product ions steadily increases above 10 V and there
are few ions from four-stranded qDNA above 34 V. Dissociation studies have been
performed on similar sequences.93, 132, 193 Mazzitelli et al. reported studies of a sequence,
(TGGGGT)4, with one less guanine and thymine base, than Q4.193 In these experiments
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the precursor ions were also NH4+ adducts. This sequence was reported to initially lose a
single strand to give a three-stranded structure, followed by guanine base loss, where
the ammonium ions were not described and were presumably lost first. Rosu et al.
performed the same experiments using a Q-TOF mass spectrometer with ions which had
incorporated NH4+ ion adducts. They also reported the loss of ammonium ions first,
followed by single strand loss and then depurination. 93 The pathway observed in the
current study where the loss of ammonium ions, followed by depurination, and then
complete strand separation was observed is different to that observed for the sequence
(TGGGGT)4. While this seems to be in contradiction, the study by Mazzitelli et al.
observed that when the number of guanine tetrads was increased, covalent cleavage of
guanine residues was favored over non-covalent strand separation.193 This may account
for the difference observed in this study since Q4 (TTGGGGGT)4 has one more guanine
tetrad to stabilise the structure.

Figure 3.27: Summary of product ions arising from [Q4+4NH4+-9H]5-, as a function of
increasing trap energy.
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CID experiments were attempted selecting the 4- and 6- ions of Q4 as precursors. The 6ions were not sufficiently abundant to obtain any CID spectra. The [Q4+4NH4+-8H]4ion was also of very low abundance but it was possible to obtain CID spectra. Although
it was not possible to calculate reliable relative abundances given the low signal-to-noise
ratios, it was possible to make some comparisons with the CID of [Q4+4NH4+-9H]5-. In
common with the CID spectra for the 5- ions, initial loss of ammonium ion was observed
followed by a loss of guanine. The 4- was of low abundance such that it was not possible
to observe ions where more than one guanine was lost if they were generated. Since
higher gas phase stability has been observed for ions from DNA duplexes carrying fewer
charges,239 it was expected that the stability of the precursor ions would follow the
order: [Q4+4NH4+-7H]4- > [Q4+4NH4+-8H]5- > [Q4+4NH4+-8H]6-. The low intensity of
the 4- and 6- ions makes this difficult to confirm. Loss of thymine from Q4 did not occur
under any of the conditions used in the experiments described here. Similar observations
have been made in MS/MS studies of duplex DNA.238, 240-242 The retention of thymine
has been accounted for by proposing that the lower proton affinity of the base relative to
the other DNA bases makes it a much less stable leaving group.236, 242

3.8.2 CID of Q1
CID experiments were performed on the [Q1-4H]4- ion by increasing the trap energy.
These spectra are shown in Figure 3.28 (A) and a graph showing the relative
abundances of the precursor and product ions is shown in Figure 3.29. As the trap
energy was increased from 6 V to 14 V the loss of a guanine base was observed. As the
energy was increased further to 22 V, the loss of up to two guanine bases was observed.
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At a trap collision energy of 30 V, ions corresponding to [Q1-3G-4H]4- emerged. At
greater trap energies additional ions corresponding to DNA fragments were observed.
The ion mobility spectra showed that loss of guanine did not greatly affect the mobility
of the DNA.

Figure 3.28: (A) Negative ion CID of [Q1-4H]4- at different trap energies. ■ [Q1-4H]4-; [Q1G-4H]4-; ● [Q1-2G-4H]4-; □ [Q1-3G-4H]4-. G is guanine. (B) Driftscope spectrum at trap energy
= 30 V. a [Q1-4H]4-, b [Q1-G-4H]4-, c [Q1-2G-4H]4-, d [Q1-3G-4H]4-.
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Figure 3.29: Summary of product ions arising from [Q4+4NH4+-9H]4- as a function of
increasing trap energy.

Figure 3.30 shows the spectra obtained for CID of the precursor ion [Q1-5H]5-. As the
trap collision energy was increased from 6 V to 10 V it was possible to observe the loss
of one guanine base. At 22 V up to two guanine bases were lost and the relative
abundance of the precursor ion was decreased. Above 30 V virtually no precursor ion
remained and the predominant ions were from cleavage of the phosphodiester backbone.

Figure 3.30: Negative ion MS/MS of [Q1-5H]5- at different trap collision energies. ■ [Q1-5H]5-,
[Q1-G-5H]5-; ● [Q1-2G-5H]5-; □ [Q1-3G-5H]5-; ♦ [Q1-4G-5H]5-. G is guanine.
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3.8.3 CID of Q2
CID experiments were performed on the [Q2-5H]5- ion by increasing the trap energy.
Figure 3.31 (A) shows the dissociation profile of the [Q2-5H]5- ion and the relative
intensities of all ions is shown graphically in Figure 3.32. At 6 V [Q2+NH4+-5H]5- could
be observed at about 50% of the abundance of the precursor ion [Q2-5H]5-. At 22 V,
ions at m/z 1484.2 and 1261.8 were observed. The former ion is [Q2-G-5H]5-. This ion
was also reported to occur in MS/MS experiments on the same two-stranded quadruplex
by Brodbelt and co-workers.193 The ion at m/z 1261.8 corresponds to [ssQ2-3H]3-.

Figure 3.31: Negative ion CID of [Q2-5H]5- at different trap energies.  [Q2+NH4+-6H]5-; 
[Q2-5H]5-; [Q2-G-5H]5-; ■ [ssQ2-3H]3-; ○ [ssQ2-G-3H]3-;  [ssQ2-2G-3H]3-. G is guanine.
(B) Driftscope spectrum at trap CE = 22 V. a [Q2-5H]5-, b [ssQ2-3H]3-, c [ssQ2-G-3H]3-.

At 30 V dissociation of the single-stranded [ssQ2-3H]3- ion begins to occur as a new
ion at m/z 1211.5 corresponding to [ssQ2- G-3H]3- (c), appeared. At 28 V the precursor
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ions are no longer present and an ion at m/z 1161.1 corresponding to the loss of 2
guanines from the single-stranded species was observed.

Figure 3.32: Summary of product ions arising from [Q4+4NH4+-9H]-5 as a function of
increasing trap energy.

Figure 3.33 (A) shows the tandem mass spectra obtained when CID was performed on
the precursor ion [ssQ2-5H]3-. This strand was observed to lose up to 2 guanine residues
at 38 V. Beyond this voltage the strand degraded to DNA fragments. Figure 3.33 (B)
shows the ion mobility driftscope obtained of the [ssQ2-5H]3- ion at a trap collision
energy of 22 V.
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Figure 3.33: CID of [ssQ2-3H]3- at different trap energies. (A) Mass spectra, ■ [ssQ2-3H]3-; ○
[ssQ2-G-3H]3-; ♦ [ssQ2-2G-3H]3-. G is guanine. (B) Driftscope spectrum at trap CE = 22 V. a
[ssQ2-3H]3-, b [ssQ2-G-3H]3-.

3.9 Chapter summary
Quadruplex DNA structures were successfully prepared and detected using ESI-MS and
circular dichroism. Additionally, in the case of Q4, the requirement of a stabilising
cation for the stability of quadruplex DNA was confirmed using CID experiments since
the quadruplex was less stable once NH4+ dissociated from the structure. In the case of
Q1 no NH4+ stabilising cations could be observed, however, multiple salt adducts were
present which were retained under the conditions of the mass spectrometer. The qDNA
Q2 was found to be the least stable quadruplex. This qDNA was stabilised by NH 4+
adducts; however, these were only retained under very gentle conditions and though
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3NH4+ adducts were expected, only 2NH4+ adducts were observed as the predominant
ions under optimised conditions.

Ion mobility experiments provided useful insight into the structures of each of the
quadruplexes and supported that these secondary structures could be maintained in the
gas phase. The quadruplexes Q1 and Q2 both gave driftscope data consistent with the
presence of polymorphic quadruplexes which has previously been indicated by nonmass spectrometric methods. These preliminary results provide strong evidence for the
maintenance of quadruplex DNA structure under the conditions studied. Additionally,
refinement of the optimised conditions would form a solid basis for further studies and
the analysis of ligand-DNA complexes.
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Chapter 4: Preparation and improved purification procedures
of berberine derivatives
4.1 Introduction
The compound berberine, (Figure 4.1(A)), has been used for centuries in Chinese herbal
medicine to treat gastrointestinal disorders. 243 This isoquinoline alkaloid compound has
anti-malarial, anti-bacterial, anti-fungal and anti-viral properties. It is found in many of
the genera of plants from the Papaveraceae family.244 Additionally, it has recently been
found to have many other beneficial activities such as an anti-inflammatory, antitumour, anti-hypertensive, anti-convulsant, and anti-arrhythmic as well as having
activity in respiratory stimulation and suppression of uterine contraction.244, 245 It has
also been found to be an effective analgesic and to be successful in the treatment of
various skin conditions.164 Berberine may however, cause neonatal jaundice, so its use
is not recommended for pregnant women.246 Additionally, the use of berberine has
caused nausea, vomiting, hypertension, breathing problems, chest pain, skin hives and
skin rashes, and prolonged use over several weeks may cause liver problems.246

Berberine‟s planar, polycyclic structure allows it to interact with many biomolecules,
including enzymes and receptors,247 as well as intercalate into nucleic acids, thereby
inhibiting enzymes involved in nucleic acid synthesis and recognition such as
polymerases and reverse transcriptase.244 There are reports that it is able to intercalate
into GC-rich regions of dsDNA. Recently, however, this has come under scrutiny by
Mazzini and co-workers,248 who have reported that berberine is a minor groove
binder.248 Berberine has also been reported to induce topoisomerase I-mediated DNA
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cleavage (i.e. is a topoisomerase I poison).249 It has also been shown that berberine
induces apoptosis in human leukemia HL-60 cells. 250 Wu and co-workers251 have shown
that nucleophosmin/B23 (a phosphoprotein which is a potential regulator of cell
proliferation), and telomerase activity is down-regulated during berberine-induced
apoptosis of HL-60 cells,251 suggesting that this may be an important mechanism of
action in berberine-induced apoptosis.

Berberine derivatives have been synthesised with a view to developing new, more
selective drugs. The significance of the 9-substituent in berberine and its interactions
with topoisomerase II was demonstrated by Krishnan and co-workers.161 They reported
the synthesis of three berberine analogues; 9-ethoxycarbonyl berberine (I), 9-N,Ndimethylcarbamoyl berberine (II), and 12-bromoberberine ((ΙΙΙ), methoxy group at 9position). Compound I selectively inhibited topoisomerase II and stabilised cleavage
complexes predominantly at unique sites; compound II was not a topoisomerase II
poison but had similar DNA binding properties to I. In contrast, compound III was a
stronger DNA binding agent but a much weaker enzyme poison both in vitro and in
cell-based assays.161 The results showed that the 9-substituent within the domain has a
major influence on the interactions of berberine derivatives with biomolecules. 161
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A
B
C
D

Figure 4.1: Structures of compounds used in this work. (A) Berberine, 1, with 13 position
highlighted, (B) oSS14, 8 (C) mSS14, 14 (D) pSS14, 15 (E) SS104, 16 (F) KG01, 13 (G) BT80
17. Berberine moieties are shown in red. The aromatic rings on berberine are labelled A, B, C
and D. The names given are the laboratory names; the numbers given in bold here are consistent
with those given where the synthetic/purification methods are described below. Since a range of
compounds were synthesised to finally arrive at the compounds used in this work, these
numbers are not necessarily consecutive. In order to exclusively identify the compounds for the
purpose of the discussion in this thesis, the laboratory names, rather than the numbers, are used
throughout the text.
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Overall there are four main features which are thought to be important for activity in the
berberine series of compounds: a quaternary nitrogen atom, aromaticity of ring C, the
type of O-alkyl substituent on rings A and D, and the size of the substituent at C-13.160
Figure 4.1 (B) shows an example of a compound, named SS14, that was prepared in our
laboratory as a dual action antibacterial agent with the potential to bind to bacterial
DNA.252 Its components are the berberine molecule attached at the 13-position to an
indole-based bacterial efflux pump blocking agent. SS14 (labelled here as oSS14 where
berberine is linked to the indole at the ortho position) was found to be a potent
antibacterial with activity against Gram-positive bacteria202 and was also found to have
significant in vitro antimalarial activity against Plasmodium falciparum.253 In
preliminary experiments we showed using mass spectrometric studies that oSS14 has
significant selectivity for quadruplex DNA over dsDNA. This selectivity is not
exhibited by berberine.138 Given the fascinating activity of this compound, additional
compounds were synthesised to investigate the activities of analogues of berberine. In
separate work from our laboratory, the compounds mSS14 and pSS14 have recently
been investigated for their antibacterial + NorA efflux pump inhibitory activity in S.
aureus cells.163

4.2 Scope of this chapter
This chapter describes the development of changes to the synthetic procedures for
oSS14 in order to increase the overall yield. The novel compound KG01 was
synthesised using the modified oSS14 procedure in fair yield. The compounds mSS14
and pSS14 needed additional purification steps in preparation for mass spectrometry.
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The development of the HPLC procedure used to purify these compounds is also
described.

4.3 Development of an improved synthetic procedure for
oSS14 and synthesis of KG01
The compound oSS14 (8) was originally synthesised by Siritron Samosorn in the
School of Chemistry, the University of Wollongong, using the methods outlined in
Scheme 4.1.252 Procedures in the final two reactions were modified in the current study
in attempts to increase the yield and purity of the oSS14 produced. The two reactions
studied involved the formation of a key benzylic bromide intermediate 7 via the Appel
reaction254,

255

and its subsequent reaction with 8-allyldihydrobeberine (3) to form

oSS14.

Scheme 4.1: Reported synthesis of oSS14.202
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In the Appel reaction, an alcohol is reacted with triphenylphosphine and carbon
tetrabromide254,

255

to form the corresponding alkyl bromide and triphenylphosphine

oxide as a by-product. The mechanism for this reaction is shown in Scheme 4.2. It was
noted when carrying out this reaction that benzylic alcohol 6 was not readily soluble in
diethyl ether, the solvent originally used for the reaction. It was postulated that this was
leading to very slow conversion to the bromide and unwanted side reactions. For
example, it is known that triphenylphosphine reacts with carbon tetrabromide in the
absence of alcohols to form the corresponding triphenylphosphine dihalomethylene
ylide 9 and triphenylphosphine dihalide 10 (Scheme 4.3).256

Scheme 4.2: Mechanism for the bromination of alcohols using carbon tetrabromide and
triphenylphosphine (Appel reaction).257

In an attempt to avoid this unwanted side reaction, carbon tetrabromide and the alcohol
were dissolved completely in a 1:1 mixture of Et 2O and THF before subsequently
adding the triphenylphosphine in one portion. The reaction was observed to proceed
vigorously and monitoring by TLC showed that it was complete after 10 minutes.
Purification was carried out using column chromatography with 20% EtOAc: Pet.SP.
The desired benzyl bromide 7 was obtained in 75% yield with this modified procedure.
This is a substantial improvement in the yield (41%) reported by Samosorn et al..202 The
correct structure was confirmed by NMR spectroscopy and HRMS (EI) data. The details
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of the characterisation for this compound and also for the other compounds
purified/synthesised in this work are presented in section 4.5.

Scheme 4.3: Reaction of triphenylphosphine with carbon tetrabromide.256

The step involving alkylation of the indole benzyl bromine derivative 7 to give the final
product was also modified. Previously, the reaction was permitted to proceed for 24 h at
100°C resulting in a 34% yield. Scheme 4.4 shows how this reaction proceeds via an
initial enamine alkylation of 3 to give the intermediate 11, followed by a [3,3]sigmatropic rearrangement to give 12 and a final retro-ene reaction258 to give oSS14 (8)
and propene.160 In order to prevent the reformation of berberine, it was decided to
investigate the effect of temperature with the aim that it not be high enough to reform
berberine, but sufficient to form the intermediate 11. To do this the temperature was
initially raised to only 60°C. The reaction was monitored by ESI-MS, and after 24 h
there appeared to be no remaining 3. The temperature was then raised to 100°C to push
the reaction to completion. Monitoring by ESI-MS revealed that the reaction had gone
to completion after 48 h. Using the modified procedures, oSS14 was obtained in 63%
yield, where previously only a 34% yield was reported. 160 The oSS14 synthesised using
this modified procedure was found to be spectroscopically identical to the previously
reported compound.202
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100°C

Scheme 4.4: Proposed mechanism for the formation of the 13-substituted berberine derivatives
SS14 (8) and KG01 (13). Adapted from Bremner et al..160

The synthetic procedure for oSS14 also afforded a route to a naphthalene derivative of
berberine, KG01 (13 in Scheme 4.4). KG01 13 was synthesised from 8allyldihydrobereberine 3 and 2-bromomethylnaphthlene in 58% yield using the new
reaction conditions used for oSS14.

4.4 HPLC purification of oSS14, mSS14, pSS14 and KG01
In order to increase the purity of the berberine derivatives to be used for DNA binding
studies (Chapter 5), improved chromatographic methods were developed. The
compound oSS14 had previously been purified on silica gel (6% MeOH in DCM).202 In
order to improve the purity of the compound, HPLC separation using a C18 reversephase column was investigated. In order to test the conditions, analytical HPLC was
performed using the conditions described in section 2.3 (solvents A (100% H2O, 0.1%
HCl) and B (10% H2O, 90% CH3CN, 0.1% HCl). Crude oSS14 was dissolved in methanol
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prior to injection. Figure 4.2 shows the chromatogram obtained. ESI-MS was then used
to analyse the fractions and showed that the retention time (tR) of oSS14 under these
conditions was ~15 min.

Figure 4.2: Analytical HPLC chromatogram acquired for oSS14 prior to purification.
Conditions are detailed in section 2.3. The numbers 571 and 644 refer to the masses of the
compounds in these fractions.

In order to purify greater quantities of oSS14, semi-preparative RP-HPLC was carried
out using a Waters LC-150 chromatography system fitted with a Waters 2489 dual
wavelength detector set to wavelength 254 nm. The separations were performed using
gradient elutions (30% solvent B to 100% solvent B over 30 min, where solvents A and
B were maintained the same as for analytical HPLC) on a Waters RadPak C18 150 x 40
mm column at a flow rate of 40 ml.min-1 with detection at 254 nm. The purest fractions
as determined by ESI-MS were pooled and freeze dried. Analytical HPLC was then
used to determine the purity of the combined fractions (section 2.3). Figure 4.3 shows
the chromatogram of purified oSS14. Since the solvent for semi-preparative HPLC used
HCl, this method is expected to yield mixed Cl-/Br- salts (where the Br- comes from the
final reaction for the preparation of oSS14). In order to obtain exclusively the chloride
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salt, anion exchange was carried out using an Amberlite IRA-904 quaternary
ammonium Cl- anion exchange resin to yield the final Cl- salt product.

Figure 4.3: Analytical HPLC chromatogram acquired for oSS14 after purification. Conditions
are detailed in section 2.3.

In initial ESI mass spectrometric studies investigating the binding of mSS14 and pSS14
with DNA, the spectra were of very poor quality. In order to confirm the purity of these
compounds, analytical HPLC was performed using the conditions described in section
2.3. The compounds m- and pSS14 were dissolved in methanol to allow injection. The
resulting chromatogram for mSS14 is shown in Figure 4.4. A very similar
chromatogram was observed for pSS14 (not shown). When different fractions were
collected and analysed by ESI-MS, it was not possible to identify the shoulder at tR = 19
min as this was present at very low abundance in the mass spectra.
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Figure 4.4: Analytical HPLC trace acquired for mSS14. Conditions are detailed in section 2.3.

The initial methods for HPLC re-purification using semi-preparative HPLC employed
the methods previously described by Kelso et al.201 This used gradient elutions of 30%
solvent B to 100% solvent B over 30 minutes with solvent A (100% H 2O), B (10%
H2O, 90% CH3CN, 0.1% HCl). The m- and pSS14 purified in this way also gave ESI
mass spectra in DNA binding studies that were of poor quality. It was thought that the
heterogeneity arising from the combination of bromide ion (from the final step in the
synthesis in SS14 analogues, see section 4.3) and chloride ion from the HPLC solvent
may have contributed to this. The small percentage of acid that was added is believed to
aid in separation by charging the quaternary nitrogen present in the SS14 analogues. For
this reason the HCl was replaced with HBr. Mass spectrometry of fractions separated
using this new solvent revealed an ion at m/z 666 (at low relative abundance), in most of
the m- or pSS14 fractions collected. The mass of m- and pSS14 is 586 ([M++H]+ = 585),
so the ion at m/z 666 may be due to addition of bromine (molecular mass 79.902), either
to small amounts of m- and pSS14 or other impurities of the same molecular weight.
This ion was not observed when HPLC purification of oSS14 and KG01 was
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performed, suggesting that p- and mSS14 may be more susceptible to side reactions
using this method. The peak was eluted at almost the same time as the analogues
themselves, such that purification using HBr for acidification was extremely difficult
and resulted in a low overall yield (15%).

Finally, semi-preparative HPLC was performed by omitting the acid from the buffer
system and using the conditions detailed in section 2.3.1. This method gave no
unexplained peaks and this was confirmed by analytical HPLC. Figure 4.5 shows the
analytical HPLC chromatogram obtained for pSS14, where tR = 15.9 min. The
chromatogram for mSS14 was very similar, but tR = 15.0 min. The compound mSS14
was determined to be ~97 % pure and pSS14 was ~96% pure.

Figure 4.5: Analytical HPLC chromatogram for purified pSS14. The HPLC conditions are
described in section 2.3.

There was no difficulty in purifying the compound KG01 so the procedure used
remained the same as for oSS14, where hydrochloric acid was present. Since this
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yielded the mixed Cl-/Br- salt, ion exchange was performed to give the Cl- salt. The
analytical HPLC trace for purified KG01 is shown in Figure 4.6.

Figure 4.6: Analytical HPLC chromatogram for purified KG01. The HPLC conditions are
described in section 2.3.

4.5 Summary of synthetic procedures and characterisation of
ligands
All spectra, unless otherwise stated, were recorded in CDCl3 and referenced to TMS
(1H, 0.00 ppm) and chloroform mid (13C, 77 ppm). Chemical shifts (δ) in ppm were
measured relative to the internal standard. Multiplicities are reported as singlet (s),
broad singlet (bs), doublet (d), doublet of doublets (dd), triplet (t), quartet (q) and
multiplet (m). Coupling constants (J) are reported in Hertz. Details of instruments used
are presented in section 2.3.
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4.5.1 Preparation

of

2-(2-Bromomethylphenyl)-5-nitro-1H-

indole (7)
A yellow suspension of [2-(5-Nitro-1H-indol-2-yl)phenyl]-methanol, 1, (130 mg, 0.49 mmol), prepared
as outlined by Samosorn et al.,252 and carbon
tetrabromide (484 mg, 1.4 mmol) in anhydrous diethyl ether/THF:50/50 (8 ml) under a
nitrogen atmosphere was stirred in an ice bath until all reagents were dissolved.
Triphenylphosphine (380 mg, 1.46 mmol) was then added and the reaction was allowed
to proceed to completion (approx. 5 min). The reaction was monitored by TLC using
50:50 DCM/PET, where the product Rf was 0.98. The reaction mixture was then filtered
and the filtrate concentrated. The residual yellow oil was purified by column
chromatography on silica gel (20% EtOAc/Pet. sp) to give 7 (120 mg, 75%) as a yellow
solid, m.p. 164-166oC. 1H NMR (300MHz, CDCl3,): δ 4.64 (s, 2H, CH2Br), 6.93 (d, J =
1.2 Hz, 1H, H-3), 7.43-7.58 (m, 5H, H-7, ArH), 8.16 (dd, J = 9.0, 2.1 Hz, 1H, H-6),
8.64 (d, J = 2.1 Hz, 1H, H-4), 9.14 (s, 1H, NH). HRMS (EI); m/z calculated for
C15H11N2O2Br [M]+: 330.0003; found: 330.0011.
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4.5.2 Preparation of 9,10-Dimethoxy-13-[2-(5-nitro-1H-indol-2yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6a]quinolizinium bromide, oSS14 (8)
A solution of 8-allyldihydroberberine 3 (57.0
mg, 0.15 mmol), prepared as outlined in
Samosorn et al.,252 and the bromide 7 (102.3
mg, 0.30 mmol) in dry CH3CN (3 ml) was
heated at 60°C in a sealed vial. After 24 h, an
aliquot was removed from the reaction and RPHPLC analysis showed complete enamine alkylation. The vial was then heated to 100oC
and the reaction monitored by RP-HPLC for 2 days until all of the alkylated enamine
intermediate had been consumed. The crude reaction was purified by semi-preparative
RP-HPLC to yield the mixed Cl-/Br- salt of 13. The mixed salt was redissolved in
MeOH and stirred at rt for 2 h with excess Amberlite IRA-904 quaternary ammonium
Cl- anion exchange resin. The resin was filtered and solvent removed in vacuo to give 8
(62.4 mg, 63%) as a yellow solid; m.p. 205oC.1H NMR (300 MHz, CD3OD): 3.03 (t, J =
5.5 Hz, 2H, H-5), 4.01 (s, 3H, OCH3), 4.17 (s, 3H, OCH3), 4.80 (br.s, 2H, H-6), 4.84 (s,
2H, CH2Ph), 5.96 (s, 2H, OCH2O), 6.72 (s, 1H, H3´), 6.86 (s, 1H, H-4a), 6.90 (s, 1H, H14a), 6.96 (d, J = 7.8 Hz, 1H, H-6), 7.27 (td, J = 7.7, 1.5 Hz, 1H, H-5), 7.37 (br.t, J =
7.5 Hz, 1H, H-4), 7.42 (d, J = 9.0 Hz, 1H, H-7´), 7.58 (dd, J = 7.7, 1.1 Hz, 1H, H-3´´),
7.78 (d, J = 9.3 Hz, 1H, H-11b), 7.88 (dd, J = 9.0, 2.4 Hz, 1H, H-6´), 7.94 (d, J = 9.3
Hz, 1H, H-12b), 8.34 (d, J = 2.1 Hz, 1H, H-4´), 9.8 (s, 1H, H-8). HRMS (ES): m/z
calculated for C35H28N3O6 [M]+: 586.1978; found: 586.1984.
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4.5.3 Synthesis of 9,10–dimethoxy–13-(2-naphthylmethyl)-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
chloride, KG01 (13)
A solution of 8-allyldihydroberberine160 3 (100.0 mg, 0.27
mmol) and 2-(bromomethyl)-naphthalene (59.0 mg, 0.27
mmol) in dry CH3CN (3 ml) was heated at 60°C in a sealed
vial. After 24 h, an aliquot was removed from the reaction and
RP-HPLC analysis showed complete enamine alkylation. The
vial was then heated to 100oC and the reaction monitored by RP-HPLC for 2 days until
all of the alkylated enamine intermediate had been consumed. The crude reaction was
purified by semi-preparative RP-HPLC to yield the mixed Cl-/Br- salt of 13. The mixed
salt was redissolved in MeOH and stirred at rt for 2 h with excess Amberlite IRA-904
quaternary ammonium Cl- anion exchange resin. The resin was filtered and solvent
removed in vacuo to give 13 (74.5 mg, 58%) as a yellow solid; m.p. 144-145oC. 1H
NMR (500 MHz, CDCl3):

3.23 (br.s, 2H, H-5), 4.05 (s, 3H, OCH3), 4.25 (s, 3H,

OCH3), 4.81 (br.s., 2H, H-6), 4.95 (s, 2H, Ch2Ph), 5.98 (s, 2H, OCH2O), 7.06 (br.s, 1H,
H-3′′), 7.10 (br.s, 1H, H-12), 7.42 (s, 1H, H-4), 7.48( m, 4H, H-1′′), 7.63 (d, J = 6.5, 1H,
H-6′′), 7.87-7.91 (m, 1H, H-4′′), 8.0 (d, J = 6.5, 1H, H-5′′), 9.95 (s, 1H, H-8). 13C NMR
(125 MHz, CD3OD/CDCl3):

29.5 (C5), 36.3 (CH2), 56.5 (OCH3), 57.9 (C6), 61.8

(OCH3), 102.5 (OCH2O), 108.3 (C4), 108.6 (C14), 120.3 (C13b), 121.8 (C3′′), 121.9
(C8a), 126.2 (C6′′), 126.3 (C7′′), 126.5 (C1′′), 126.6 (C11), 127.4 (C4′′), 127.6 (C8′′),
129.2 (C12), 131.1 (C4a′′), 132.6 (C8a′′, C12a), 133.9 (C2′′), 136.8 (C13), 138.0
(C13a), 145.1 (C9), 147.4 (C3a), 150.3 (C14a), 150.8 (C10). HRMS (ES) m/z calculated
for C31H26N1O4 [M]+: 476.1866; found: 476.1862.
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4.6 Chapter summary
The compound oSS14 was successfully re-synthesised with an improved yield. The
same procedure was readily applicable to the design and synthesis of the novel
compound KG01 (13). The compounds mSS14 and pSS14 required HPLC
repurification prior to analysis via ESI-MS. A procedure was established and the
compounds were successfully obtained in 97 and 96 % purity for mSS14 and pSS14,
respectively.
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Chapter 5: DNA binding properties of berberine analogues

5.1 Introduction
ESI-MS can be used as a screening method for developing a binding affinity profile for
different ligands with particular DNA sequences, as well as for evaluating the
selectivity of the ligand.183, 190, 192, 259 The first report of a non-covalent dsDNA-drug
complex was in 1994 by Gale et al..260 Using a 12 mer self-complementary dsDNA
sequence, 5 -dCGCAAATTTGCG-3 , they observed a non-covalent complex of the
duplex with distamycin A. Depending on the concentration of the ligand, complexes
with a 1:1 or 2:1 distamycin: dsDNA ratio were observed. These observations were
consistent with other data from solution studies for this drug.260 Acquisition of these
spectra required gentle ESI-MS conditions as well as careful consideration of the salt
concentration required to maintain native interactions.260 This work led to a more
detailed investigation of the complexes formed between dsDNA and distamycin, in
addition to two other minor groove binders, pentamidine and Hoechst 33258.260 This
study explored the effects of changing various ESI-MS ionization source parameters
including the capillary-skimmer potential, as well as collision-induced dissociation
experiments in order to establish the stabilities of the drug-DNA complexes formed.
These experiments revealed no evidence for non-specific formation of dimers or trimers
of the dsDNA-ligand complexes.260

Nogalamycin and daunomycin were among the first intercalators to be studied using
ESI-MS.190 Complexes of nogalamycin and daunomycin with 12-mer and 16-mer
152

dsDNA were observed. By varying the ratios of drug to dsDNA, and observing the
resulting spectra, the complexation numbers of the drugs were determined. Under the
conditions used, both of these drugs were shown to bind between four and six molecules
per DNA strand. Gabelica and co-workers have also examined the interactions between
sequences of dsDNA with anti-tumour agents.191 Competition experiments were carried
out to determine the relative binding affinities of the minor groove binding and
intercalating drugs which were studied.183, 191

Wan et al. studied complexes formed between ten different compounds, including
minor groove binders, intercalators, porphyrins and metallophophyrins, and dsDNA
derived from 6- to 12-mer self-complementary oligonucleotides.192 Using an ESI-ion
trap mass spectrometer they showed that the minor groove binders distamycin, Hoechst
33258, Hoechst 33342, and berenil preferred to bind to AT-rich dsDNA, and that the
intercalator actinomycin D preferred to bind to GC-rich dsDNA in agreement with
results from solution studies.192 Rosu et al. used ESI-MS to detect the selective binding
of Hoechst 33342 and Hoechst 33258 to different DNA sequences.261 By using the 12mer DNA strands dGGGG(A/T)GGGG it was shown that the binding affinity of both
drugs was dependent on the central four base sequence. The affinity was found to
increase in the order AAAA < ATAT < AATT. These experiments demonstrated the
potential of ESI-MS for characterisation of non-covalent complexes formed between
small molecules and dsDNA.

More recently, higher order structures of DNA and complexes with ligands have been
studied by ESI-MS. As described in sections 1.5.2 and 3.1, these structures are
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becoming important targets in cancer therapy. The first such study was that of Brodbelt
and co-workers, who compared the binding of the compounds Tel01, distamycin A and
diethylthiocarbocyanine iodide (DTC), to double-stranded DNA and a parallel fourstranded DNA quadruplex [d(TTGGGGGT)]4.262 By examining dissociation patterns of
ions arising from non-covalent complexes in MS/MS experiments, evidence was
obtained that supported the results of previous solution studies. These suggested Tel01
interacts with G-quadruplex DNA by end-stacking with a guanine tetrad, whereas
distamycin A and DTC interact by binding to the grooves of the quadruplex. In the same
year Gabelica and co-workers were the first to use ESI-MS to study triple helices and
among the first to look at G-quadruplexes in this way.93 They showed that triplex and
quadruplex structures can be studied by electrospray ionization mass spectrometry
giving the same type of information as for dsDNA. To date there have been only 6
reports of triplex DNA structures and 15 reports of quadruplex structures analysed using
ESI-MS‡.

In 1993 Goodlett et al. examined the stability of the G-quadruplex formed by the
sequence d(CGCGGGGGGCG)2.263 When the sample was desalted and analysed by
ESI-MS, only ions corresponding to single-stranded DNA species were observed. These
results agree with other experimental evidence that shows that G-quadruplex formation
is only possible in the presence of suitable cations (see section 3.1). Rosu and coworkers later reported an ESI-MS study of three different quadruplexes: a four-stranded
parallel quadruplex [d(TGGGGT)]4, an antiparallel dimer [d(GGGGTTTTGGGG)] 2,

‡

Based on searches in SciFinder Scholar. December 2009.
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and an intramolecular monomeric quadruplex with the sequence d((GGG(TTAGGG)3)
that mimics the human telomere sequence.93

Binding of ligands to DNAs can induce a change in its structure. In some cases this has
been used to show a shift from an antiparallel to a parallel conformation. Tel01, a
perylene derivative, induces a change in the human telomeric sequence from the parallel
to the antiparallel as evidenced by CD.264 Additionally, this experiment showed an
overall increase in the percentage of quadruplex DNA in solution after addition of the
drug. Using a combination of ESI-MS and CD, Zhou et al. were able to show that the
four-stranded quadruplex d(AGGGTT)4 undergoes a transition from a mixture of
parallel and antiparallel quadruplexes to parallel quadruplex alone with increasing
concentrations of the ligand Tel01. 264

5.2 Scope of this chapter
In this work, the DNA binding properties of the compound berberine and its novel
derivatives oSS14, mSS14, pSS14, BT80, SS104 and KG01 (Figure 4.1), were
investigated using ESI-MS. Daunomycin is an extensively studied anthracycline whose
anti-cancer properties are well documented.190,

265, 266

The binding of the intercalator

daunomycin (Figure 1.3) to dsDNA has been previously studied using ESI-MS in our
laboratory.190, 265, 266 Therefore daunomycin was used for comparison with the alkaloid
berberine, which has been reported as an intercalator and minor groove binder in
different studies.159, 248 This is the first study of the DNA binding properties of oSS14

155

and its derivatives. This study investigated the binding properties of these ligands with
three dsDNA sequences, and three quadruplex DNA sequences.

5.3 DNA binding experiments using ESI-MS
Each of the eight compounds discussed above in (Figure 4.1 and Figure 1.3) were tested
for binding with three different dsDNA sequences (D1, D2 and F10), and three
quadruplex DNA sequences (Q4, Q1, Q2) using ESI-MS. The sequences are shown in
Table 2.1. Briefly, D1 and D2 are two different 16-mer dsDNA sequences while F10 is
a forked DNA sequence. The latter contains a base-paired 10-mer dsDNA region with a
ten nucleotide (d(A)) extension on each strand that cannot base pair. The qDNA, Q1,
Q2 and Q4 are named to designate the number of strands forming the quadruplex
structure (Chapter 3). The calculated m/z values expected for the various ions in ESI
mass spectra for D1: ligand, D2: ligand, F10: ligand, Q1: ligand, Q2: ligand and Q4:
ligand complexes are shown in the Appendix.

5.3.1 Binding to dsDNA
5.3.1.1 D1 16-mer dsDNA
The technique for analysis of double-stranded DNA by ESI-MS is well-established in
our laboratory.189, 190 Spectra for D1 (CCTCTCTGGACCTTCC)§ were acquired in 100
mM NH4OAc, pH 7. Figure 5.1 (A) shows that under these experimental conditions, the

§

Only one strand of the DNA is shown for each dsDNA. The other strand was the 16 base pair
complementary sequence.
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[D1-6H]6- and the [D1-5H]5- ions were present at m/z 1626.6 and 1952.0, respectively,
in agreement with the calculated values of 1626.4 and 1951.8. The most abundant ion
was the [D1-6H]6- ion. Figure 5.1 (B-E) shows the spectra as the concentration of
daunomycin relative to D1 was increased. As the concentration of daunomycin
increased, the number of daunomycin molecules bound to DNA increased. In the 1:6
and 1:9 mixtures there was no remaining free DNA. The most abundant complex in the
1:9 mixture (E) was from D1 with five molecules bound. There were also ions of low
abundance from daunomycin bound to ssDNA. This has been observed in previous
studies,190,

265, 266

and may be the result of non-specific interactions in the ionization

source. These types of interactions were minimised by maintaining low concentrations
of analyte ( 10 µM), and a relatively high salt (ammonium acetate) concentration that
is expected to minimize non-specific electrostatic interactions.190 Therefore, it is also
possible that those ions were either from complexes that dissociated in the mass
spectrometer or from genuine binding to remaining ssDNA in the stock solution. Simple
intercalators have been proposed to follow the “neighbour exclusion” principle whereby
they are only able to slot in between every two DNA base pairs.267 Glycosylated
intercalators such as daunomycin are larger, more complex molecules and are able to
form hydrogen bonds with the outside of the DNA helix which may affect the sites
available for binding to a given DNA sequence.268 This may result in steric hindrance
preventing intercalation between every other base pair.
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Figure 5.1: Negative ion ESI mass spectrum of 16-mer D1, dsDNA-Daunomycin (Dn)
mixtures. (A) D1 alone, (B) D1: Dn = 1:1, (C) D1: Dn = 1:3, (D) D1: Dn = 1:6, (E) D1: Dn =
1:9. ■ D1 alone; ∆ D1+1Dn; ♦ D1+2Dn; □ D1+3Dn; ▲ D1+4 Dn; ○ D1+5 Dn; ● D1+6 Dn; ◊
D1+7 Dn; ssDNA + Dn.

For daunomycin, as the concentration of ligand increased more daunomycin molecules
bound with saturation at around 4-5 molecules as evidenced by the similarities in
abundance of the complexes in the 1:6 and 1:9 mixtures. The binding profile for the D1daunomycun interaction is shown in Figure 5.4 (H), where the relative intensity of ions
from each complex as a percentage of the total intensity of all ions in the mass spectrum
is plotted against the different complexes present in the ESI mass spectra. Figure 5.4
compares the binding profiles for all the ligands (mass spectra described below) and
will be referred to as the binding of each ligand to D1 is described.
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Figure 5.2 shows the negative ion ESI mass spectra of mixtures of D1 and berberine. As
observed for daunomycin, berberine bound to D1 as evidenced by the absence of ions
from free DNA in the 1:3 to 1:9 mixtures. The binding profile was, however, different
from that of the well-established intercalator, daunomycin. The binding profile in Figure
5.4 (A) shows that the most abundant complex was [D1+2 Berb-5H]5-, at m/z 2086.0, in
the 1:9 mixture. The binding sites on D1 for berberine appear to be saturated when 2-3
molecules of drug were bound as evidenced by the overlap of the binding profiles for
the 1:3, 1:6 and 1:9 mixtures (cf. 4-5 Dn molecules in Figure 5.4 (E)). The ability of
berberine to bind to this type of sequence supports (but does not prove) that this drug
may be able to intercalate between base pairs. 159 Berberine was also observed to bind to
ssDNA. As with daunomycin, this may be from complexes that dissociated in the mass
spectrometer or from genuine binding to remaining ssDNA in the stock solution.
65-

Figure 5.2: Negative ion ESI mass spectra of 16-mer D1, dsDNA-berberine mixtures. (A) D1
alone, (B) D1: Berb = 1:1, (C) D1: Berb = 1:3, (D) D1: Berb = 1:6, (E) D1: Berb = 1:9. ■ D1
alone; ∆ D1+1 Berb; ♦ D1+2 Berb; □ D1+3 Berb; ▲ D1+4 Berb; ○ D1+5 Berb; ● D1+6 Berb; ◊
D1+7 Berb; ssDNA + Berb.
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Figure 5.3 shows ESI mass spectra of 1:9 mixtures of all the remaining compounds with
D1. When compared to the binding for daunomycin and berberine the spectra are clearly
very different with few ligand molecules bound and at low abundance. These ligands
have little affinity for D1. The binding profiles for the derivatives, oSS14, mSS14,
pSS14, KG01, SS104 and BT80 are shown in Figure 5.4 (B)-(G). The most binding is
seen for BT80 (F in Figure 5.3). For oSS14 at the highest concentration (1:9 mixture),
the only complex present, dsDNA+1 SS14, was present in a relative abundance of only
4% (Figure 5.4 (B)). The compound clearly does not have a high affinity for the doublestranded D1 sequence, and since it was present in low abundance, it is possible that this
was a non-specific interaction. The relative abundance of D1+1 pSS14 was even lower
at <2% at the highest concentration of ligand. On the other hand, mSS14 shows a
slightly higher affinity with the dsDNA+1 mSS14 complex present at 10% relative
abundance. The binding profile for SS104 was similar with binding only occurring at
the highest concentration (11%). The analogues oSS14, mSS14, pSS14, and SS104 are
expected to be positively charged at pH 7 as they are quaternary ammonium salts. On
this basis they are likely to form weak electrostatic interactions with the phosphodiester
backbone of DNA. If these “non-specific” complexes formed in solution or in the
ionization source, they were not stable in the mass spectrometer. Considering the
extensive binding of berberine to dsDNA (Figure 5.2 and Figure 5.4 (A)), the addition
of the phenylmethylnitroindolyl moiety to berberine has clearly hindered binding.
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Figure 5.3: Negative ion ESI mass spectra of 16-mer D1, 1:9 dsDNA-ligand mixtures. (A) D1:
oSS14, (B) D1: mSS14, (C) D1: pSS14, (D) D1: SS104, (E) D1: KG01, (F) D1: BT80. ■ D1
alone; ∆ D1+1 ligand; ♦ D1+2 ligands.

The compound KG01 also has a low affinity for this dsDNA sequence as judged by
ESI-MS. There was however, an anomaly in the way in which this molecule was
observed to bind. The binding of KG01 was 6% in the 1:3 mixture, but only 2% in the
1:9 mixture. At the very low abundances the percentage error in the measurements is
quite high, but these observations were reproduced on several occasions. These results
indicate that the ligand itself may be self-associating at higher concentrations within the
mixture. Naphthalene, and naphthalene core compounds are known to self-associate.269
It was not possible to observe dimers at low m/z (at m/z 952 for singly charged and
475.5 for doubly charged); however, since KG01 has a quaternary nitrogen this may
affect the ability of the dimer to ionize and be detected in negative ESI mode. The
strength of binding to the dsDNA sequence appears to be lower than the ability of this
compound to self-associate. This trend was not observed with BT80 which also has a
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naphthalene component. In the case of BT80 the affinity of the molecule for D1 may
have been stronger than the propensity to self-associate. BT80 was observed to bind
only in the 1:6 and 1:9 reaction mixtures. In the 1:6 reaction mixture, the relative
abundance of the D1+1 BT80 complex was ~5%. In the 1:9 reaction mixture the relative
abundances of D1+1 BT80 and D1+2 BT80 were 28% and 3%, respectively.

Previous experiments (Gornall, Honours thesis215) examining the DNA-binding
properties of oSS14, berberine, and daunomycin were performed over a greater
concentration range of the ligands, with the most concentrated reaction mixtures
containing up to 1:48 DNA: ligand.138 These preliminary data showed that the duplex
and quadruplex DNA were saturated with daunomycin, berberine and oSS14 in the 1:9
mixtures, since the relative amount of complexed DNA did not substantially increase
when the ratio of DNA/drug was decreased. In the current work the mixtures containing
mSS14, pSS14, SS104 and BT80 however, gave very noisy spectra for mixtures where
ligand concentration was greater than in the 1:9 mixtures, so that it was not possible to
increase the ligand concentration.
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Figure 5.4: Relative abundances of D1 dsDNA: ligand complexes in 1:1-1:9 mixtures
determined from negative ion ESI-mass spectra. 1:1; 1:3; 1:6; 1:9.
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5.3.1.2 D2 16-mer dsDNA
D2 (GCTGCCAAATACCTCC) is a sequence with an AT tract in the centre, and it is
expected that molecules with classic minor groove binding characteristics will bind with
high affinity and specificity.41 The binding of all eight compounds with D2 was
investigated using the same ligand: DNA mixtures as for D1. Figure 5.5 (A) shows the
ESI mass spectra obtained for D2 alone as well as those for pSS14 (B), BT80 (C),
berberine (D) and daunomycin (E) in 1:9 mixtures with D2. In the spectrum of D2
alone, the [D2-6H]6- and the [D2-5H]5- ions were observed at m/z 1626.9 and 1952.0, in
agreement with the calculated values of m/z 1626.6 and 1951.7. The spectrum for pSS14
shows no ligand binding in the 1:9 mixture, while BT80 shows very low affinity. The
major complex observed was [D2+1 BT80-5H]5- at m/z 2052.2. On the other hand
berberine and daunomycin both bound significantly and no free DNA remained in the
1:9 mixture of the latter. The major complexes observed for daunomycin in the 1:9
mixture were [D2+4 Dn-5H]5- and [D2+5 Dn-5H]5- at m/z 2373.7 and 2479.2 (Figure
5.5 (E)). The spectra for D2 mixtures with the remaining compounds are not shown as
very little binding was observed. Figure 5.6 shows the binding profiles for titrations of
this sequence with the eight compounds. Daunomycin showed a very similar binding
stoichiometry for this sequence compared to D1. This is in agreement with our previous
work.189, 190
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Figure 5.5: Negative ion ESI mass spectra of 16-mer D2-ligand complexes in 1:9 mixtures. (A)
D2: alone (B) D2: pSS14, (C) D2: BT80, (D) D2: Berberine, (E) D2: Daunomycin. ■ D1 alone;
∆ D2+1 ligand; ♦ D2+2 ligands; □ D2+3 ligands; ▲ D2+4 ligands; ○ D2+5 ligands; ● D2+6
ligands; ◊ D2+7 ligands; ssDNA+ ligand/s.

Comparison of Figure 5.4 (A) and Figure 5.6 (A), shows that berberine had similar
binding profiles and affinities for D1 and D2, though overall more molecules bound to
D1. For example, in the 1:9 mixtures [dsDNA+4 Berb] was 11% and 9% for D1 and
D2, respectively. For D2 the maximum number of molecules bound was only 5,
compared to 7 for D1 (though only at very low intensity, < 1%). As was the case for D1,
D2 dsDNA was also saturated when 2-3 molecules were bound as evidenced by the
similar binding profiles for the 1:3, 1:6 and 1:9 mixtures. As previously mentioned in
section 5.1, there is some controversy over the binding mode of berberine to dsDNA,
with evidence for binding by partial intercalation or minor groove-binding. Comparison
among these studies is complicated by the use of different DNA sequences and the
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different techniques used to detect the complexes. 159, 248, 270, 271 The binding constant for
the interaction of d(AAGAATTCTT)2 with berberine as determined by UV
spectroscopic analysis of the effect of drug binding on the duplex melting temperature
was 1x104 M.248 This method gives an average for the binding of berberine molecules
and cannot distinguish different binding affinities for each berberine molecule bound to
a molecule of duplex DNA. It is difficult to obtain a binding constant using the ESI
mass spectra since several binding sites are revealed by these experiments.

The compounds pSS14, oSS14 and SS104 showed no binding affinity for D2, with no
binding observed even when the compounds were present in nine-fold excess
(representative spectrum for pSS14 in a 1:9 mixture is shown in Figure 5.5 (B)). The
observations indicate that these compounds do not readily bind dsDNA as they were not
able to bind to either an AT- (D2) or GC- (D1) rich sequence. BT80 (Figure 5.5 (C))
and mSS14 (spectrum not shown, see Figure 5.6 (C)) both had a low affinity for D2.
The relative abundance of the D2+1 mSS14 complex in the 1:6 mixture was 4% and this
did not increase in the 1:9 mixture. In the 1:9 mixture of D2 and BT80 the relative
abundance of the D2+1 BT80 complex was 16%, and 2% for D2+2 BT80. Since the
affinity for these compounds is so low, it is possible that there was some dissociation in
the mass spectrometer. Dimeric berberine derivatives linked via ether group formation
at the 9-position show greatly increased affinity for dsDNA as assessed by fluorescence
spectrophotometry.272 This is of interest since substitution in the 13 position in the
current study seems to hinder dsDNA binding.
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Figure 5.6: Relative abundances of D2 dsDNA: drug complexes in 1:1-1:9 mixtures determined
from negative ion ESI mass spectra. 1:1; 1:3; 1:6; 1:9.
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5.3.1.3 F10 dsDNA binding
F10 (dTGCTGGACGAAAAAAAAAA) is a DNA-sequence with a 10 base pair
double-stranded region and stretches of contiguous adenines at the ends of each strand
to produce a non-H-bonded forked structure. Previously in our laboratory we have used
sequences such as this to investigate whether Watson-Crick base-paired dsDNA is
essential for ligand-binding. For example, if the binding profile for the 10-mer dsDNA
core of F10 is the same as for F10 with its ssDNA extension, then it is likely that the
ligand binds exclusively to the base-paired double-stranded sequence. Figure 5.7 shows
the spectra for F10 alone (A), and with berberine (B), SS104 (C), KG01 (D), BT80 (E),
and daunomycin (F) in 1:9 mixtures. Spectra for F10 titrations were acquired as
described in section 2.4.1. For the sequence F10 alone, the [F10-6H]6- and [F10-5H]5ions were observed at m/z 2052.5 and 2463.1, in agreement with the calculated values of
2052.5 and 2463.2. The 6- ions of F10 were more abundant than the 5 - ions. The spectra
show, as expected based on the observations made for D1 and D2, that only
daunomycin and berberine showed significant binding affinity towards F10.

Figure 5.8 shows the binding profiles for titrations of this sequence with the eight
compounds. Daunomycin showed a very similar binding stoichiometry for this sequence
compared to D1. This is in agreement with our previous work. 189,

190

Since D1 is a

longer dsDNA sequence (16-mer) than the double-stranded region of F10 (10-mer), this
suggests that some daunomycin is binding to the poly dA ssDNA ends. In our
laboratory the binding of daunomycin to the 10-mer dsDNA core of F10 and to the fulllength F10 has previously been compared. 273 It was found that the dsDNA F10 core
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saturated at 3 molecules of daunomycin while F10 bound predominantly 4-5 molecules
as was observed here (Figure 5.8 (H)). In the current work, ions carrying seven negative
charges were observed when daunomycin and berberine were present, but were not
observed in their absence. The complexes for [F10+X ligand-7H]7- were observed for
each of these compounds in the 1:6 and 1:9 reaction mixtures for 3, 4, 5, 6 and 7 ligands
binding (Figure 5.7 (B) and (F)). Berberine showed a high affinity for F10 and up to
eight molecules were bound to the DNA in the 1:9 mixture, leaving only 2%
uncomplexed DNA. The sequence appeared to be saturated when 4-5 molecules were
bound as evidenced by the overlap of the binding profiles for the 1:6 and 1:9 mixtures
(Figure 5.8 (A)). Since the binding profiles for 16-mer dsDNA were similar to those for
F10 it is likely that berberine is binding to the single-stranded ends of F10. Berberine
was also able to bind to the ssDNA which remained in solution after annealing (Figure
5.7 (B)).

Figure 5.7: Negative ion ESI mass spectra of forked DNA F10, 1:9 dsDNA-ligand mixtures.
(A) F10 alone; (B) F10: Berb; (C) F10: SS104; (D) F10: KG01; (E) F10: BT80; (F) F10: Dn. ■
F10 alone; ∆ F10+1 ligand; ♦ F10+2 ligands; □ F10+3 ligands; ▲ F10+4 ligands; ○ F10+5
ligands; ● F10+6 ligands; ◊ F10+7 ligands; Х F10+8 ligands; ssDNA+X ligand.
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The compounds pSS14, oSS14, mSS14 and BT80 all displayed weak affinity for the
sequence F10 with a maximum stoichiometry of one molecule bound, albeit at very low
abundance. In the 1:1 mixtures the only one of these compounds that was present in a
1:1 complex with DNA was BT80, but at only 1% relative abundance. The 1:9 mixtures
for these compounds show relative abundances for F10+1 ligand up to ~5% each,
except for BT80 where 15% of the DNA was present in the F10+1 BT80 complex. The
binding of oSS14 and pSS14 to F10 was greater than for D1 and D2 suggesting that this
binding is non-specific (i.e. including to the single-stranded tails of F10). The
compound mSS14 had a greater (but still low) affinity for D1 than F10, while BT80
showed lower affinity for F10 than D1 or D2. F10 bound a maximum of two SS104
molecules in the 1:9 mixtures with F10+1SS104, at a relative abundance of 17%.
Binding of one molecule of KG01 to F10 was observed in the 1:3 and 1:6 mixtures at
~7%, and no binding was observed in the 1:1 and 1:9 reaction mixtures, suggesting selfassociation of KG01 at the higher concentrations as discussed above.
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Figure 5.8: Relative abundances of F10 dsDNA: drug complexes in 1:1-1:9 mixtures
determined from negative ion ESI mass spectra. 1:1; 1:3; 1:6; 1:9.
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None of the compounds tested (except for the parent compound, berberine, and the
known intercalator, daunomycin) bound to dsDNA to any appreciable extent. Given that
weak but selective binding of oSS14 to tetrameric G-quadruplex DNA (Q4) had
previously been observed in our laboratory.138, 215 ESI-MS was used to test for binding
of the compounds described above to the qDNA sequences Q4, Q2 and Q1
characterised in Chapter 3.

5.3.2 Q4 Q DNA binding
Titrations of quadruplex DNA Q4 with the eight compounds were performed under the
conditions described in section 2.4.3. Figure 5.9 shows the ESI mass spectra acquired
for the 1:9 reaction mixtures of Q4 with all of the compounds. In the spectrum of Q4
alone (A) the [Q4+4NH4+-9H]5- ion was the most abundant at m/z 2010.0 with two other
substantially less abundant ions, [Q4+4NH4+-10H]6- at m/z 1674.8 and [Q4+4NH4+8H]4- at m/z 2512.7. The ions carrying four negative charges ([M+4NH4+-8H]4-) could
not be conclusively assigned in these experiments as a consequence of their low
abundance. A summary of the binding profiles for all the titration mixtures is shown in
Figure 5.10. There is one major binding site on Q4 for daunomycin as evidenced by the
overlap of the curves for the 1:1-1:9 mixtures at this stoichiometry (Figure 5.10 (H));
however, up to 4 Dn molecules bound in the 1:6 and 1:9 mixtures. Overall daunomycin
exhibited a lower stoichiometry of binding than for the dsDNA sequences (above).
Additionally, in mixtures with Q4, there were ions of significant abundance from free
Q4+4NH4+, with the major ion, [Q4+4NH4++1 Dn–9H]5-, at m/z 2111.8.
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Figure 5.9: Negative ion ESI mass spectra of 8-mer Q4, qDNA-ligand in 1:9 mixtures. (A) Q4
alone; (B) Q4: berberine; (C) Q4: Dn; (D) Q4: oSS14; (E) Q4: mSS14; (F) Q4: pSS14; (G) Q4:
SS104; (H) Q4: KG01; (I) Q4: BT80. ■ Q4 alone; ∆ Q4+1 ligand; ♦ Q4+2 ligands; □ Q4+3
ligands; ▲ Q4+4 ligands; ○ Q4+5 ligands; ● Q4+6 ligands; ◊ Q4+7 ligands; Х Q4+8 ligands; 
Q4+9 ligands.
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An X-ray structure of the complex of daunomycin with the similar tetrameric
quadruplex, d(TGGGGT)4 (one fewer T and guanine tetrad), revealed that three
daunomycin molecules stack on the end of the terminal guanine tetrad. 131 The
stoichiometries observed here in the ESI-MS experiments most likely reflect sequential
binding of daunomycin molecules at the ends of Q4 (d(TTGGGGGT)4). The difference
in the ESI-MS and X-ray results may reflect an important difference between the two
techniques. The tetrameric quadruplex-(daunomycin)3 structure that crystallised may
have done so as it was the most stable, or because this structure was the least soluble,
but able to produce diffractable crystals under the conditions. The ESI-MS results
sample all the complexes that are sufficiently stable to be maintained in the electrospray
source and through to the mass analyser for detection.

The major complexes in Q4-Berb mixtures (Figure 5.10 (A)), were Q4+2 Berb and
Q4+3 Berb with up to 9 molecules bound in the 1:9 mixture but at very low (<1%)
abundance. These low abundance complexes may arise from weak non-specific
interactions occurring in the ionization source. In the 1:1 mixture, Q4+4NH4+ and
Q4+4NH4++1 Berb were present in approximately equal abundance. Since the final
concentration of all Q4 in the mixture was 5 μM, this suggests that the binding constant
reflected by the ESI mass spectra is of the order of μM. Overall berberine had a high
affinity for Q4.

SS14 analogues also bound significantly to Q4. For oSS14 there were three binding
sites (Figure 5.10 (B)), although these complexes were all present at lower abundance
(28%, 18% and 8% for the 1, 2 and 3 ligand-bound complexes, respectively, in the 1:9
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mixture). This is in contrast to the other binding experiments with oSS14 (above),
which showed almost no binding to dsDNA under the experimental conditions. This
suggests there is some preference of oSS14 for binding to the tetrameric quadruplex
over duplex DNA. In mixtures with the compound mSS14, the major ions observed
were [Q4+4NH4++1 mSS14-5H]5- and [Q4+4NH4++2 mSS14-5H]5- at m/z 2127.1 and
2244.2, respectively. In the 1:9 mixture with mSS14, the major complex, Q4+4NH4++2
mSS14, was observed at a relative abundance of 26%, where there was also some
remaining free Q4 at a relative abundance of 17%. The compound pSS14 bound with a
maximum stoichiometry of 4 under the conditions where the major complex for the 1:6
and 1:9 mixtures was Q4+4NH4++4 pSS14 (m/z 2127.5 for the 5- charge state), at 40%
and 35%, respectively. Even in the 1:9 mixture, ions corresponding to free Q4 were
observed (Figure 5.9 (F) and Figure 5.10 (D)). The spectra for the pSS14 mixtures also
had unexpected ions between m/z 2650-3200 (not shown). These ions could not be
assigned to Q4+4NH4++X pSS14 complexes. It is believed that these ions may arise
from assemblies of multiple Q4 units. Additional experiments were performed to
attempt to identify these ions. These experiments and the ESI mass spectra are described
in section 5.3.2.1.
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Figure 5.10: Relative abundances of Q4 QDNA: drug complexes in 1:1-1:9 mixtures
determined from negative ion ESI mass spectra. 1:1; 1:3; 1:6; 1:9.
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Considering the extensive binding of berberine to dsDNA (Figure 5.3 (A), Figure 5.6
(A) and Figure 5.8 (A)), the addition of the phenylmethylnitroindolyl moiety to
berberine hinders binding to dsDNA. In contrast, KG01, BT80 and SS104 showed
similar binding to Q4 as was observed for pSS14, where each had a maximum
stoichiometry of 4. In the case of KG01 and BT80 there was negligible remaining free
qDNA in the 1:9 mixtures. The major complex for KG01 was Q4+4NH4++1KG01 in the
1:6 and 1:9 mixtures, observed at m/z 2105.4 and 1754.3 (very low intensity) for the 5 and 6- ions, respectively. Unlike the binding for dsDNA, KG01 did not display any
signs of self-association when in mixtures with Q4. This gives an insight into the
strength of binding of this ligand to Q4.

Berberine and its derivatives display different binding affinities to DNA. The addition
of the nitroindolic group in the SS14 series and SS104 provides selectivity for different
structures. The indolic group is attached to the 13-position of the berberine skeleton via
a CH2 thus adding rotational freedom to this molecule. Furthermore, all of the analogues
(including BT80 and KG01) contain a quaternary nitrogen atom which is a favorable
attribute for stacking interactions with a G-quartet.137 Recently, minimum energy
conformational analyses of the molecules oSS14, mSS14 and pSS14 have been carried
out.163 Figure 5.11 shows representative structures from the low energy conformational
ensembles of oSS14 (A), mSS14 (B), pSS14 (C) and equilibrium conformational
ensembles of oSS14 (D), and mSS14 (E). The molecules were not planar as required for
classical minor groove binding and intercalation into dsDNA. It can be speculated that
they may be able to bind to the strands in the quadruplex via a mechanism such as end
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on stacking with either the nitroindolic group or the berberine moiety interacting with
the grooves of the qDNA.

Figure 5.11: Representative structures from the low energy conformational ensembles of oSS14
(A), mSS14 (B), pSS14 (C) and equilibrium conformational ensembles of oSS14 (D), and
mSS14 (E). The low energy conformations of pSS14 (B) did not differ from the equilibrium
conformation (not shown). Structures were calculated using a simulated annealing/energy
minimization protocol within DS Modeling 1.6 (Accelrys, San Diego, 2006). Taken from
Tomkiewicz, D. et al..163

The abilites of berberine, coralyne (a related compound) and a 13-substituted piperidino
berberine derivative (e.g. 13-[3-(1-piperidinyl) propyl]berberine), to bind to qDNA have
also been previously investigated. Using gel electrophoresis and two different
oligonucleotides, named 2HTR and TSG4, where the latter can form both dimeric and
tetrameric qDNA, it was determined that all three molecules had some degree of
selectivity for qDNA. Their findings and those of the current study seem consistent with
decreased binding to dsDNA when increasing the 13 position of berberine is substituted.
Berberine and coralyne were found to have specificity for the particular quadruplex
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DNAs used. In the current study there was little selectivity for Q4, with berberine
slightly favoring the dsDNA sequences.

For all berberine derivatives that bound Q4, it was observed that as binding increased,
the relative amount of free Q4+4NH4+ decreased compared to free Q4+3NH4+. An
example is given in Figure 5.12 where the spectra of Q4 (A), Q4 and berberine (B), and
Q4 and KG01 (C) are shown. When binding of berberine to Q4+4NH4+ was compared
with binding to Q4+3NH4+, the ratio of Q4+4NH4 + X Berb/ Q4+3NH4+X Berb was ≈ 2.
This is in agreement with the relative abundance of Q4+3NH4+ and Q4+4NH4+ in the
absence of ligands (Figure 3.4 (B)). If the Q4+3NH4+ ions represent a slipped structure
(see section 3.3.2) then the ligands have lower affinity for „slipped‟ Q4. In the case of
KG01, the only complex observed were those in which 4NH4+ were present. This
suggests that KG01 stabilises the Q4 qDNA structure with four bound ammonium ions
and implies that the observation of Q4+3NH4++X Berb results from loss of NH4+ in the
mass spectrometer. It is also possible that “slipped” structures present in solutions
containing Q4 are also present as Q4+4NH4+, but one NH4+ is lost in the mass
spectrometer. KG01 may be able to bind to the slipped structure, but stabilises it, so that
it retains 4 bound ammonium ions in the mass spectrometer.
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Figure 5.12: View of 5- ions in ESI mass spectra. (A) Q4 alone, (B) Q4 and berberine in a 1:9
reaction mixture, (C) Q4 and KG01 in a 1:9 reaction mixture. ● Q4+3NH4+; ■ Q4+4NH4+; □
Q4+3NH4++X ligand; ♦ Q4+4NH4++X ligand.

5.3.2.1 Unusual binding of pSS14
In reaction mixtures containing Q4 and pSS14, not all ions were readily identifiable.
Aside from the expected complexes of Q4+X pSS14, there were a number of ions
observed in the region between m/z 2600-3200 which could not be readily assigned. The
presence of these peaks appeared to increase when the sample was left to equilibrate for
longer periods of time and was not observed in the mixtures for any other compound
used in this study. Figure 5.13 shows a spectrum of Q4: pSS14 in a 1:9 reaction mixture
where the unidentified ions lie in the highlighted region of the figure. These ions were
observed at m/z 2659.3, 2754.2, 2952.3, 3029.5 and 3098.4, and are labelled a, b, c d
and e respectively, in Figure 5.13. Each ion was associated with adducts to higher m/z
values. Part of the difficulty in identifying these ions was the broadness of these peaks.
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The broadness did however, suggest that these were non-covalent complexes that
retained salt adducts and possibly water bound within the structure.

Figure 5.13: Negative ion ESI mass spectrum of 8-mer Q4, qDNA-ligand in 1:9 mixture with
pSS14. ■ Q4 alone; ∆ Q4+1 pSS14; ♦ Q4+2 pSS14; □ Q4+3 pSS14; ▲ Q4+4 pSS14. The
highlighted ions are at m/z 2659.3 (a), 2754.2 (b), 2952.3 (c), 3029.3 (d) and 3098.4 (e).

In initial attempts to identify these ions the possibilities of higher order structures of
qDNA were examined. Smargiasso et al. have previously shown that quadruplex
multimers, such as the ones shown in Figure 5.14, are able to form under certain
conditions.221 Using circular dichroism, ESI-MS, native gel electrophoresis and UV
thermal denaturation they found that sequences with short loops can form very stable
multimers (i.e. more than one entire quadruplex unit) even at low DNA concentrations.
Using ESI-MS it was possible to identify dimers and trimers of quadruplexes. In
Chapter 3 there was some evidence in ESI-IM mass spectra that Q4 and Q2 might form
dimers. With the possibility in mind that pSS14 may induce the formation of multimers,
the m/z values expected for different multimers of Q4+ pSS14 were determined and
compared to the spectra obtained. The ion at a, m/z 2659.3 may correspond to
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[2*Q4+8NH4++2 pSS16-16H]8- (calculated m/z 2660.2); ion d at m/z 3029.5 may
correspond to [2*Q4+4NH4++2 pSS14-11H]7- (calculated m/z 3029.5); ion e at m/z
3098.4 could correspond to [Q4+dsQ4+6NH4++6 pSS14-12H]6- (calculated m/z 3098.3),
or

[2*Q4+7NH4++8 pSS14-15H]8- (calculated m/z 3097.5); ion c 2952.4 may

correspond to [2*Q4+8NH4++6 pSS14-16H]8- (calculated m/z 2953.3), or to
[2*Q4+7NH4++1 pSS14-14H]7- (calculated m/z 2953.1); ion b at m/z 2754.2 could not
be readily assigned.

Figure 5.14: Representation of possible structures of a parallel quadruplex dimer, trimer, and
tetramer. The direction of the arrows represents the direction of the strands. Taken from
Smargiasso et al..221

In an attempt to confirm the identity of the most intense ions, CID experiments were
performed using the QTOF UltimaTM; however, only the ion at m/z 3029.5 was
sufficiently abundant. The spectra are shown in Figure 5.15. Upon increasing the
collision energy to 14 V, the predominant ion observed was at m/z 3025.5. When the
collision energy was increased to 16 V, an ion proposed as [Q4+4NH4++1 pSS14-9H]5-,
at m/z 2127.9 was observed. If this is correct it suggests that a single qDNA structural
unit of Q4 was retained when the proposed multi-qDNA structure (2*Q4+4NH4++2
pSS14) dissociated. Additionally a new ion was observed ion at m/z 2778.1. From m/z
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3025.5 this corresponds to the loss of ~1739 Da if the charge on the ions is assumed to
be 7-. This could correspond to the loss of one pSS14 ligand and guanine residues (e.g.
the ion [2*Q4-8G+6NH4+]7- has m/z 2778.0). These spectra were of low signal-to-noise;
especially in the case of the latter ions, making these suggestions speculative.

Figure 5.15: Negative ion CID of the ion at m/z 3029.5 at collision energy = 6 V and 16 V.
Where ■ is m/z 3029.5, ◊ is m/z 3025.5, ● m/z 2778.1, ○ m/z 2127.9.

Experiments were performed to confirm that the changes induced by pSS14 were time
dependant. ESI mass spectra of a 1:9 reaction mixture of Q4: pSS14 were acquired
every thirty minutes for four hours and then hourly for an additional six hours, and
finally after twenty-four hours. Figure 5.16 shows the spectra acquired at t = 0 (A), 1 h
(B), and 24 h (C) with the region (m/z 2600-3200) enlarged in the inset. At t = 0 the
relative amount of pSS14 binding to Q1 was 87%, however, at t = 24 this dropped to
24%, with 45% of the total ion abundance represented by the „unidentified‟ peaks.
These relative abundances contain significant error considering the broadness of the
peaks. The spectrum at t = 0 is the same as that shown in Figure 5.13, where the
tentative assignments have been discussed above. After the first hour, the appearance of
the ion f (Figure 5.16 (B)), was observed at m/z ~2690. No other major changes were
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observed until t= 24 h, where the ions a, b, and e, were absent, and the ion g, at m/z
2624.6 became the most abundant of the ions in this region (Figure 5.16 (C)).
Furthermore, close inspection of the spectrum acquired at one hour, indicates that small
amounts of the ion g were already present. The major change is a significant loss of
complexes in which qDNA Q4 was bound to one or two pSS14 molecules and a shift in
the species observed in the region m/z 2600-3200. This may suggest that with time there
is assembly of a multimeric structure involving two or more qDNA structures. The low
abundance of each of the ions in this high m/z region is most likely a reflection of the
presence of many structures involving different numbers of bound cations and/or pSS14
and may also be the result of experimental conditions (instrument settings) which are
not optimal for the detection of these species.

The two ions g and f appear to be a series of the same charge, if this is the case they
may correspond to [2*Q4+8NH4++6 pSS14-17H]9- (calculated m/z 2625.0) and
[2*Q4+8NH4++7 pSS14-16H]9- (calculated m/z 2690.1), respectively. The ion labelled c
was previously observed at m/z 2952.3; however, in the spectrum acquired after 24
hours, while this peak was still present, the most intense ion observed was at 2959.8
(also labelled c in the spectrum). None of these ions can be assigned with any certainty
and it will be interesting in future experiments to attempt to prepare greater relative
amounts of these proposed assemblies of quadruplex units. In the experiments described
above, the amounts of the assemblies were too low to enable ESI-IMMS experiments.
In order to carry out ESI-IMMS experiments it will be necessary to purify these
“assemblies”, possibly by isolation from gels or by chromatography methods if they
prove to be stable under these conditions.
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Figure 5.16: ESI mass spectra of Q4:pSS14 in a 1:9 reaction mixture over time. (A) t = 0, (B) t
= 1 h, (C) t = 24 h. ∆ Q1+1 ligand ; ♦ Q1+2 ligands ; □ Q1+3 ligands ; ▲ Q1+4 ligands. The
inset shows an enlarged view of the m/z region 2550-3200 where the labelled ions are at m/z
2659.3.3 (a), 2754.2 (b), 2952.3 (c) 3025.3 (d) 3098.4 (e), 2689.8 (f), and 2624.6 (g).

5.3.2.2 Q1 Q DNA binding
Titrations of the quadruplex DNA Q1 with the ligands were performed under the
conditions described in section 2.4.3. Figure 5.17 shows the ESI mass spectra acquired
of the 1:9 reaction mixtures of SS104 (A), oSS14 (B), KG01 (C), BT80 (D) and
daunomycin (E). Figure 5.19 shows the binding profiles for each of the compounds with
Q1. Given that the spectra acquired for Q1 alone gave many salt adducts, the spectra
acquired for ligand titrations were similar and were difficult to interpret. The peaks
associated with the 3- charge state ([Q1-3H]3-) could not be conclusively assigned in
these experiments as this region was very noisy. BT80 bound significantly to Q1 (D),
with up to two molecules bound to the quadruplex. The binding was not as substantial
as to Q4, with free Q1 (20%) remaining in the 1:9 mixture. The compounds SS104 (A),
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oSS14 (B), and mSS14 (not shown) bound with little affinity to Q1 with a maximum
stoichiometry of 1 and more than 80% free DNA even in the 1:9 mixtures (Figure 5.19).
Two molecules of KG01 bound to Q1 in the 1:9 mixture. The relative abundances for
the complexes Q1+1KG01 and Q1+2KG01 were 25 and 8%, respectively. The
compound pSS14 appeared to have no affinity under the experimental conditions for the
quadruplex Q1.

Figure 5.17: Negative ion ESI mass spectrum of 21-mer Q1, qDNA-ligand in 1:9 mixtures. (A)
Q1: SS104, (B) Q1: oSS14, (C) Q1: KG01, (D) Q1: BT80, (E) Q1: Dn. ■ Q1 alone, ∆ Q1+1
ligand, ♦ Q1+2 ligands, □ Q1+3 ligands.

There seems to be one major binding site on Q1 for daunomycin as evidenced by the
overlap of the graphs for the 1:1-1:9 mixtures at these stoichiometries (Figure 5.19 (H)).
Overall a maximum of 3 daunomycin molecules bound to Q1, a significantly lower
stoichiometry when compared to ssDNA binding and binding to Q4 (four-stranded
qDNA). Since Q1 is a 21-mer sequence, and daunomycin has shown an affinity for
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single-stranded DNA (see sections 5.3.1 and 5.6), it is possible that the daunomycin is
binding to unfolded Q1.

Figure 5.18 shows ESI mass spectra of Q1: berberine mixtures in 1:1, 1:3, 1:6 and 1:9
ratios. In contrast to daunomycin, berberine bound significantly to Q1 with up to five
molecules binding, and only 2% unbound Q1 remaining in the 1:9 mixture. Close
inspection of the spectra shows that berberine is binding to Q1 with and without the
multiple salt adducts. In particular there seemed to be a preference for binding to the
structure of Q1 with three (adventitious) K+ adducts (labelled with

in Figure 5.18).

This may be an indication that this structure of Q1 is quite stable and may aid ligand
binding.

(A)

(B)
(C)
(D)

(E)

Figure 5.18: Negative ion ESI mass spectrum of 21-mer Q1, qDNA-berberine mixtures. (A) Q1
alone, (B) Q1: Berb = 1:1, (C) Q1: Berb = 1:3, (D) Q1: Berb = 1:6, (E) Q1: Berb = 1:9. ■ Q1
alone; ∆ Q1+1Berb; ♦ Q1+2Berb; □ Q1+3 Berb; ▲ Q1+4 Berb; ○ Q1+5 Berb; ● Q1+6 Berb; ◊
Q1+7 Berb; Q1+X Berb+3K+.
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Of the novel compounds, BT80 had the greatest affinity for Q1. The compounds oSS14,
mSS14, pSS14, SS104 and KG01 all bound with little affinity giving rise to low
abundance complexes. Other compounds which have shown some binding selectivity
for G-quadruplexes include the triazines (demonstrated to cause telomere shortening),
the fluoroquinophenoxazines, telomestatin and the pentacyclic acridines.177, 274 Read et
al. designed a 9-anilinoprofloavine to have specificity for the human telomeric
quadruplex DNA structure.177 Additionally, telomestatin and diseleno sapphyrin
(Se2SAP) have been demonstrated to bind selectively to two different forms of the
human telomeric G-quadruplex.143 It was shown that telomestatin binds preferentially to
the basket-type G-quadruplex structure with a 2:1 stoichiometry, while Se2SAP binds to
a different form with a 1:1 stoichiometry in K+. CD studies were used to determine that
Se2SAP binds to the hybrid G-quadruplex (parallel and antiparallel characteristics).
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Figure 5.19: Relative abundances of Q1 QDNA: drug complexes in 1:1-1:9 mixtures
determined by negative ion ESI mass spectra. 1:1; 1:3; 1:6; 1:9.
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5.3.3 Q2 Q DNA binding
Titrations of the quadruplex DNA Q2 with the ligands were performed under the
conditions described in section 2.4.3. Figure 5.20 shows the ESI mass spectra acquired
for the 1:9 reaction mixtures of Q2 with berberine (A), mSS14 (B), KG01 (C), BT80
(D) and daunomycin (E). Figure 5.22 summarises the binding profiles for each of the
compounds with Q2. Berberine bound with a maximum stoichiometry of two, albeit
with weak binding as judged by the relatively high percentage of free DNA in the
mixture. The major complex in all reaction mixtures was Q2+3NH4+, followed by
Q2+3NH4++1 Berb. The relative amount of Q2+3NH4++2 Berb did not increase
significantly among the 1:3, 1:6 and 1:9 reaction mixtures with relative abundances in
each of the mixtures of 5%, 6% and 8%, respectively. Berberine had a comparatively
low affinity for Q2 compared to the other qDNA sequences. Daunomycin bound with a
maximum stoichiometry of 4 molecules, but at low abundance. In the 1:9 Q2: Dn
reaction mixtures the major complex was Q2+3NH4+, at a relative abundance of 55%
(Figure 5.20 (E) and Figure 5.22 (H)). Therefore, daunomycin had the lowest affinity
for Q2 out of the three qDNAs studied.

Under the experimental conditions, BT80 had the greatest binding affinity for Q2 out of
the ligands used in the current study (Figure 5.20 (D) and Figure 5.22 (G)). In reaction
mixtures containing BT80, there was no free Q2+3NH4+ in the 1:6 and 1:9 reaction
mixtures. The major complex observed was Q2+3NH4++2 BT80, at 66% and 86%,
respectively, suggesting that Q2 is saturated when 2 BT80 molecules are bound. The
compounds oSS14, pSS14 and mSS14 weakly bound to Q2 (e.g. mSS14, Figure 5.20
(B)) all bound only one molecule to Q2. The binding of SS104 was negligible (Figure
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5.22 (E)). Up to two molecules of KG01 (Figure 5.20 (C)) bound to Q2, but at low
affinity with free qDNA, Q2+3NH4+, the major component of the mixture (94% and
84% for the 1:6 and 1:9 reaction mixtures, respectively). Q2+3NH4++1KG01
constituted 6% and 11% of the 1:6 and 1:9 reaction mixtures, respectively.

Figure 5.20: Negative ion ESI mass spectra of 8-mer Q2, qDNA-ligand in 1:9 mixtures. (A)
Q2: Berb, (B) Q2: mSS14, (C) Q2: KG01, (D) Q2: BT80, and (E) Q2: Dn. ■ Q2 alone; ∆ Q2+1
ligand; ♦ Q2+2 ligands; □ Q2+3 ligands; ▲Q2+4 ligands; ○ Q2+5 ligands; ● Q2+6 ligands; ◊
Q2+7 ligands, ssDNA+ ligand/s.

As mentioned previously in sections 3.5.2 and 3.6.3, ammonium adducts of Q2 were not
abundant in the ESI mass spectra. In contrast, when ligands where bound, there was a
change in the distribution of ions for the 5- charge state (the 4- ions remained in the form
[Q2+3NH4+-7H]4-). Figure 5.21 shows an enlarged view of the 5- ions for Q2 alone (A)
and in a 1:9 mixture with BT80 (B). When Q2 was alone, the major ion corresponds to
Q2+2NH4+ (see section 3.5.2); however, when the ligands in this study were bound to
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Q2 the major free DNA ion corresponded to Q2+3NH4+. This effect is confirmation that
the ligands are not binding non-specifically, since there appears to be a preference for,
or stabilization, of a folded structure with bound NH4+ present.

Figure 5.21: Enlarged in view of 5- ions of Q2. (A) Q2 alone, (B) Q2 and BT80 in a 1:3
reaction mixture. ● Q2+2NH4+; ■ Q2+3NH4+; □ Q2+2NH4++X BT80; ♦ Q2+3NH4++X BT80.
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Figure 5.22: Relative abundances of Q2 QDNA: drug complexes in 1:1-1:9 mixtures
determined by negative ion ESI mass spectra. 1:1; 1:3; 1:6; 1:9.
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5.4 CID of Q4 DNA-ligand complexes
The CID experiments described in section 3.8 can also be used to select precursor ions
arising from DNA-ligand complexes. Comparison of the energies required to dissociate
different DNA-ligand complexes allows a comparison of gas phase binding affinities. In
order to compare the stabilization of the quadruplex Q4 by the ligands in this study,
each of the eight compounds was equilibrated with Q4 and the Q4+4NH4++1 ligand ion
was selected for CID. Figure 5.23 shows the spectra obtained at a trap collision energy
of 22 V for the compounds berberine (A), BT80 (B), KG01 (C), daunomycin (D), and
SS104 (E). Given the low relative abundance of ions it was not possible to confidently
calculate relative percentages of products.

For berberine, the precursor ion was at m/z 2077.2. No dissociation was observed at 22
V and at 26 V it was not possible to detect the precursor ion. The precursor ion for the
compounds m-, o-, and pSS14 was at m/z 2127.5 and was present at low relative
abundance (not shown) making detection of products challenging. At 18 V, ssDNA
([ssQ4-2H]2-) was observed as well as the ion [Q4+1 mSS14-5H]5- (no ammonium
ions). At 26 V only ssDNA remained and at 30 V it was impossible to detect products.

The [Q4+4NH4++1 BT80-9H]5- precursor was observed at m/z 2108.4. At 18 V, one
ammonium ion was lost to give [Q4+3NH4++1 BT80-8H]5- at m/z 2105.3. At 22 V, the
predominant ions were [Q4+3NH4++1 BT80-8H]5- and [Q4+1 BT80-5H]5- (loss of all
ammonium ions). At 26 V (not shown) both [Q4+1 BT80-5H]5- and [Q4-G+1 BT805H]5- were observed. This suggests that BT80 is bound tightly to Q4 since it remained
bound, although a guanine base was lost. The ion [Q4-G+1 BT80-5H]5- was lost at 30
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V, however the ion [Q4+1 BT80-5H]5- was still present at 42 V, until it was unable to
be detected at 46 V. In the case of Q4 alone, the loss of all ammonium ions was
observed at 22 V.

The [Q4+4NH4++1 KG01-9H]5- precursor ion was observed at m/z 2105.2. At 18 V, the
ion [Q4+3NH4++1 KG01-8H]5- was observed, in which one ammonium ion had been
dissociated. At 22 V, [Q4+1 KG01+3NH4+-8H]5- remained the predominant ion. At 26
V the [Q4+1 KG01+3NH4+-8H]5- was still present but the most abundant ion was [Q4+1
KG01-5H]5- in which all the ammonium ions had been lost. At 30 V both [Q4-G+1
KG01-5H]5- and [Q4+1KG01-5H]5- were present. These ions remained until it was
impossible to obtain CID spectra at 50 V. In summary, although ammonium ions
dissociated from the Q4+1 KG01 complex, it remained intact showing that this complex
was highly stable in the mass spectrometer. In contrast, when CID experiments were
carried out using Q4 alone [Q4+4NH4+-9H]5- as precursor (section 3.8.1), guanine bases
were dissociated from Q4 at trap energies ≥ 10 V.

The dissociation pathway observed for daunomycin was very different to that observed
for BT80 and KG01. The precursor ion [Q4+4NH4++1 Dn-9H]5- was observed at m/z
2115.5. At 14 V, the ions [Q4+3NH4+-8H]5- and [Q4+NH4+-6H]5- were the products.
This is the major difference from BT80 and KG01. The ligand was lost first in the case
of daunomycin, consistent with a different mode of binding. At 22 V, [Q4-5H]5- at m/z
1996.6 was present (calculated m/z 1996.4). At 30 V no precursor ion remained and
only the ions [Q4+3NH4+-8H]5-, [Q4-5H]5- and [Q4-G-5H]5- were present. At 38 V the
ion [Q4-G-5H]5- was observed as well as single-stranded DNA at m/z 1247.5 ([ssQ4195

5H]5-). At 42 V, the only ion which remained was [Q4-2G-5H]5-. Above 42 V it was not
possible to obtain CID spectra. For the compound SS104 the precursor ion
[Q4+4NH4++1 SS104-9H]5- was observed at m/z 2130.5. SS104 had a similar
dissociation pathway to Dn which suggests a different mode of binding to BT80 and
KG01. At 22 V the major ion detected was [Q4+3NH4++1 SS104-8H]5- with
[Q4+4NH4+-9H]5- also present; above this voltage it was not possible to obtain CID
spectra.

Figure 5.23: Negative ion ESI CID mass spectra of [Q4+4NH4++1ligand-9H]5- obtained at trap
collision energy of 22 V for the ligands berberine (A), BT80 (B), KG01 (C), daunomycin (D),
and SS104 (E). ■ Precursor ion [Q4+4NH4++1 ligand-9H]5-; ∆ [Q4+3NH4++1 ligand-8H]5-; ♦
[Q4+1 ligand-5H]5-; ○ [Q4+4NH4+-9H]5-; ▲ [Q4-5H]5-.

Overall these compounds stabilised Q4 in the order KG01 > BT80 > daunomycin >
SS104. The berberine derivatives o-, m-, and pSS14 could not be compared in CID
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experiments since the spectra were of poor quality. Attempts were made at obtaining
CID spectra of Q2- and Q1-ligand complexes but the spectra were of poor quality and
did not allow firm conclusions to be made about the relative stabilities of complexes.

5.5 Circular dichroism of DNA-ligand complexes
In order to investigate the effects of ligand binding in solution, CD spectra of Q4- and
D1-ligand complexes were obtained. CD spectroscopy has proven useful in the past for
providing both qualitative and quantitative measures of the strength of interactions
between ligands and dsDNA,181, 182, 275, 276 and more recently also for interactions with
qDNA.134, 143, 144 In addition, it has proven to be a useful technique for detecting changes
in DNA conformation caused by drug interactions with DNAs.277, 278,279 The compounds
telomestatin and Se2SAP (discussed previously in section 5.3.2.2 ) have been found to
induce a change in the type of G-quadruplex formed by the human telomeric sequence
upon binding using CD.143 Telomestatin induced the formation of the basket-type Gquadruplex from a random coil human telomeric oligonucleotide in the absence of
added monovalent cations (e.g. K+ or Na+). In contrast, Se2SAP was found to convert
the preformed basket G-quadruplex to a hybrid structure in the presence of K+.143 The
significance of these results is that the presence of different ligands can determine the
type of telomeric G-quadruplex structures formed in solution.

Figure 5.24 shows the CD spectra of solutions containing different ratios of ligands and
Q4. As previously described in section 3.3.1, the spectrum of Q4 itself is consistent with
those previously reported for tetrameric qDNA, which typically have a positive CD
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band with a maximum near 265 nm and a negative CD band with a minimum near 240
nm.93,

125, 193, 208, 280

Q4 also has a second positive band at 210 nm. Addition of

increasing amounts of each of the compounds, berberine, oSS14, mSS14, pSS14 and
KG01 resulted in a decrease in the ellipticity of the two positive CD bands, while only
minor changes in ellipticity at 240 nm were observed. The decrease in ellipticity was
smallest for beberine. For example, for the CD signal at 262 nm, Δ values (change in
ellipticity) of 0.43, 2.39, 3.91, 2.68 and 2.66 mdeg were found for berberine, oSS14,
mSS14, pSS14 and KG01, respectively. The similarity in the CD spectra for SS14
berberine analogues probably reflects both the relatively small ellipticities observed for
the CD signals of Q4 under the conditions used, and the similar qDNA binding affinities
between the berberine analogues which have already been revealed by ESI-MS studies
(section 5.3.2).For KG01, Figure 5.24 (E), for all the ratios of Q4: KG01 the CD spectra
developed a shoulder at ~230 nm. This change may indicate either drug binding
inducing a conformational change in the DNA, the adoption of a second binding mode,
or a combination of both.

White et al. found that distamycin bound weakly to a synthetic analogue of the human
telomeric sequence, this however, produced virtually no change in CD signals.96 This is
believed to be consistent with an end-stacking binding mode.96 Using a 3.3 μM solution
of the sequence d[AG3(T2AG3)3] in HEPES buffer containing 50 mM KCl they used
ligand-DNA ratios from 0.5:1 to 5:1. In contrast, large changes to the magnitude of
induced CD signals were believed to indicate a mechanism involving binding to the
quadruplex grooves.96 The current data suggest a difference in the binding of KG01 to
Q4 compared with SS14 analogues.
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Figure 5.24: Circular dichroism spectra of solutions containing different ratios of ligand
complexes and Q4: (A) Berberine; (B) oSS14; (C) mSS14 ; (D) pSS14 and (E) KG01. Ratio of
Q4: ligand = 1:0
, 1:1
, 1:4
, 1:8
, 1:12
, 1:16
.

These observations suggest that the binding of the SS14 series and berberine, (berberine
in particular), is only a weak stacking interaction based on the results of White et al..
Molecular modeling based on crystal structures of the human quadruplex sequence have
been used to investigate the mode of binding of berberine.137 These experiments
indicated that an end on stacking mode was used by berberine and that a piperidino
analogue of berberine had a similar binding mode, but its side chain was also able to
interact with the grooves of the quadruplex (Figure 5.25). It is possible that a similar
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binding mode is exhibited by the SS14 series. In the case of KG01 however, there may
be some additional binding sites available. CD spectra of complexes of Q4 with BT80
and SS104 were not carried out owing to the small amount of sample available.

Figure 5.25: Model for the complexes of berberine with a monomeric G-quadruplex (blue) and
ligand molecules (yellow). Taken from Franceschin et al..137

5.6 Other activities of Berberine and its analogues
As part of another project, berberine and its analogues were tested for anti-bacterial
activity against wild-type (8325-4), NorA knockout (K1758) and NorA overexpressing
(K2378 and K2361) Staphylococcus aureus strains (where NorA is a bacterial efflux
pump252). The data are shown in Table 5.1. The methods for the bacterial culture
conditions and the antimicrobial assay are described in Ball et al. and were performed
by Gabriel Casadei at the Antimicrobial Discovery Centre in Boston, USA.202 The
results for berberine, oSS14, SS104 and BT80 have previously been reported in the
literature.162, 202
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Table 5.1: Minimum inhibitory concentrations (MIC, M) for berberine and derivatives against
S. aureus strains.
S. aureus
Wt 8325-4
70.00

S. aureus
K1758
40.00

S. aureus
K2361
1360.00

S. aureus
K2378
1360.00

oSS14202

3.38

3.38

6.75

3.38

mSS14163

20.10

20.10

20.10

nt*

pSS14163

37.94

20.10

1.13

nt

SS104162

1.88

1.88

1.88

1.88

4.49

6.06

24.4

12.31

11.01

5.51

22.02

nt

Berberine202

KG01
BT80162

*nt indicates that the sample was not tested.

The anti-bacterial activity of each of the compounds was greater than that of the parent
compound berberine. This is an indication that these compounds are poor substrates of
NorA since its presence or absence does not affect the activity. It is expected that an
antibacterial acting as a substrate for the NorA efflux pump should show increased
activity against a NorA-knockout strain when compared to the wild type as well as
reduced activity against a NorA overexpressing strain. BT80 on the other hand, did
show a NorA inhibitory effect as evidenced by the increased activity in the NorA
overexpressed strain. These data are unlikely to be reflective of qDNA binding.
Nevertheless, it would be of interest to further investigate the mechanism by which this
antibacterial activity is affected.
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5.7 Chapter summary
ESI-MS can be used to screen non-covalent binding interactions between ligands and
double-stranded DNA, by providing information about the relative amounts and
stoichiometry of non-covalent complexes present. The current study shows that ESI-MS
can also provide detailed information about binding interactions involving ligands and
quadruplex DNA. Figure 5.26 shows the binding preferences of daunomycin, berberine,
oSS14, mSS14, pSS15, BT80, SS104, and KG01 for the six different DNA sequences
used in this study. Berberine showed a slight preference for binding to quadruplex DNA
over D1. Berberine and daunomycin bound to duplex DNA and quadruplex DNA, but
with a slight preference for the duplex structures.

With the exception of BT80, none of the berberine analogues bound significantly to any
of the dsDNA sequences studied. In contrast, all compounds were able to bind
substantially to the four-stranded qDNA Q4. The behaviour of the ligand pSS14 was
consistent with the formation of qDNA dimers. Binding of the berberine analogues to
Q1 and Q2 was modest. It was possible however, to observe improved stability of the
quadruplex Q2 when ligands were bound. These observations may lead to applications
of these berberine analogues as leads for quadruplex DNA-specific chemotherapeutic
agents or as molecular probes for qDNA structures in cells.
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Figure 5.26: Relative abundances of DNA: ligand complexes for each ligand in 1:1-1:9
mixtures determined by negative ion ESI mass spectra.
Reaction mixtures with D1;
reaction mixtures with D2;
reaction mixtures with F10;
reaction mixtures with Q1;
reaction mixtures with Q2; reaction mixtures with Q4.
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Chapter 6: Conclusions and future directions
6.1 Conclusions
The ability to bind quadruplex DNA selectively over dsDNA may be an advantage for
some therapeutic applications. Possible anti-cancer drug targets that are thought to
contain quadruplex DNA structures are telomeres in rapidly dividing cells.93 Therefore,
compounds that prefer to bind quadruplex DNA over dsDNA might display some
selectivity for cancer cells.

In preliminary studies, oSS14 was shown to have at least a four-fold preference for
binding to qDNA over dsDNA based on relative abundances of ions in ESI mass
spectra.138 Since the binding to dsDNA was negligible and the binding to qDNA was
relatively weak, there is considerable margin for error in this selectivity factor. In the
current work, new derivatives based on berberine and oSS14 were prepared to obtain
ligands that bound qDNA more tightly while retaining the selectivity for qDNA. The
ligands oSS14 and KG01 were synthesised in fair yield and purified to a standard
compatible with mass spectrometric studies. In the case of mSS14 and pSS14 a slightly
modified semi-preparative HPLC purification procedure afforded compounds with ≥
98% purity making these sufficiently pure for ESI-MS. BT80 was another novel ligand
that was tested for its DNA-binding ability and compared against berebrine and the
intercalating anti-cancer drug, daunomycin.

Quadruplex DNA was successfully detected and optimised using both ESI-MS and ESIIMMS. Several qDNA types were selected for study. These were the four-stranded Q4,
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the two-stranded Q2, and the single-strand Q1. Since ESI-MS was to be the method for
judging DNA binding, it was important to provide evidence that the folded structures
were maintained in the gas phase. This is because Q1 will give the same mass whether it
is in its folded conformation or not. Further for qDNA (or dsDNA) with an even number
of strands and carrying an even number of charges, the assignment of the strand
stoichiometry can be ambiguous when the strands comprising the secondary structure
have the same mass. For example, a two-stranded structure of Q2 with four charges will
have the same m/z as a single strand with two charges. Circular dichroism spectra were
acquired of each qDNA sample to determine whether folded qDNA was present under
the solution conditions (150 mM ammonium actetate, pH 7.0) to be used for ESI-MS. In
order to provide evidence that supported the maintenance of folded qDNA structures in
the gas phase, ESI ion mobility mass spectra were obtained. Solution and instrument
conditions were then changed so that qDNA was destabilised. The appearance of new
ions with different mobilities supported that under the more gentle conditions folded
qDNA was present.

The berberine derivatives mSS14, pSS14 and SS104 bound more tightly to Q4 than
oSS14 while retaining their selectivity for Q4 (a parallel four-stranded quadruplex) over
dsDNA. The compound pSS14 gave ESI mass spectra which suggested the presence of
Q4 quadruplex dimers. KG01 and BT80, in particular, bound to all three qDNA types.
The selectivities of BT80 for Q4, Q2 and Q1 over the dsDNA sequence, D2, were 5.7,
5.8 and 4.5, respectively, based on the ratios of the relative abundances of complexes
compared to free DNA in the 1:9 mixtures (Figure 5.27) . The abundance of complexes
where BT80 bound to D2 in this mixture was quite low (<18%), which is one factor that
205

makes these selectivity factors approximations. Additionally, ESI mass spectra showed
that the less stable quadruplex, Q2, was stabilised by ligand binding. CID experiments
showed that Q1 was more stable against unfolding in the gas phase when ligands were
bound.

6.2 Future directions
The berberine derivatives studied in this project exhibited selectivity for qDNA. In
order to determine the structural principles that target a particular ligand for a particular
qDNA structure, further studies are needed to quantify the binding characteristics of the
ligands and to determine the structures of the complexes.

In this work, ion mobility ESI mass spectrometry was use to gain insight into the DNA
secondary structures that were maintained in the gas phase. Currently the ion mobility
separation between complexes using the TWIMS mobility cell of the HDMS™
SynaptTM is not sufficient to determine whether, for example, complexes in which the
same number of ligands is bound to DNA are homogeneous in their structure or whether
there may be more than one binding mode. Recently, the Waters Synapt TM G2 has been
released; this instrument has greater ion mobility “resolution”. Greater ion mobility
separation in this or in future instrumentation may enable binding modes among ligands
to be distinguished as they induce different conformational changes in DNA. The
berberine derivatives o-, m-, and pSS14 are excellent ligands for this work since they all
have the same mass; therefore, any differences in mobility will be the result of
conformational changes.
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Another question to be addressed is whether there is any preference for a particular
stoichiometry of DNA/drug binding. This would be consistent with a preferred binding
site (or sites) which, when occupied, hinder binding at sites of lower affinity. Related to
this is the determination of the maximum number of drug molecules that can bind to a
particular structure/sequence. These properties can be exploited in drug design and
development to target specific regions of genes that might be important in the
expression of diseases such as cancer or in bacterial or parasitic growth and/or
reproduction. This is of particular interest for comparing the effect of derivatization of
berberine on its interactions with DNA. Once conditions were optimised for analysis of
the qDNA/ligand complexes, ESI-MS provided a rapid method for screening binding
interactions and in qualifying relative binding abilities of the ligands. Other biophysical
methods will need to be carried out to quantify the stabilities of the complexes. There
have been several reports of the use of surface plasmon resonance for investigating the
binding interactions of qDNA with ligands and this seems a promising method.96, 130, 134,
140, 142, 143, 177

Finally, before conclusions can be drawn regarding the precise mode of

binding, NMR or X-ray crystallographic structures of these compounds binding to both
the dsDNA and quadruplex will enable a detailed analysis of the important non-covalent
interactions. At the commencement of this work, attempts were made to obtain crystals
of an oSS14/Q4 complex. This attempt was unsuccessful and this is perhaps not
surprising given oSS14 is a relatively weak binder. Crystallization trials involving BT80
and KG01 are currently in progress.

While targeting telomerase activity by discovery of qDNA-selective ligands is an anticancer strategy, there may also be other uses of such compounds. Protozoan parasites
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and trypanosomes constitute a large number of human and animal pathogens which
significantly impact on the health and economy of many countries. The most virulent of
the malaria parasites is Plasmodium falciparum, which is the cause of approximately 1.5
million deaths per year.102, 281 During its complicated life cycle these parasites use both
the mosquito vector Anopheles and humans as its host.282 These types of parasites
usually reproduce very rapidly and have been shown to maintain constant telomere
length during the stage of the life cycle in which they are present in the host‟s blood.281
This has led to an interest in targeting plasmodial telomeres to limit the growth of these
parasites. In 2001 it was shown that telomerase is active throughout the lifecycle of
Plasmodium falciparum,283 making the telomeric DNA of this parasite a prime target
for anti-malarial therapeutics that may interfere with the actions of telomerase and other
proteins at the chromosomal ends.

Sequences that may form RNA quadruplexes have been found in fifty untranslated
sequences of different genes.284 This less understood counterpart to quadruplex DNA
may be of high biological relevance. Recently, Collie et al. demonstrated that a number
of small molecules have specificity for qRNA over qDNA. 285 It would be of great
interest to characterize qRNA using ion mobility and to test the ligands investigated
here for their binding affinities to these structures.
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Appendices
Appendix A: Ions observed in ESI mass spectra of dsDNA: ligand
complexes

Calculated values of m/z for ions in the negative ion ESI spectra used to calculate the
data shown in Chapter 5. The masses of berberine (1), oSS14 (2), mSS14 (3), pSS14
(4), SS104 (5), KG01 (6), BT80 (7), Daunomycin (8) are 336.4, 586.6, 586.6, 586.6,
602.6, 476.5, 492.2, and 527.5 Da, respectively. The masses of D1, D2, F10, and Q1,
Q2 and Q3 are 9762.4, 9763.5, 12321.2, 9986.8, 6653.3, and 7577.0 Da, respectively.
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Table A. 1: Ions observed in ESI mass spectra of D1 dsDNA: ligand mixtures.
Complex

Calculated m/z

D1 dsDNA ions

[M-5H]5-

[M-6H]6-

[D1]

1951.9

1626.4

[D1+1Berberine]

2019.2

1682.5

[D1+2 Berberine]

2086.4

1738.5

[D1+3 Berberine]

2153.7

1794.6

[D1+4 Berberine]

2221.0

1850.7

[D1+5 Berberine]

2288.3

1906.7

[D1+6 Berberine]

2355.6

1962.8

[D1+7 Berberine]

2422.8

2018.9

[D1+8 Berberine]

2490.1

2074.9

[D1+1Dn]

2057.4

1714.3

[D1+2Dn]

2162.9

1802.2

[D1+3Dn]

2268.4

1890.2

[D1+4Dn]

2373.9

1978.1

[D1+5Dn]

2479.4

2066.0

[D1+6Dn]

2584.9

2154.0

[D1+7Dn]

2690.4

2241.8

[D1+8Dn]

2795.9

2329.8

[D1+1o-, m-, pSS14]

2069.2

1724.2

[D1+1KG01]

2047.2

1705.8

[D1+1BT80]

2050.3

1708.4

[D1+2BT80]

2148.8

1790.5

[D1+1SS104]

2072.3

1726.8
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Table A. 2: Ions observed in ESI mass spectra of D2 dsDNA: ligand mixtures.
Complex

Calculated m/z

D2 dsDNA ions

[M-5H]5-

[M-6H]6-

[D2]

1951.7

1626.3

[D2+1Berberine]

2019.2

1682.5

[D2+2 Berberine]

2086.4

1738.5

[D2+3 Berberine]

2153.7

1794.6

[D2+4 Berberine]

2221.0

1850.7

[D2+5 Berberine]

2288.3

1906.7

[D2+1Dn]

2057.2

1714.2

[D2+2Dn]

2162.7

1802.1

[D2+3Dn]

2268.2

1890.0

[D2+4Dn]

2373.7

1977.9

[D2+5Dn]

2479.2

2065.8

[D2+6Dn]

2584.7

2153.8

[D2+1mSS14]

2069.0

1724.0

[D2+1KG01]

2047.0

1705.7

[D2+1BT80]

2050.1

1708.3

[D2+2BT80]

2148.6

1790.3
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Table A. 3: Ions observed in ESI mass spectra of F10 dsDNA: ligand mixtures.
Complex

Calculated m/z

F10 DNA ions

[M-5H]5-

[M-7H]6-

[M-7H]7-

[F10+1Berb]

2530.5

2108.6

1807.2

[F10+2Berb]

2597.8

2164.7

1855.3

[F10+3Berb]

2665.1

2220.7

1903.3

[F10+4Berb]

2732.4

2276.8

1951.4

[F10+5Berb]

2799.6

2332.9

1999.5

[F10+6Berb]

2866.9

2388.9

2047.5

2445.0

2095.6

3001.5

2501.1

2143.6

[F10+1Dn]

2568.7

2140.5

1834.5

[F10+2Dn]

2674.2

2228.4

1909.9

[F10+3Dn]

2779.7

2316.3

1985.2

[F10+4Dn]

2885.2

2404.2

2060.6

[F10+5Dn]

2990.7

2492.1

2136.0

[F10+6Dn]

3096.2

2580.0

2211.3

[F10+7Dn]

3201.7

[F10+7Berb]
[F10+8Berb]

2934.2

2668.0

2286.7

3307.2

2755.9

2362.0

[F10+1o-, m-, pSS14]

2580.4

2150.2

N/A

[F10+1KG01]

2558.5

[F10+1BT80]

2561.7

2134.6

N/A

[F10+1SS104]

2583.8

2153.0

N/A

[F10+2SS104]

2704.3

2253.4

N/A

[F10+8Dn]

2132.0

N/A
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Table A. 4: Ions observed in ESI mass spectra of Q4 quadruplex DNA: ligand mixtures.
Complex
Q4 QDNA ions
[Q4]
[Q4+1Berb]
[Q4+2Berb]
[Q4+3Berb]
[Q4+4Berb]
[Q4+5Berb]
[Q4+6Berb]
[Q4+7Berb]
[Q4+8Berb]
[Q4+9Berb]
[Q4+1Dn]
[Q4+2Dn]
[Q4+3Dn]
[Q4+4Dn]
[Q4+5Dn]
[Q4+6Dn]

Calculated m/z
[M+4NH4+-9H]5-

[M+4NH4+-10H]6-

2009.98

1674.81

2077.26

1730.88

2144.54

1786.95

2211.82

1843.01

2279.10

1899.08

2346.38

1955.15

2413.66

2011.21

2480.94

2067.28

2548.22

2123.35

2615.50

2179.41

2115.48

1762.73

2220.98

1850.65

2326.48

1938.56

2431.98

2026.48

2537.48

2114.40

2642.98

2202.31
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Table A. 5: Ions observed in ESI mass spectra of Q4 quadruplex DNA: ligand mixtures.
Complex
Q4 QDNA ions
[Q4+1o-, m-, pSS14]
[Q4+2o-, m-, pSS14]
[Q4+3o-, m-, pSS14]
[Q4+4o-, m-, pSS14]
[Q4+5o-, m-, pSS14]
[Q4+6o-, m-, pSS14]
[Q4+1KG01]
[Q4+2KG01]
[Q4+3KG01]
[Q4+4KG01]
[Q4+1BT80]
[Q4+2BT80]
[Q4+3BT80]
[Q4+4BT80]
[Q4+SS104]
[Q4+2SS104]
[Q4+3SS104]
[Q4+4SS104]

Calculated m/z
[M+4NH4+-9H]5-

[M+4NH4+-10H]6-

2127.30

1772.58

2244.62

1870.35

2361.94

1968.11

2479.26

2065.88

2596.58

2163.65

2713.90

2261.41

2105.28

1754.23

2200.58

1833.65

2295.88

1913.06

2391.18

1992.48

2108.42

1756.85

2206.86

1838.88

2305.30

1920.91

2403.74

2002.95

2130.50

1775.25

2251.02

1875.68

2371.54

1976.11

2492.06

2076.55
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Table A. 6: Ions observed in ESI mass spectra of Q1 quadruplex DNA: ligand mixtures.
Complex

Calculated m/z
[Q1-4H]4-

[Q1-5H]5-

[Q1]

1662.3

1329.7

[Q1+berb]

1746.4

1396.9

[Q1+2Berb]

1830.5

1464.2

[Q-1+3Berb]

1914.6

1531.5

[Q1+4Berb]

1998.7

1598.8

[Q1 +5Berb]

2082.8

1666.1

1794.1

1435.1

1925.9

1540.5

2057.7

1646.0

1808.9

1446.9

1781.5

1425.0

1900.6

1520.3

1785.4

1428.1

1908.4

1526.5

1813.0

1450.2

Q1 qDNA ions

[Q1+1Dn]
[Q1+2Dn]
[Q1+3Dn]
[Q1+1o-, m-, pSS14]
[Q1+1KG01]
[Q1+2KG01]
[Q1+1BT80]
[Q1+2BT80]
[Q1+1SS104]
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Table A. 7: Ions observed in ESI mass spectra of Q2 quadruplex DNA: ligand mixtures.
Complex
Q2 qDNA ions
[Q-DNA]
[Q-DNA+1Berb]
[Q-DNA+2Berb]
[Q1+1Dn]
[Q1+2Dn]
[Q1+3Dn]
[Q1+4Dn]
[Q1+1o-, m-, pSS14]
[Q1+1KG01]
[Q1+2KG01]
[Q1+1BT80]
[Q1+2BT80]
[Q1+3BT80]
[Q1+1SS104]

Calculated m/z
[M+3NH4+-7H]4-

[M+3NH4+-8H]5-

1906.02

1524.61

1990.12

1591.89

2074.22

1659.17

2037.82

1630.05

2169.62

1735.49

2301.42

1840.93

2433.22

1946.37

2052.57

1641.85

2025.14

1619.91

2144.27

1715.21

2029.07

1623.05

2152.12

1721.49

2275.17

1819.93

2056.67

1645.13
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